Molecular mechanisms and biomarkers of familial FTD/ALS by Lehmer, Carina
 
 
 
Aus dem Deutschen Zentrum für Neurodegenerative Erkrankungen   
und dem Adolf-Butenandt-Institut  
Lehrstuhl: Stoffwechselbiochemie  
im Biomedizinischen Zentrum der  
Ludwig-Maximilians-Universität München 
Vorstand: Prof. Dr. rer. nat. Dr. h.c. Christian Haass 
 
 
 
Molecular mechanisms and biomarkers of 
familial FTD/ALS 
 
 
- Dissertation - 
zum Erwerb des Doktorgrades der Naturwissenschaften (Dr. rer. nat.)  
an der Medizinischen Fakultät der Ludwig-Maximilians-Universität München 
 
 
 
vorgelegt von 
Carina Petra Lehmer 
aus Burglengenfeld 
 
2018 
1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gedruckt mit Genehmigung der Medizinischen Fakultät der Ludwig-Maximilians-
Universität München 
Betreuer: Prof. Dr. rer. nat. Dr. h.c. Christian Haass 
Zweitgutachter: Prof. Dr. Christian Behrends 
Dekan: Herr Prof. Dr. med. dent. Reinhard Hickel 
 
Tag der mündlichen Prüfung: 04.12.2018
2
Eidesstattliche Versicherung 
 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Dissertation mit 
dem Thema selbständig verfasst, mich außer der angegebenen keiner 
weiteren Hilfsmittel bedient und alle Erkenntnisse, die aus dem Schrifttum 
ganz oder annähernd übernommen sind, als solche kenntlich gemacht und 
nach ihrer Herkunft unter Bezeichnung der Fundstelle einzeln nachgewiesen 
habe.  
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in 
gleicher oder in ähnlicher Form bei einer anderen Stelle zur Erlangung eines 
akademischen Grades eingereicht wurde.  
 
München, 25.3.2019 
 
 
 
Carina Petra Lehmer 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4
  
 
Table of Contents 
List of Abbreviations .................................................................................................................... 6 
Publications of this thesis ............................................................................................................ 9 
I. Introduction .................................................................................................................... 10 
1. Frontotemporal Dementia and Amyotrophic Lateral Sclerosis ........................................ 10 
1.1. Clinical, genetic and neuropathological features of FTD, ALS and FTD/ALS .................. 10 
1.1.1. Clinical features of FTD .................................................................................................. 10 
1.1.2. Clinical features of ALS .................................................................................................. 11 
1.1.3. Clinical features of FTD/ALS .......................................................................................... 11 
1.1.4. Genetic evidence and pathological inclusions in FTD/ALS ............................................. 12 
1.2. Pathogenic mechanisms in FTD/ALS ............................................................................. 13 
1.2.1. Protein homeostasis ...................................................................................................... 14 
1.2.2. Mitochondria .................................................................................................................. 18 
2. C9orf72 –mutations are the most common cause of familial FTD/ALS ........................... 20 
2.1. Function and genetic link to FTD/ALS ............................................................................ 20 
2.2. Current hypothesis of C9orf72 disease related pathomechanisms ................................. 20 
3. CHCHD10 - A mitochondrial link to FTD/ALS ................................................................. 23 
3.1. Structural features and mitochondrial import .................................................................. 23 
3.2. Function and genetic link to FTD/ALS ............................................................................ 26 
3.3. Current hypothesis of CHCHD10 disease-related pathomechanisms ............................. 28 
4. Clinical biomarkers and therapy approaches in FTD and ALS ........................................ 29 
4.1. Biomarkers for neurodegenerative diseases .................................................................. 29 
4.2. Therapeutic approaches for FTD/ALS ............................................................................ 30 
II. Zusammenfassung ........................................................................................................ 32 
III. Summary ....................................................................................................................... 35 
IV. Results ........................................................................................................................... 37 
1. Publication I and contribution ......................................................................................... 37 
2. Publication II and contribution ........................................................................................ 57 
3. Publication III and contribution ....................................................................................... 82 
4. Publication IV and contribution ....................................................................................... 95 
References .............................................................................................................................. 115 
Acknowledgements ................................................................................................................. 130 
5
 
 
 
List of Abbreviations 
aa Amino acid 
Aβ β-amyloid 
AD Alzheimer´s disease 
AICAR AMPK activator 5-amino-1-β-D-ribofuranosylimidazole-4-carboxamide  
AIF Apoptosis inducing factor 
ALS Amyotrophic lateral sclerosis 
AMPK AMP-activated protein kinase 
ASO Antisense oligonucleotide 
Atg5 Autophagy related 5 
Atg7 Autophagy related 7 
ATP Adenosin triphosphate 
bvFTD Behavioral variant frontotemporal dementia 
C9orf72 Chromosome 9 open reading frame 72 gene (C9orf72) 
CHCHD10 Coiled-coil-helix-coiled-coil-helix domain containing protein 10 
CHMP2B Charged multivesicular body protein 2b 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CytC Cytochrome C 
CPC Cysteine-proline-cysteine 
COX Cytochrome C oxidase 
CX9C Cysteine-X9-Cysteine 
DENN After differentially expressed in neoplastic versus normal cells 
DM2 Myotonic dystrophy type 2 
DPR Dipeptide repeat 
E1 Ubiquitin-activating enzyme 
E2 Ubiquitin-conjugating enzyme 
E3 Ubiquitin-ligating enzyme 
Erv1 Essential for respiration and vegetative growth 
FDA Food and drug administration 
FTD Frontotemporal dementia 
FUS Fused in sarcoma 
G-Q G-quadruplex 
GA Glycine-alanine 
GEF Guanine nucleotide exchange factor 
GOF Gain-of-function 
GP Glycine-proline 
GR Glycine-arginine 
GRN Progranulin 
IMM Inner mitochondrial membrane 
IMS Intermembrane space 
6
  
 
 
iPSC Induced pluripotent stem cells 
KD Knock down 
KO Knock out  
LCD Low complexity domain 
LCL Lymphoblastoid cell lines 
LOF Loss-of-function 
MAPT Microtubule-associated protein tau 
Mia Mitochondrial intermembrane space import and assembly 
MICOS Mitochondrial contact site and cristae organizing system 
miRNA MicroRNA 
mito. Mitochondrial  
MM Mitochondrial myopathy 
MND Motor neuron disease 
MPP Mitochondrial processing peptidase 
MRI Magnetic resonance imaging 
MTS Mitochondrial targeting signal 
NMD Nonsense-mediated mRNA decay 
OMM Outer mitochondrial membrane 
OPTN Optineurin 
ORE Oxygen responsive element 
OXPHOS Oxidative phosphorylation 
PA Proline-alanine 
PAM Presequence translocase associated import motor 
PD Parkinson´s disease 
PET Positron emission tomography 
PLS Primary lateral sclerosis 
PMA Progressive muscular atrophy 
PNFA Progressive non-fluent aphasia 
PGC-1α PPARγ coactivator-1α 
PPA Primary progressive aphasia 
PPARγ Peroxisome proliferator-activated receptor gamma 
PR Proline-arginine 
PrP Prion protein 
Rab Ras-related in brain 
RAN Repeat-associated non-ATG 
RBP RNA-binding protein 
ROS Reactive oxygen species 
SAM Sorting and assembly machinery 
SCA8 Spinocerebellar ataxia type 8 
SD Semantic dementia 
SMCR8 Smith-magenis syndrome chromosome region, candidate 8 
SOD1 Superoxide dismutase 1 
7
  
 
 
SQSTM1/p62 Sequestome 1 
TBK1 TANK-binding kinase 1 
TDP-43/TARDBP TAR DNA-binding protein 43 
TIA-1 T-cell intracellular antigen 1 
TIM Translocase of the inner mitochondrial membrane 
TOM Translocase in the outer membrane of mitochondria 
TREM2 Triggering receptor expressed on myeloid cells 2 
UBQLN2 Ubiquilin 2 
UPS Ubiquitin-proteasome system 
VCP Valosin-containing protein 
WDR41 WD repeat domain 41 
 
  
8
  
 
 
Publications of this thesis 
 
I. A novel CHCHD10 mutation implicates a Mia40-dependent mitochondrial import deficit 
in ALS 
 
Lehmer C, Schludi MH, Ransom L, Greiling J, Junghänel M, Exner N, Riemenschneider H, 
van der Zee J, Van Broeckhoven C, Weydt P, Heneka MT, Edbauer D. 
 
EMBO Mol Med. 2018, doi: 10.15252/emmm.201708558 
 
 
 
II. In situ structure of neuronal C9orf72 poly-GA aggregates reveals proteasome 
recruitment 
 
Guo Q, Lehmer C, Martínez-Sánchez A, Rudack T, Beck F, Hartmann H, Pérez-Berlanga M, 
Frottin F, Hipp MS, Hartl FU, Edbauer D, Baumeister W, Fernández-Busnadiego R. 
 
Cell. 2018, doi: 10.1016/j.cell.2017.12.030 
 
 
 
III. Poly-GP in cerebrospinal fluid links C9orf72-associated dipeptide repeat expression to 
the asymptomatic phase of ALS/FTD  
 
Lehmer C, Oeckl P, Weishaupt JH, Volk AE, Diehl-Schmid J, Schroeter ML, Lauer M, 
Kornhuber J, Levin J, Fassbender K, Landwehrmeyer B; German Consortium for 
Frontotemporal Lobar Degeneration, Schludi MH, Arzberger T, Kremmer E, Flatley A, 
Feederle R, Steinacker P, Weydt P, Ludolph AC, Edbauer D, Otto M.  
 
EMBO Mol Med. 2017, doi: 10.15252/emmm.201607486 
 
 
 
IV. Antibodies inhibit transmission and aggregation of C9orf72 poly‐GA dipeptide repeat 
proteins 
 
Zhou Q, Lehmer C, Michaelsen M, Mori K, Alterauge D, Baumjohann D, Schludi MH, Greiling 
J, Farny D, Flatley A, Feederle R, May S, Schreiber F, Arzberger T, Kuhm C, Klopstock T, 
Hermann A, Haass C, Edbauer D. 
EMBO Mol Med. 2017, doi:  10.15252/emmm.201607054 
 
9
  
 
 
I. Introduction 
1. Frontotemporal Dementia and Amyotrophic Lateral Sclerosis  
Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two severe 
neurodegenerative disorders without cure and with very limited treatment options (Tsai and 
Boxer, 2016). FTD is one of the major causes of early-onset dementia and the third most 
common form of dementia in all age groups worldwide (Bang et al., 2015; Vieira et al., 2013). 
ALS is the most common form of motor neuron diseases (MND). Both FTD and ALS have 
overlapping clinical, pathological and genetic features and therefore are often referred to as the 
extreme ends of a disease spectrum with multisystem degeneration (Ferrari et al., 2011). 
1.1. Clinical, genetic and neuropathological features of FTD, ALS and FTD/ALS 
1.1.1. Clinical features of FTD 
In 1892, FTD was described for the first time by the Czech neuropsychiatrist Arnold Pick in a 
71-year-old man with cognitive defects and aggressive behavior, but normal motor function. 
Autopsy revealed severe brain atrophy in the left hemisphere (Berrios and Girling, 1994). 
Approximately 5-15% of all dementia cases suffer from FTD. Predominantly, presenile 
individuals (< 65 years) are affected by FTD and the disease duration is typically 6-12 years 
(Kansal et al., 2016; Rademakers et al., 2012). The diagnosis of FTD is mainly done by clinical 
assessment and neuroimaging techniques. Atrophy of the frontal lobes can be visualized using 
magnetic resonance imaging (MRI) and computer tomography. Furthermore, changes in brain 
activity can be assessed by measuring glucose metabolism by positron emission tomography 
(PET) (Rascovsky et al., 2011).  
Depending on symptoms, FTD is further classified into different clinical subgroups: Behavioral 
variant frontotemporal dementia (bvFTD) and primary progressive aphasia (PPA), which is 
subdivided into semantic dementia (SD) and progressive non-fluent aphasia (PNFA). Although, 
these syndromes often overlap, a particular feature is usually dominant (Bang et al., 2015; 
Ferrari et al., 2011). Among these variants, bvFTD is the most common form and is mainly 
characterized by cognitive impairment and behavior problems, e.g. changes in personal and 
social conduct, disinhibition, apathy, loss of sympathy or empathy. These symptoms originate 
from degeneration of the frontal lobe (Bang et al., 2015; Hogan et al., 2016; Rosen et al., 2002). 
PPA-patients often present progressive and insidious language impairment interfering with their 
daily life. The two main criteria for SD are anomia and single word comprehension deficits 
caused by degeneration of the anterior lobe. In contrast, atrophy in the left posterior frontal and 
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insular region is predominantly present in PNFA patients who suffer from agrammatism as well 
as hesitant and nonfluent speech (Bang et al., 2015; Gorno-Tempini et al., 2011). 
In later stages, FTD symptoms of the three clinical syndromes often converge, affecting large 
regions in the frontal and temporal lobes and leading to globally impaired cognitive and motor 
deficits. Patients usually die due to pneumonia or other secondary infections (Bang et al., 2015).  
1.1.2. Clinical features of ALS 
ALS was first reported by Jean-Martin Charcot in 1874. He identified ALS as a primary neuronal 
disease, by linking its symptoms to the loss of motor neurons in brain and spinal cord. Charcot 
and his colleague Joffrey observed that lesions in the anterior horn, but not in the lateral column 
of the spinal cord lead to muscle atrophy (Kumar et al., 2011; Rowland, 2001). 
ALS is the most prevalent form of MND and has an average age of onset of 55 years. ALS is 
ruthlessly progressive with 50% of patients dying within 30 months after symptom onset (Chio et 
al., 2013; Ferrari et al., 2011; Kiernan et al., 2011). Diagnosis of ALS consists of a combination 
of physical examination and neurological testing such as nerve conduction studies and 
electromyography. To exclude alternative pathological changes in patients, additional MRI is 
often used (Brooks et al., 2000; Kiernan et al., 2011).  
No biomarkers allow definitive distinction between the pure upper motor neuron disease, primary 
lateral sclerosis (PLS), and the pure lower motor neuron disease, progressive muscular atrophy 
(PMA), during the early stages (Al-Chalabi et al., 2016). Clinically, PLS usually leads to 
hyperreflexia accompanied by spasticity, while PMA is associated with progressive muscle 
weakness and wasting. The main cause for death in ALS patients is respiratory failure (Ferrari et 
al., 2011).  
1.1.3. Clinical features of FTD/ALS  
In 1981, in-depth neuropathological analysis revealed that ALS pathology is often accompanied 
by degeneration of the frontal and frontotemporal regions of the brain, as well as atrophy of the 
substantia nigra and globus pallidus (Ferrari et al., 2011; Hudson, 1981). 
In the following years, cognitive dysfunction and other signs of FTD have been detected in ALS 
patients (up to 50% of patients) and, vice versa, motor deficits have been documented in FTD 
patients suggesting shared pathomechanisms between the two diseases (Burrell et al., 2011; 
Ozel-Kizil et al., 2013; Strong et al., 2003). 
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1.1.4. Genetic evidence and pathological inclusions in FTD/ALS 
Approximately 40% of all FTD patients and 10% of all ALS cases have a positive family history 
suggestive of autosomal dominant inheritance (Rademakers et al., 2012; Snowden et al., 2002; 
Van Damme and Robberecht, 2009).  
In recent years, a number of genes causing pure FTD, ALS or mixed FTD/ALS have been 
identified. Mutations in the microtubule-associated protein Tau (MAPT), progranulin (GRN) or 
less frequently in charged multivesicular body protein 2b (CHMP2B) and triggering receptor 
expressed on myeloid cells 2 (TREM2) are connected to pure FTD (Baker et al., 2006; Borroni et 
al., 2014; Cruts et al., 2006; Hutton et al., 1998; Skibinski et al., 2005). In contrast, mutations in 
the superoxide dismutase 1 (SOD1), TAR DNA-binding protein 43 (TARDBP) and fused in 
sarcoma (FUS) are the most frequent genes associated with pure ALS (Kwiatkowski et al., 2009; 
Rosen et al., 1993; Sreedharan et al., 2008; Vance et al., 2009). In 2011, two groups 
independently identified a massive GGGGCC-repeat expansion mutation upstream of the coding 
region of the chromosome 9 open reading frame 72 gene (C9orf72) (DeJesus-Hernandez et al., 
2011; Renton et al., 2011). These C9orf72 repeat expansions are the most common cause of 
familial FTD/ALS (Majounie et al., 2012; van Blitterswijk et al., 2012). Less common mutations in 
the coiled-coil-helix-coiled-coil-helix domain containing protein 10 (CHCHD10), sequestome 1 
(SQSTM1/p62), optineurin (OPTN), valosin-containing protein (VCP), TANK-binding kinase 1 
(TBK1) and ubiquilin 2 (UBQLN2) are linked to FTD/ALS as well (Fig. 1A) (Bannwarth et al., 
2014; Cirulli et al., 2015; Deng et al., 2011; Fecto et al., 2011; Maruyama et al., 2010; Pottier et 
al., 2015; Rubino et al., 2012; Watts et al., 2004). 
 
Figure 1 Schematic illustration of most common genes and neurophathological inclusions linked to familial FTD and ALS.  
(A) FTD (red) and ALS (blue) are thought as the extreme ends of a disease spectrum. Genes linked to FTD are illustrated in red, to 
ALS in blue and genes associated to both diseases are mixed colored. Genes are arranged based on their frequency in familial 
cases. Adapted from (Guerreiro et al., 2015). (B) Neuropathological protein inclusions in FTD and ALS are classified according to the 
main aggregating protein. TDP-43 and FUS inclusions depict the pathological overlap of these disorders. Adapted from (Ling et al., 
2013). 
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In 2006, the RNA-binding protein (RBP) TDP-43 was identified as the major ubiquitinated protein 
that is present in inclusions of ~45% of FTD and nearly all ALS cases (97%) (Arai et al., 2006; 
Neumann et al., 2006). Subsequently, another RBP, FUS, was found in pathological inclusions 
of FTD patients without TDP-43 pathology resulting in a reclassification of FTD based on the 
main aggregated protein (Mackenzie et al., 2010). Thus, FTD is nowadays divided in FTLD-TAU 
(45%), FTLD-TDP-43 (45%), FTLD-FUS (9%) and FTLD-UPS (ubiquitin-proteasome system, 
1%) (Fig. 1B). Inclusions in TDP-43 and FUS represent the pathological overlap in FTD and 
ALS.  
Altogether, FTD and ALS share several clinical, genetic and pathological features implying 
common pathogenic pathways are involved in disease onset and progression. 
1.2. Pathogenic mechanisms in FTD/ALS 
Similar to other neurodegenerative diseases, multiple pathomechanisms related to protein 
aggregation, protein-homeostasis and mitochondrial functions as well as cell-to-cell transmission 
of protein aggregates that ultimately lead to neuron death, have been described in FTD/ALS 
(Fig. 2). Since two common aggregating proteins in FTD/ALS are RBPs, RNA metabolism plays 
a special role.  
 
Figure 2 Putative pathogenic mechanisms described in FTD/ALS. 
Pathogenic protein aggregates (orange) impair RNA metabolism, autophagy, proteasomal and mitochondrial functions. Moreover, 
cell-to-cell transmission has been described in several neurodegenerative diseases. FTD/ALS associated mutated and/or 
aggregated proteins disrupt these pathways by loss-of-function and/or gain-of-function mechanisms and are listed in red below the 
respective pathway. 
13
  
 
 
The nuclear proteins TDP-43 and FUS are involved in multiple steps of RNA processing but both 
proteins form cytoplasmic aggregates in different subtypes of FTD and ALS (Fig. 1) (Neumann 
et al., 2006; Vance et al., 2009). Cells with cytoplasmic TDP-43 and FUS aggregates show 
pronounced nuclear clearance of the respective protein suggesting that nuclear loss-of-function 
(LOF) and cytoplasmic gain-of-function (GOF) mechanisms may contribute to disease (Ling et 
al., 2013; Vance et al., 2009). Rare mutations in the aggregation-prone low complexity domain 
(LCD) of TDP-43 and FUS lead to FTD and ALS and promote protein aggregation (King et al., 
2012). LCDs mediate reversible liquid-liquid phase separation into liquid droplet and transition to 
more solid hydrogel states (Conicella et al., 2016; Murakami et al., 2015), which is crucial for the 
physiological formation of dynamic RNA containing compartments like stress granules (Alberti 
and Hyman, 2016; Courchaine et al., 2016). Since TDP-43 and FUS inclusions contain stress 
granule proteins, it has been suggested that liquid droplets/stress granules are precursors to 
pathological aggregates in FTD/ALS (Alberti and Hyman, 2016; King et al., 2012; Ling et al., 
2013). 
Moreover, the expanded repeat RNA in C9orf72 FTD/ALS, forms nuclear RNA foci that are 
thought to sequester various RBPs and thereby impair their function (Cooper-Knock et al., 2014; 
Mori et al., 2013b). Unconventional translation of sense and antisense repeat transcripts results 
in five aggregating dipeptide repeat (DPR) proteins (poly-GA, -GP, -GR, -PA, -PR), unique to 
C9orf72 patients (Mori et al., 2013a; Mori et al., 2013c). Of those DPR proteins, poly-GR 
and -PR interfere with many LCD-containing RBPs and thereby disrupt their phase separation 
ability (Lee et al., 2016). 
Since the research focus of this thesis is on FTD/ALS-causing mutations in C9orf72 and 
CHCHD10, with a focus on protein aggregation, impaired protein degradation, cell-to-cell 
transmission and mitochondrial impairment, I will describe these pathways in the following 
paragraphs in more detail. 
1.2.1. Protein homeostasis 
The term protein homeostasis describes cellular processes that together maintain the proteome 
intact. Protein biogenesis, folding, trafficking and degradation are tightly controlled and 
coordinated by a complex network. Proteins are co-translationally folded with the help of 
chaperons that recognize misfolded proteins with hydrophobic residues on the protein surface 
and/or incorrect disulfide bond formation. However, some proteins remain misfolded or later 
aggregate due to mutations or cellular stressors such as oxygen radicals or heavy iron metals. 
Protein misfolding and aggregation may cause LOF and GOF mechanisms. Therefore, an intact 
protein quality control system with chaperons, which are constantly monitoring protein folding, is 
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crucial for cells. If misfolded proteins cannot be refolded in their correct conformation, they are 
normally targeted to and finally eliminated by the major protein clearance pathways: autophagy 
and the UPS (Fig. 3) (Ciechanover and Kwon, 2015; Shahheydari et al., 2017; Webster et al., 
2017). 
 
Figure 3 Main degradation pathways of misfolded proteins.  
Cellular chaperons constantly facilitate refolding of misfolded proteins. Misfolded proteins are guided to the UPS by poly-ubiquitin 
(Ub) chains that are added by the three enzymes (E1, E2 and E3). After ubiquitination, those proteins are targeted to the 26S 
proteasome for proteolysis. Misfolded proteins that cannot be degraded via the UPS form poly-ubiquitinated cytoplasmic inclusions 
which are delivered to the autophagosome via the adaptor SQSTM1/p62. Subsequently, fusion of the autophagosome with the 
lysosome occurs forming the autophagolysosome and leading to aggregate digestion by lysosomal hydrolases. Adapted from 
(Ciechanover and Kwon, 2015). 
 
The UPS and its dysfunction in FTD/ALS 
The UPS is a primary route for degradation of short-lived and misfolded proteins. First, lysine 
residues of misfolded proteins are marked by ubiquitin chains added through a specific cascade 
of three major enzymes: the ubiquitin activating (E1), the ubiquitin conjugating (E2) and the 
ubiquitin ligating (E3) enzyme (Shahheydari et al., 2017). Then, poly-ubiquitinated proteins are 
recognized and degraded by the 26S proteasome. The proteasome is a multimeric adenosine 
triphosphate (ATP)-dependent protease complex containing one or two 19S regulatory cap 
subunits and a proteolytic 20S core chamber. After poly-ubiquitinated substrates are bound and 
unfolded by the 19S subunit, they are guided into the 20S core particle. The latter has 
chymotrypsin-like, trypsin-like and caspase-like catalytic activities cleaving substrates into small 
peptides (Driscoll and Goldberg, 1989; Eytan et al., 1989; Heinemeyer et al., 1997; Voges et al., 
1999).  
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Evidence from familial and sporadic cases of ALS supports proteasome dysfunction in disease. 
Pathogenic mutations inhibit substrate delivery to the proteasome (VCP, UBQLN2) and overall 
proteasome activity (SOD1, VCP) (Cheroni et al., 2009; Dai and Li, 2001; Deng et al., 2011; Ko 
et al., 2004; Webster et al., 2017). Additionally, sporadic ALS cases have decreased 20S 
proteasome subunit levels and impaired proteasomal activity in spinal cord (Kabashi et al., 
2012). Conditional knock out (KO) of the proteasome subunit Rpt3 in mice results not only in 
motor neuron degeneration and locomotor defects but also in TDP-43 and FUS containing 
inclusions (Tashiro et al., 2012). In addition, the poly-GA and -PR DPR species in C9orf72 
FTD/ALS have been linked to UPS dysfunction. Poly-GA causes cellular toxicity and traps UPS 
components, however, the mechanistic link of protein aggregation to impaired UPS function is 
unclear (Gupta et al., 2017; May et al., 2014). 
 
The autophagy pathway and its dysfunction in FTD/ALS 
Autophagy is a cellular pathway for degrading cytoplasmic components like misfolded proteins 
or damaged organelles and is especially important in post-mitotic cells such as neurons. 
Misfolded proteins are recruited via autophagy receptors, like SQSTM1/p62 and OPTN, to the 
growing phagophore. The phagophore engulfs the cargo by forming a double membrane 
compartment, the so-called autophagosome. Fusion with lysosomes results to degradation of its 
content by hydrolases (Webster et al., 2017). 
Several genes mutated in familial FTD/ALS are involved in distinct stages of autophagy, e.g. 
initiation (C9orf72), substrate delivery to the autophagosome (UBQLN2, OPTN, SQSTM1/p62, 
TBK1), maturation of the autophagosome (VCP) and autophagic degradation (CHMP2B) 
(Filimonenko et al., 2007; Goode et al., 2016; Ju et al., 2009; Maruyama et al., 2010; Osaka et 
al., 2015; Webster et al., 2016; Webster et al., 2017). Furthermore, mice lacking essential 
autophagy genes, like Atg5 or Atg7, show poly-ubiquitinated inclusions, axonal dystrophy, 
neurodegenerative symptoms and impaired motor function (Hara et al., 2006; Komatsu et al., 
2006).  Since C9orf72 is part of the autophagy initiation complex (Sellier et al., 2016; Webster et 
al., 2016) and decreased levels of the C9orf72 protein have been described in patient brain 
(Waite et al., 2014), impaired autophagy may contribute to disease pathogenesis. Ubiquitin and 
SQSTM1/p62 are enriched in the cytoplasmic inclusions in FTD/ALS (Al-Sarraj et al., 2011; Mori 
et al., 2013a; Neumann et al., 2006; Vance et al., 2009). The cytoplasmic TDP-43, FUS and the 
DPR proteins are probably not sufficiently degraded by the impaired autophagic system and 
accumulate in insoluble inclusions in FTD/ALS (Webster et al., 2016). Taken together, these 
indicate that autophagy is crucial for neuronal health and has a primary role in the pathogenesis 
of FTD/ALS. 
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Seeding and spreading mechanisms 
Prion diseases are a group of rare fatal neurodegenerative disorders characterized by misfolded 
prion protein (PrP) that is orally transmissible. The first prion disease described in humans was 
Creutzfeldt-Jakob disease (Zabel and Reid, 2015). The infectious cycle starts with a 
conformational change of normal α-helical PrPC to a β-sheet-rich conformation termed PrP 
scrapie (PrPSc). PrPSc triggers conversion of further PrPC into the pathological PrPSc 
conformation in a positive feedback loop that is associated with extremely fast clinical disease 
progression (Jucker and Walker, 2011).  
Later, prion-like templated-aggregation was described as a characteristic feature in common 
non-infectious neurodegenerative diseases for extracellular and intracellular aggregating 
proteins: β-amyloid (Aβ) peptide and tau in Alzheimer´s disease (AD), α-synuclein in Parkinson´s 
disease (PD) and huntingtin in Huntington´s disease (Jucker and Walker, 2011; Luk et al., 2012; 
Sanders et al., 2014). Biophysical characterization and recently cryo-electron tomography 
analyses clearly show that these macromolecular aggregates form β-sheet-rich amyloid fibrils 
(Bauerlein et al., 2017; Fitzpatrick et al., 2017; Guerrero-Ferreira et al., 2018; Schmidt et al., 
2015). For intracellular aggregates template directed aggregation is associated with cell-to-cell 
transmission possibly along synaptic connections. Here, misfolded proteins with amyloid-like 
conformation, serve as templates for further aggregation of native proteins in the receiver cell 
(Fig. 4). This is the molecular correlate of the spreading of Tau pathology through the brain 
during progression of Alzheimer’s disease (Braak and Braak, 1991). 
 
Figure 4 Prion like cell-to-cell transmission of aggregates.   
Misfolded proteins form a seed of aggregation and thereby initiate misfolding of wildtype proteins leading to further seeded 
aggregation. Afterwards, aggregates are released to the extracellular space where they are uptaken by neighboring cells. Here, 
aggregates further induce misfolding and aggregation. Adapted from (Ling et al., 2013). 
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In familial ALS, this prion-like phenomenon was also reported for mutant SOD1, which forms 
fibrils, aggregates with misfolded wildtype protein and shows spreading abilities (Chattopadhyay 
et al., 2008; Grad et al., 2011; Munch et al., 2011). Furthermore, TDP-43 and FUS contain LCDs 
that might contribute to aggregation and seeding (Gitler and Shorter, 2011; Johnson et al., 2008) 
and several in vitro studies demonstrate amyloidogenic features of TDP-43 and FUS (Guo et al., 
2018; Murray et al., 2017).  Insoluble TDP-43, isolated from FTD or ALS patient brains with 
TDP-43 pathology, triggers aggregation of transfected TDP-43 in cultured cells (Nonaka et al., 
2013). Additionally, neuropathological studies of FTLD-TDP-43 cases suggest propagation of 
phosphorylated TDP-43 aggregates in patient brain along anatomical connections 
(Brettschneider et al., 2014). Altogether, these findings suggest a prion-like spreading 
mechanism exists in FTD/ALS.   
Although, short DPR peptides are taken up by cells (Chang et al., 2016; Kwon et al., 2014), 
release and uptake of larger aggregates has not been shown. Studying seeding and spreading 
of DPR proteins is crucial as the poor spatial correlation of all C9orf72-specific changes, 
including DPR inclusions with TDP-43 pathology and neurodegeneration, suggests the non-cell 
autonomous and/or synergistic effects are crucial for C9orf72 pathogenesis. 
1.2.2. Mitochondria  
Mitochondria are essential cellular organelles that regulate energy metabolism, calcium 
homeostasis and apoptosis. Neurons completely depend on an aerobic metabolism and 
mitochondrial calcium homeostasis, e.g. for regulating neurotransmitter release (Fig. 5). 
Moreover, mitochondria are also the main source of reactive oxygen species (ROS) leading to 
oxidative stress, e.g. damages of mitochondrial DNA, proteins and membranes (Fig. 5A). 
Oxidative stress can even induce Cytochrome C release resulting in apoptosis (Fig. 5C).  
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Figure 5 Overview of three major mitochondrial features.  
Mitochondria are essential for many cellular processes. (A) Mitochondria produce most cellular ATP. At the inner mitochondrial 
membrane (IMM), electrons (e-) from NADH and FADH2 pass through the electron transport chain complexes (I-IV) to oxygen (O2) 
reducing it to water (H2O). The released energy is used to generate a proton (H+) gradient across the IMM by actively pumping H+ 
into the intermembrane space (IMS). Finally, ADP is phosphorylated to ATP by the ATP-synthase complex V with the energy of the 
H+ gradient (Hatefi, 1985). Mitochondria are also the major reactive oxygen species (ROS) producers, which can lead to further 
oxidative damage in mitochondria. (B) Mitochondria are capable for storing calcium (Ca2+) and are therefore important for the cellular 
Ca2+ homeostasis. Ca2+ is taken up into the matrix by the mitochondrial Ca2+ uniporter in the IMM (Contreras et al., 2010). (C) The 
intrinsic/mitochondrial apoptotic pathway is characterized by permeabilisation of the outer mitochondrial membrane (OMM) and 
release of Cytochrome C (CytC) into the cytoplasm. CytC is the major inducer of caspase activation downstream of 
mitochondria. First, CytC is involved in the formation of the apoptosome (purple star), a multi-protein complex initiating the 
activation of the caspase cascade through caspase 9. Caspase 9 activates caspase 3 leading to cell death (Elmore, 2007).  
Post-mitotic neurons are vulnerable to accumulation of damage arising from impaired 
mitochondria (Smith et al., 2017). In PD, mitochondrial DNA damage, compromised mitophagy 
and dysfunctional respiratory chain complexes have been observed in patient brains providing a 
solid link between neurodegeneration and mitochondrial impairment (Dolle et al., 2016; Gao et 
al., 2017). In familial ALS, mutant SOD1 accumulates to mitochondria, whereby overexpression 
models show impaired electron transport, inefficient calcium buffering, altered mitochondrial 
morphology and aberrant import mechanism (Damiano et al., 2006; Li et al., 2010; Magrane et 
al., 2012). It is associated with cellular energy imbalance, apoptosis and impaired calcium 
homeostasis (Fig. 5) (Magrane et al., 2014). Additionally, mutations in SOD1 lead to misfolding 
on mitochondrial membranes resulting in a toxic GOF (Vande Velde et al., 2011). Similarly, 
translocation of mutant FUS to mitochondria seems to have an important role in disease 
progression (Deng et al., 2015). Colocalization of TDP-43 with mitochondria in motor neurons 
correlates with damage to mitochondria (Wang et al., 2013). Furthermore, the repeat expansions 
in C9orf72 are linked to mitochondrial dysfunction via characteristic DPR aggregates with poly-
GR, that induce oxidative stress and alterations of mitochondrial architecture (Lopez-Gonzalez 
et al., 2016). Moreover, mutations in mitochondrial CHCHD10 are linked to FTD/ALS, but some 
geneticists are concerned by the low penetrance. Since the precise molecular function of 
CHCHD10 and the molecular mechanism of CHCHD10 mutations remain largely unknown, 
further functional analyses are required. 
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2. C9orf72 –mutations are the most common cause of familial FTD/ALS 
Five years after a locus on chromosome 9p21, associated with FTD and ALS, was identified, two 
groups finally pinpointed the mutation to a GGGGCC- repeat expansion located in a non-coding 
region of the C9orf72 gene (DeJesus-Hernandez et al., 2011; Morita et al., 2006; Renton et al., 
2011; Vance et al., 2006). This mutation is by far the most common known genetic cause of FTD 
and ALS with a prevalence of roughly 25% in familial FTD and 34% in familial ALS in Europe. An 
additional 5% of sporadic FTD and ALS are caused by the C9orf72 mutation (Ng et al., 2015; 
Zou et al., 2017). Clinically, C9orf72 patients have been reported to show a younger age of 
onset, a higher frequency of cognitive deficits and a faster disease progression compared to 
non-C9orf72 FTD/ALS patients (Byrne et al., 2012; Chio et al., 2012).  
2.1. Function and genetic link to FTD/ALS 
The first hint for the cellular functions of the C9orf72 protein came from identification of a so-
called differentially expressed in normal and neoplastic cells (DENN) domain within C9orf72 
suggesting it could act as a guanine nucleotide exchange factor (GEF) of small GTPases, e.g. 
the Rab protein family, comparable to other members of the DENN-like superfamily. Rab 
GTPases are molecular switches involved in several steps of cellular membrane trafficking 
(Levine et al., 2013). Indeed, C9orf72 forms a complex with WDR41 and SMCR8, another 
DENN protein, and interacts with several Rab proteins suggesting C9orf72 might play a role in 
endocytosis and autophagy (Fig. 6C) (Farg et al., 2014; Sellier et al., 2016).  
Three broadly expressed C9orf72 transcripts potentially result in two distinct isoforms of the 
protein. The longer protein product is by far most abundant and is localized to the cytoplasm 
(Saberi et al., 2018). The FTD/ALS linked GGGGCC-repeat expansion is present between the 
two non-coding exons 1a and 1b. Depending on the transcript, the GGGGCC-repeat is either 
located in intron 1 (for V1 and V3) or in the promoter region (for V2) (Fig. 6) (DeJesus-
Hernandez et al., 2011). 
2.2. Current hypothesis of C9orf72 disease related pathomechanisms 
How the GGGGCC-repeat expansion in C9orf72 causes FTD/ALS remains elusive. Both LOF 
and GOF mechanisms through three main mechanisms have been discussed. First, the 
GGGGCC-repeat expansion impairs expression of the longer isoform and may thus cause 
C9orf72 haploinsufficiency. Second, the GGGGCC sense and antisense repeat transcripts 
accumulate in RNA foci that are thought to sequester RBPs (RNA toxicity). Third, repeat 
containing transcripts are unconventionally translated into DPR proteins, which form aggregates 
and trap important cellular proteins (protein toxicity) (Fig. 6) (Edbauer and Haass, 2016). 
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Figure 6 Overview of current hypothesis of C9orf72 repeat expansion mediated pathogenic mechanisms. 
The human C9orf72 gene (grey: non-coding region; green: coding exons) harbors a hexanucleotide (GGGGCC)n repeat expansion 
(purple) between the alternative exons 1a and 1b. Three C9orf72 transcripts are produced. Sense and antisense transcription of the 
repeat RNA also occurs. The three mutually non-excluse pathomechanisms are depicted (see text). Adapted from (Gitler and Tsuiji, 
2016; Ling et al., 2013). 
Based on these three hypothesized mechanisms, many research groups made huge efforts to 
decipher and verify the individual processes. Both, mRNA and protein levels have been reported 
to be reduced in C9orf72 FTD/ALS cases suggesting haploinsufficiency as a possible disease 
cause (DeJesus-Hernandez et al., 2011; Waite et al., 2014). Although C9orf72 knock down (KD) 
in zebrafish led to reduced axon length of motor neurons and locomotion impairment, C9orf72 
ablation in neuron specific KO mice did not show any FTD/ALS-like pathology, such as motor 
neuron degeneration, or motor defects (Ciura et al., 2013; Koppers et al., 2015). Complete KO of 
C9orf72 causes systemic inflammation in mice (Sudria-Lopez et al., 2016). Therefore, C9orf72 
LOF is likely not the main driving mechanism of FTD/ALS but could contribute to disease by 
inhibiting autophagy or promoting inflammation (Fig. 6C) (Sellier et al., 2016; Webster et al., 
2016; Yang et al., 2016).  
Interestingly, it has been shown, that both sense and antisense repeat transcripts form stable 
inter- and intramolecular structures, such as G-quadruplexes (G-Q), R-loops or hairpins, in 
C9orf72 patients. Nuclear RNA foci are found in many cell types and may sequester crucial 
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RBPs (e.g. hnRNPs), and thereby impair overall RNA metabolism (Fig. 6A) (Cooper-Knock et 
al., 2014; Gendron et al., 2013; Kumar et al., 2016; Mori et al., 2013b). 
Repeat associated non-AUG translation was first discovered for CAG repeats in spinocerebellar 
ataxia type 8 (SCA8) and Myotonic dystrophy type 2 (DM2), and has since been reported in 
other repeat expansion disorders (Zu et al., 2011). Surprisingly, even the intronic 
GGGGCC-expansion in C9orf72 is translated in all reading frames into coaggregating DPR 
proteins: poly-glycine-alanine (GA), poly-glycine-proline (GP), poly-glycine-arginine (GR), poly-
proline-arginine (PR) and poly-proline-alanine (PA) (Fig. 6B). These DPR proteins form 
pathological inclusions in neurons of C9orf72 patients. Poly-GA is most abundant in patients 
followed by poly-GP and poly-GR (Mori et al., 2013a; Mori et al., 2013c). DPR inclusions 
colocalize with SQSTM1/p62 in star-shaped cytoplasmic, nuclear, or neuritic inclusions, and only 
rarely colocalize with TDP-43 (Mori et al., 2013c). Several studies showed toxicity of the different 
DPR species in distinct cellular systems, primary neurons, and mice (Jovicic et al., 2015; May et 
al., 2014; Schludi et al., 2017; Yamakawa et al., 2015; Zhang et al., 2016). Poly-GA is highly 
aggregation prone in vitro and GA15 peptides form β-sheet structures with cell-to-cell 
transmission properties (Chang et al., 2016). Poly-GA inclusions trap essential cellular proteins, 
including various components of the UPS, which leads to UPS impairment and thus to toxicity 
(May et al., 2014; Yamakawa et al., 2015; Zhang et al., 2016; Zhang et al., 2014). The arginine 
rich DPR species, poly-GR and poly-PR, trigger nucleolar stress, nuclear transport impairment, 
and RNA processing alterations. Furthermore, they interact with the translation complex and 
ribosomal proteins, thereby impairing overall protein translation and causing neurotoxicity 
(Kanekura et al., 2016; Mizielinska et al., 2014).  
However, it still remains unknown how DPR aggregates exactly contribute to C9orf72 FTD/ALS. 
A better resolution of DPR aggregate structure would provide relevant information, e.g. to 
unravel spreading properties of distinct DPR aggregates or to help to identify interacting cellular 
organelles or macromolecules. 
Of note, in end-stage patient brains neither DPR pathology, RNA foci nor C9orf72 mRNA/protein 
levels robustly correlate with neurodegeneration (Mackenzie et al., 2013). However, the 
temporal course of events cannot be deciphered via post-mortem studies for a rare disease such 
as FTD/ALS. Several neuropathology case reports suggest DPR accumulation starts early in 
disease, before TDP-43 pathology is present, but further cross-sectional and ideally longitudinal 
studies are required to clarify the role of DPR proteins in C9orf72 FTD/ALS pathogenesis 
(Baborie et al., 2015; Proudfoot et al., 2014; Vatsavayai et al., 2016). For this purpose, poly-GP 
might be a suitable biomarker candidate not only because of its relatively high solubility but also 
due to its high expression throughout the central nervous system (CNS) (Peters et al., 2015; 
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Schludi et al., 2015). Furthermore, poly-GP has been detected in cerebrospinal fluid (CSF) in a 
small case series of C9orf72 FTD/ALS (Su et al., 2014). It is unknown whether extracellular poly-
GP reaches the CSF by unconventional secretion or by release from dead cells. Developing an 
in vivo biomarker for repeat translation will be important for preclinical studies, e.g. to monitor 
potential therapies. 
 
3. CHCHD10 - A mitochondrial link to FTD/ALS 
Mitochondria have long been suspected to play a causative, primary role in ALS pathogenesis, 
which was supported by the identification of a CHCHD10 missense mutation (S59L) in a family 
with late onset myopathy and motor and cognitive phenotypes, including MND- and FTD-like 
symptoms (Bannwarth et al., 2014). 
3.1. Structural features and mitochondrial import  
CHCHD10 encodes a soluble 142 amino acid (aa) protein, which is predominantly present in the 
IMS of mitochondria (Bannwarth et al., 2014). It consists of a positively charged N-terminus, a 
central hydrophobic helix and a CHCH domain located at the C-terminal region of the protein 
(Ajroud-Driss et al., 2015; Cozzolino et al., 2015; Perrone et al., 2017) (Fig. 7A). CHCH domains 
are mainly found in mitochondrial localized proteins and are involved in metal binding and in 
protein import in the IMS (Banci et al., 2009b). For other members of the CHCH protein family, 
disulfide bridge formation within two Cysteine-X9-Cysteine (CX9C) motifs stabilizes the protein 
and has been linked to mitochondrial import (Fig. 7B).  
 
Figure 7 Structure of CHCHD10 and its CHCH domain. 
(A) The N-terminal end of CHCHD10 is often referred to as a putative mitochondrial targeting signal (MTS?, blue) and is followed by 
a hydrophobic (purple) and a C-terminal CHCH domain (green). (B) Between two CX9C motifs, disulfide bonds are formed in the 
CHCH domain of CHCHD10. 
Nearly all mitochondrial proteins are encoded in the nucleus, synthesized as cytosolic precursor 
proteins and transported into mitochondria via diverse import machineries (Harmey et al., 1977; 
Modjtahedi et al., 2016; Zhou et al., 2017). The translocase in the outer membrane of 
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mitochondria (TOM) complex is the first contact for proteins entering the mitochondria (Hase et 
al., 1983; Kang et al., 2017; Kiebler et al., 1990; MacPherson and Tokatlidis, 2017). Targeting 
signals within the immature precursor proteins guide them on different transport routes to their 
final mitochondrial localization.  
β-barrel proteins harbor a β-signal and are handed over to the small translocase of the inner 
mitochondrial membrane (TIM) chaperons in the IMS where they are subsequently delivered to 
the outer mitochondrial membrane (OMM) via the sorting and assembly machinery (SAM) 
complex (Kozjak et al., 2003; Lutz et al., 2003; Paschen et al., 2003). The import pathway of 
hydrophobic carrier proteins that are present in the IMM of mitochondria is also mediated by 
small TIM chaperons in conjunction with the translocase TIM22 complex (Dudek et al., 2013; 
Kerscher et al., 1997; MacPherson and Tokatlidis, 2017; Sirrenberg et al., 1996). Moreover, the 
TIM23 complex is the central junction of the mitochondria import pathway for presequence 
containing proteins. Such proteins are either inserted into the IMS or imported to the matrix. For 
matrix translocation an additional motor, named presequence translocase associated import 
motor (PAM), is required. After entering the matrix, presequences are proteolytically cleaved by 
mitochondrial processing peptidases (MPP) (Dudek et al., 2013; Frazier et al., 2004; Kozany et 
al., 2004). Proteins of the IMS, that harbor a cysteine-rich signal (CXnC), typically located in a 
CHCH domain, are imported via the mitochondrial intermembrane space import and assembly 
(Mia) pathway (Fig. 8) (Chacinska et al., 2004). Thus, the Mia pathway could also mediate 
import of CHCHD10, although it also has a predicted N-terminal presequence. 
 
Figure 8 Mitochondrial import pathways.  
Precursor proteins such as β-barrel proteins, carrier proteins, presequence containing proteins and proteins with cysteine-rich 
signals (CXnC) are imported in a post-translational manner via specific pathways (see text). The majority of mitochondrial proteins 
enter the mitochondria through the TOM complex. Adapted from (Dudek et al., 2013). 
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The oxidoreductase Mia40 contains two essential structural and functional elements: An N-
terminal redox active cysteine-proline-cysteine (CPC) motif and a C-terminal hydrophobic 
substrate binding cleft (Kawano et al., 2009). Human Mia40 physically interacts with the 
membrane-bound apoptosis inducing factor (AIF) (Hangen et al., 2015; Hofmann et al., 2005; 
Kawano et al., 2009). Mia40 additionally plays a key role in the import of small IMS proteins by 
catalyzing their intact oxidative folding and maturation via covalent disulfide bridges formation 
(Banci et al., 2009a; Weckbecker et al., 2012). Precursor proteins enter the IMS via the TOM 
complex and first interact with the hydrophobic binding pocket of Mia40 (Peleh et al., 2016). 
Oxidized Mia40 then forms transient intermolecular disulfide bonds with free cysteine residues, 
located either in CX3C or CX9C motifs of substrate proteins (Kawano et al., 2009). After complete 
disulfide bond formation, oxidized proteins are released into the IMS and Mia40 remains in its 
reduced state. Re-oxidation of Mia40 is mediated by Erv1 (essential for respiration and 
vegetative growth), a FAD-linked sulfhydryl oxidase (Lee et al., 2000; Muller et al., 2008). 
Subsequently, reduced Erv1 shuttles its electrons to CytC, where they finally enter the 
respiratory chain via the CytC oxidase (COX) complex (Fig. 9) (Dabir et al., 2007).  
 
Figure 9 The Mia40 mediated IMS import pathway. 
Cysteine-rich precursor proteins enter the IMS via the TOM complex. Mia40 forms intermediate disulfides with the emerging 
precursor proteins and catalyzes their oxidation and folding. After complete disulfide bond formation, the proteins are released into 
the IMS. Mia40 itself is reduced and requires oxidation by Erv1. Erv1 transfers electrons directly to CytC where they are finally 
transferred to the COX complex of the respiratory machinery. Adapted from (Dudek et al., 2013; Stojanovski et al., 2008). 
Due to its interspaced conserved arginine residues, several bioinformatic prediction tools 
suggest a classical N-terminal mitochondrial targeting signal (MTS) for CHCHD10. Therefore, 
the N-terminus is often referred as putative MTS (aa 1-16) in literature (Cozzolino et al., 2015; 
Perrone et al., 2017). Since mutations in the N-terminal region (R15L, R15S) still localize to 
mitochondria and mutations in the CHCH domain (Q108*) have not been functionally studied so 
far, it is not clear how CHCHD10 is imported to mitochondria (Ajroud-Driss et al., 2015; Woo et 
al., 2017). 
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3.2. Function and genetic link to FTD/ALS 
Although the exact molecular function of CHCHD10 is still unknown, previous work suggests a 
role in mitochondrial morphology, cristae structure integrity, as well as stability of the 
mitochondrial genome (Bannwarth et al., 2014; Genin et al., 2016). Additionally, it has been 
reported that CHCHD10 is part of the mitochondrial contact site and cristae organizing system 
(MICOS) complex, which is crucial for the formation and integrity of mitochondrial cristae 
structure (Genin et al., 2016). Together, CHCHD10 and CHCHD2, another CHCH containing 
protein that is associated with PD, form complexes that play a key role in cellular respiration, 
especially under stress conditions (Burstein et al., 2018; Straub et al., 2018). Furthermore, it was 
found that CHCHD10 enables phosphorylation of CHCHD2 by recruiting Abl2 kinase and 
thereby stimulating COX activity in mitochondria (Purandare et al., 2018). Rapid protein turnover 
argues for a regulatory function of CHCHD10, i.e. for metal transport and respiratory chain 
complex assembly (Burstein et al., 2018). Some argue CHCHD10 may also enter the nucleus 
and repress genes harboring an oxygen responsive element (ORE) or help to retain TDP-43 in 
the nucleus (Purandare et al., 2018; Woo et al., 2017).  
After the identification of the first missense mutations S59L in CHCHD10, other labs screened 
CHCHD10 in several distinct cohorts of ALS, FTD or mitochondrial myopathy (MM) patients and 
identified many additional missense mutations (Fig. 10) (Ajroud-Driss et al., 2015; Auranen et 
al., 2015; Blauwendraat et al., 2018; Brockmann et al., 2018; Burstein et al., 2018; Chaussenot 
et al., 2014; Dols-Icardo et al., 2014; Genin et al., 2016; Jiao et al., 2016; Johnson et al., 2014; 
Kurzwelly et al., 2015; Muller et al., 2014; Penttila et al., 2017; Perrone et al., 2017; Rubino et 
al., 2018; Straub et al., 2018; Wong et al., 2015; Woo et al., 2017; Xiao et al., 2017). 
 
Figure 10 Reported CHCHD10 variants in families with ALS, FTD, FTD/ALS or MM.  
CHCHD10 mutations and their localization in the respective regions: putative MTS (blue), hydrophobic (purple) and CHCH (green) 
domain. 
CHCHD10 variants, identified in FTD/ALS families, cluster in the N-terminus suggesting a 
functional relevance. However, a clear pathogenic mechanism has not been shown for any of 
these variants (Table 1). Pathogenicity has essential been ruled out for P34S based on genetic 
data. 
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Table 1 Reported CHCHD10 variants linked to ALS, FTD, FTD/ALS or MM and their putative pathogenic phenotypes in 
patient material, cellular and in vivo models.  
variant disease pathogenic phenotypes reference 
patient cells/in vivo 
P12S ALS - - Dols-Icardo et al. 
R15L ALS 
 
fibroblasts: 
reduced protein level, 
mitochondrial hyperfusion, 
respiration deficiency, 
altered OXPHOS 
complexes 
LCL: 
reduced protein level, 
reduced mRNA  
HEK293: 
increased protein degradation 
reduced mito. colocalization 
reduced ATP synthesis 
reduced mito. mRNA level 
NIH3T3: 
fragmented mitochondria 
reduced mito. colocolocalization 
TIA-1 granule induction  
cyto. TDP-43 accumulation 
neurons: 
cyto. TDP-43 accumulation 
reduced pre-/postsynaptic integrity 
HT22: 
increased TDP-43 ind. apoptosis 
transduced mice: 
synaptic damage 
Brockmann et al., Burstein et al., 
Müller et al., Johnson et al., 
Kurzwelly et al., Straub et al., 
Woo et al.  
R15S MM - - Ajroud-Driss et al.  
H22Y FTD - - Jiao et al. 
P23L/S FTD - - Jiao et al. 
P23T FTD - - Zhang et al. 
A32D FTD - - Jiao et al. 
P34S ALS, FTD - HeLa:  
reduced mito. nucleoids  
Brockmann et al., Chaussenot et 
al., Dols-Icardo et al., Genin et 
al., Ronchi et al., Wong et al., 
Zhang et al. 
A35D FTD,AD - - Xiao et al., Zhang et al. 
V57E FTD - - Jiao et al. 
G58R MM - HEK293:  
fragmented mitochondria  
Ajroud-Driss et al.  
S59L FTD/ALS muscle:  
ragged-red/COX-negative 
fibres,  
mtDNA deletions,  
respiration deficiency, 
altered OXPHOS 
complexes 
fibroblasts:  
fragmented mitochondria, 
ultrastructural alterations, 
respiration deficiency, 
altered OXPHOS 
complexes, 
reduced nucleoids, 
partial MICOS 
disassembly 
HeLa:  
fragmented mitochondria, 
ultrastructure alterations, 
reduced nucleoids 
Hek293: 
punctate distribution 
reduced mito. colocalization 
reduced ATP synthesis 
reduced mito. mRNA level 
NIH3T3: 
fragmented mitochondria 
reduced mito. coloclocalization 
TIA-1 granule induction  
cyto. TDP-43 accumulation 
neurons: 
cyto. TDP-43 accumulation  
reduced pre-/postsynaptic integrity 
HT22: 
increased TDP-43 ind. apoptosis 
transduced mice: 
synaptic damage 
Bannwarth et al., Blauwendraat 
et al., Burstein et al., Genin et 
al., Woo et al.  
G66V ALS fibroblasts: 
reduced protein level 
HEK293: 
increased protein degradation, 
respiration deficiency, 
increased ROS 
Auranen et al., Brockmann et al., 
Müller et al., Penttilä et al., 
Purandare et al. 
P80L ALS - HEK293:  
respiration deficiency, 
increased ROS 
Ronchi et al., Zhang et al., 
Purandare et al. 
Q82* FTD - - Dols-Icardo et al. 
P96T MM, ALS, 
FTD 
- - Dols-Icardo et al., Rubino et al., 
Teysso et al. 
Q108* FTD LCL: 
NMD of mutant transcript 
- Perrone et al.  
Abbreviations: Lymphoblastoid cell lines (LCL), mitochondrial (mito.) nonsense-mediated mRNA decay (NMD), oxidative 
phosphorylation (OXPHOS), T-cell intracellular antigen 1 (TIA-1). 
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3.3. Current hypothesis of CHCHD10 disease-related pathomechanisms 
Since very little is known about the exact molecular pathomechanisms of CHCHD10 variants, 
the debate about a LOF or a GOF mechanism is still ongoing. 
Reduced steady state protein levels of CHCHD10 mutants and decreased mRNA support a LOF 
mechanism (Brockmann et al., 2018; Straub et al., 2018). Additionally, respiration defects as 
well as decreased COX activity and ATP levels were reported upon CHCHD10 KD, in patient 
fibroblasts and KO cells (Purandare et al., 2018; Straub et al., 2018). In vivo experiments in C. 
elegans revealed that KO of har-1, the orthologue of mammalian CHCHD10, lead to reduced 
life-span and significant locomotion deficits. Moreover, mutant proteins (R15L, S59L) fail to 
rescue the KO phenotype in C. elegans (Woo et al., 2017; Zubovych et al., 2010). In vivo 
experiments with CHCHD10 KD zebrafish models further strengthened a LOF mechanism, since 
KD caused axonal motoneuron pathology, abnormalities in myofibrillar structure and motility 
deficits (Brockmann et al., 2018). However, recent CHCHD10 KO mice showed neither any 
characteristic symptoms for neurodegenerative diseases nor mitochondrial abnormalities in 
brain, muscle and heart as shown in human patient fibroblasts with reduced CHCHD10 (Burstein 
et al., 2018; Straub et al., 2018). Since impaired respiration could only be detected in muscle but 
not in brain of these mice, cell type specific effects might play an essential role in the CHCHD10 
underlying pathogenesis (Burstein et al., 2018).  
Several studies with patient cells or transiently transfected cellular models reported DNA 
instability, mitochondrial fragmentation and cristae disorganization (Ajroud-Driss et al., 2015; 
Bannwarth et al., 2014; Genin et al., 2016). Moreover, S59L CHCHD10 leads to impairment of 
the respiratory chain, shown in patient muscle as well as fibroblasts (Bannwarth et al., 2014). 
Other missense mutations, such as G66V and P80L, impaired both nuclear and mitochondrial 
function of CHCHD10 (Purandare et al., 2018). 
Since disease progression of CHCHD10 associated FTD/ALS is rather slow (6-12 years), age of 
onset usually pretty late (50s) and penetrance incomplete, some geneticists raised doubts about 
the true pathogenicity of CHCHD10 mutations. A clear underlying pathomechanism that could 
fully support CHCHD10 as bona fide FTD/ALS gene is not known for any of the CHCHD10 
mutations. Furthermore, sequencing of CHCHD10 in larger populations is needed to determine 
the mutation frequency. Functional analysis of several CHCHD10 mutations is crucial to 
strengthen the link between CHCHD10 to FTD/ALS (van Rheenen et al., 2014).  
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4. Clinical biomarkers and therapy approaches in FTD and ALS 
There is no effective disease-modifying therapy for FTD and ALS so far. Although intensive 
efforts are devoted to developing new therapies, and several clinical trials have reached phase 
II/III, only two drugs, riluzole and edaravone, are approved by the Food and Drug Administration 
(FDA) for ALS patients. Unfortunately, these drugs are not very effective. Riluzole only extends 
survival by an average of 2-3 months (Bensimon et al., 1994; Miller et al., 2012). The underlying 
mechanism of edavarone is unknown, but it is presumed to reduce oxidative stress in ALS and 
thereby may slow down disease progression specifically in patients with very aggressive disease 
(Cruz, 2018). The tremendous progress in FTD and ALS genetics in recent years has led to 
better understanding of the underlying pathomechanisms and may improve therapeutic 
interventions in the future. It is likely that many of the pathways identified in familial FTD/ALS will 
be relevant for understanding sporadic FTD/ALS because the neuropathology and clinical 
presentation is often indistinguishable. A key factor to improve future therapeutic studies is to 
include pharmacodynamic biomarkers to document a biological response to therapeutic 
treatment during preclinical and clinical studies (Balendra et al., 2017).  
4.1. Biomarkers for neurodegenerative diseases 
Presymptomatic stages of neurodegenerative diseases offer an interesting window to study early 
disease stages and are usually the ideal time to start therapy before irreversible neuronal 
damage occur. Neuroimaging biomarkers enable visualization of pathological changes in the 
brain, and have already been established for AD and Huntington´s disease. In AD, MRI is used 
to show atrophy, while PET is used to detect Aβ and tau aggregates and metabolic 
abnormalities (e.g. glucose metabolism) (Schilling et al., 2016). As imaging technologies are 
expensive and expose brain and body to radioactive compounds, developing biomarkers from 
body fluid such as CSF, blood or urine is of high interest (Gozes, 2017). Immunoassays are the 
most sensitive and specific technology to validate and measure biomarkers to date. Monoclonal 
antibodies allow a standardized analysis of biomarker levels. Another big advantage is that they 
are not vulnerable to limited availability or batch-to-batch variability, which is critical for the use 
as a therapeutic biomarker.  
Neurofilament light chain (NfL) is a powerful biomarker for axonal injury, reflecting disease 
severity and progression, as well as brain atrophy for FTD, ALS and other neurodegenerative 
disease including AD (Lu et al., 2015; Meeter et al., 2016; Scherling et al., 2014; Zetterberg et 
al., 2016). Currently Aβ42, tau, and phospho-tau are used as biomarkers to confirm AD via the 
CSF. Here, a decrease of CSF Aβ42 burden and an increase in tau correlates with amyloid 
plaque deposition, neuronal death, and accumulation of tangles (Gozes, 2017; Randall et al., 
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2013). Interestingly, soluble TREM2 was shown to change dynamically during respective AD 
stages (Suarez-Calvet et al., 2016). In C9orf72 FTD/ALS, poly-GP has been detected in CSF of 
a small cohort of ALS cases by an immunoassay using polyclonal antibodies (Su et al., 2014). 
Further studies in a large diverse cohort are required to potentially establish poly-GP as a 
pharmacodynamic biomarker. Detecting reduced levels of poly-GP may show target 
engagement in therapeutic trials, e.g. with antisense oligonucleotides (ASO). 
4.2. Therapeutic approaches for FTD/ALS  
TDP-43 is an attractive therapeutic target for FTD/ALS, since nearly all cases of ALS and 45% of 
FTD show TDP-43 positive protein inclusion. As misfolded TDP-43 leads to nuclear LOF and 
cytoplasmic toxic GOF, it would be interesting to promote refolding or degradation of misfolded 
TDP-43 via the UPS and/or autophagy (Scotter et al., 2015). In C9orf72 FTD/ALS, repeat RNA 
and DPR proteins may stepwise trigger TDP-43 pathology resulting in a brain region-specific 
neurodegeneration (Edbauer and Haass, 2016).  
In recent years, several interesting strategies to treat C9orf72-mediated disease have been 
suggested. C9orf72 haploinsufficiency is suspected to contribute to C9orf72 FTD/ALS and 
associated with impaired autophagy. Therefore, induction of C9orf72 expression, e.g. by 
targeting chromatin modification, might be a reasonable treatment strategy to rescue normal 
autophagy, but could also promote repeat-mediated RNA and protein toxicity (DeJesus-
Hernandez et al., 2011; Sellier et al., 2016). 
Another promising approach is to interfere with GGGGCC-repeat containing RNA. Chemically 
modified single-stranded ASO allow long-lasting suppression of target genes through RNase H 
mediated cleavage (Miller and Harris, 2016). For infantile-onset spinal muscular atrophy, an 
ASO-based therapy has already successfully passed phase 3 clinical studies and is now 
approved in Europe (Wan and Dreyfuss, 2017). Specific degradation of the repeat-containing 
introns using ASOs may block both RNA and DPR toxicity in C9orf72. Interestingly, several 
publications demonstrated that ASOs, targeting the GGGGCC-containing intron, reduce RNA 
foci and toxic DPR proteins without affecting overall C9orf72 mRNA levels in patient cells. 
Further ASO studies in C9orf72 BAC-transgenic mice confirmed these observations and 
successfully alleviated behavioral deficits (Donnelly et al., 2013; Jiang et al., 2016; Lagier-
Tourenne et al., 2013).   
Since both RBP sequestration and RAN translation are potentially influenced by the structure of 
GGGGCC-repeat-containing RNAs, targeting the G-Q confirmation may be another exciting 
treatment option. Small molecules targeting G-Qs reduced both RNA foci and DPR proteins in 
neurons, transdifferentiated from fibroblasts, of C9orf72 patients (Su et al., 2014). DPR proteins 
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were also reduced in GGGGCC-repeat-expressing flies and extended survival (Simone et al., 
2018). Altogether, these findings suggest that targeting repeat RNA structure is an encouraging 
strategy to slow down or even prevent C9orf72 mediated disease progression.  
Spreading of toxic protein aggregates is another mechanism thought to contribute to propagation 
of disease pathology. Therefore, antibody-based immunotherapy may slow or stop the spreading 
of protein aggregation by increasing phagocytosis through microglia and/or interfering with 
neuronal uptake. Immunotherapy targeting intracellular tau aggregates has shown beneficial 
neurological effects in a mouse model (Yanamandra et al., 2013). Aβ immunotherapy reduced 
Aβ pathology in AD patients in early disease stages (Sevigny et al., 2016). Although antibodies 
only target extracellular proteins, they are thought to also act on intracellular aggregates during 
transmission between cells. If similar transmission occurs for DPR proteins, vaccination might be 
a promising therapeutic approach to target DPR aggregates in C9orf72 FTD/ALS. 
Another attempt for FTD/ALS treatment may be to restore mitochondrial activity. Several small 
molecules have been designed to act on respiration/ATP production, apoptosis, and ROS-
induced DNA damage (Malty et al., 2015). Nicotinamide administration promotes mitophagy in 
cell culture, prevents cognitive defects, and selectively reduced phospho-tau (Thr 231) in an AD 
mouse model (Green et al., 2008; Jang et al., 2012). Interestingly, the synthetic AMP-activated 
protein kinase (AMPK) activator 5-amino-1-β-D-ribofuranosylimidazole-4-carboxamide (AICAR), 
improved motor performance in mice, e.g. by correcting COX deficiency (Viscomi et al., 2011). 
Pramipexole is a neuroprotective dopamine analogue that prevents activation of the 
mitochondrial/intrinsic apoptotic pathway, and reduces free radical levels in ALS patients (Pattee 
et al., 2003). Another strategy is to induce transcription of genes involved in mitochondrial 
biogenesis or oxidative stress response, e.g. via PPARγ coactivator-1α (PGC-1α). PGC-1α 
mRNA levels in ALS patients are reduced, and activation of PGC-1α shows protective effects in 
a SOD1 mouse model of ALS (Puigserver and Spiegelman, 2003; Thau et al., 2012).  
Edaravone, which is known to reduce oxidative stress in neurons, showed promise in fast-
progressing patients and in is the first mitochondrial therapy approved by the FDA for ALS 
(Mitsumoto et al., 2014; Poppe et al., 2014). 
Neuronal loss in FTD and ALS likely results from a combination of pathomechanisms including 
mitochondrial dysfunction, loss of RNA and/or protein homeostasis, oxidative stress and 
disrupted axonal transport processes. This may explain why single drug approaches have not 
been effective in patients. Further insights into individual pathomechanisms  and their interaction 
will hopefully uncover possibilities for single or multi-drug based disease modifying therapies. 
These studies will greatly benefit from in vivo biomarkers in preclinical and clinical trials.  
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II. Zusammenfassung  
Diese Arbeit beschäftigt sich mit Biomakern und Pathomechanismen in zwei familiären Formen 
der Frontotemporalen Demenz (FTD) und der Amyotrophen Lateralsklerose (ALS). Hierbei 
fokusierte ich mich insbesondere auf das Ubiquitin-Proteasom-System (UPS), interzellulärer 
Übertragung von Protein-Aggregaten und mitochondrialer Dysfunktion. 
Die häufigste genetische Ursache von FTD und ALS ist eine massive Verlängerung einer sonst 
kurzen (GGGGCC)n Sequenz in der Intronregion von C9orf72. Patienten haben hunderte von 
GGGGCC-Wiederholungen, die bidirektional transkribiert werden. Beide Repeat-Transkripte 
bilden RNA-Foci im Zellkern und werden auf unkonventionelle Weise in allen Leserahmen in fünf 
Dipeptid-Repeat (DPR)-Proteine (Poly-GA, Poly-GP, Poly-GR, Poly-PA und Poly-PR) translatiert, 
die im Gehirn von C9orf72 Patienten co-aggregieren. 
Sowohl in C9orf72 FTD/ALS als auch in anderen neurodegenerativen Erkrankungen wird eine 
Dysfunktion des Ubiquitin-Proteasom-Systems (UPS) als Ursache oder Folge von 
Proteinaggregation diskutiert. Um die Ultrastruktur der Poly-GA-Aggregate zu untersuchen, 
führten wir Kryoelektronentomographie in primären Neuronen durch. Dabei fanden wir, dass Poly-
GA-Aggregate aus dicht gepackten “twisted ribbons“ bestehen, an die zahlreiche 26S-
Proteasomen binden. Dabei wird das 26S-Proteasom in einem seltenen Übergangszustand 
blockiert, was auf eine gestörte Degradation hinweist. Ich konnte die Kolokalisation von Poly-GA 
mit dem Proteasom in Zellkultur bestätigten und mit biochemischer Fraktionierung die 
Sequestrierung des Proteasoms zeigen. Zusammengefasst zeigen diese Ergebnisse, dass 
Proteasomen in Poly-GA-Aggregaten eingeschlossen und inaktiviert werden und so das zelluläre 
UPS gestört wird (Publikation II). 
Die interzelluläre Übertragung von intrazellulären Proteinaggregaten scheint ein gemeinsames 
Merkmal von neurodegenerativen Erkrankungen zu sein. Im Rahmen einer größeren Studie zur 
Übertragung von DPR-Proteinen konnte ich in Ko-Kultur Experimenten die Transmission von Poly-
GA zwischen primären Neuronen nachweisen. Überraschenderweise induzierte die 
Überexpression von Poly-GA zudem die RNA-Foci Bildung in C9orf72-Fibroblasten, was auf eine 
positive Rückkopplung der Transkription schließen lässt. Die Übertragung von Poly-GA kann somit 
nicht-zellautonome Effekte in C9orf72 FTD/ALS auslösen (Publikation IV). 
Trotz der Toxizität von DPR-Proteinen in verschiedenen Zellkultur- und Tiermodellen, stellt die 
fehlende Korrelation der DPR-Protein Verteilung in humanem post-mortem Gewebe mit 
Neurodegeneration ihre kausale Rolle in Frage. Um diesen Widerspruch aufzulösen, wollte ich 
den zeitlichen Verlauf der DPR-Expression in C9orf72 Patienten detektieren. Dazu entwickelte ich 
einen neuartigen Poly-GP-Immunoassay mit monoklonalen Antikörpern und untersuchte damit in 
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einer Querschnittsstudie Liquor von C9orf72-Mutationsträgern. Hier konnte ich Poly-GP, im 
Vergleich zu gesunden Kontrollen oder Patienten mit anderen neurodegenerativen Erkrankungen, 
selektiv bei Mutationsträgern nachweisen. Außerdem detektierte ich Poly-GP in einem klinischen 
Alzheimer Patienten, bei dem ein anschließender Gentest die C9orf72 Mutation bestätigen konnte. 
Dies belegt den klinischen Nutzen des neuen Poly-GP Immunoassays. Erstaunlicherweise, waren 
die Poly-GP Mengen bei symptomatischen und asymptomatischen C9orf72-Mutationsträgern 
nahezu identisch. Dies deutet darauf hin, dass die DPR-Proteine wahrscheinlich bereits im 
Prodromalstadium den Krankheitsverlauf initieren, indem sie das UPS überlasten und nicht-
zellautonome Effekte auslösen (Publikation III). 
DPR-Proteine werden zwar mit mitochondrialer Dysfunktion in Verbindung gebracht, allerdings 
sind Mutationen im mitochondrialen Protein CHCHD10 bisher der stärkste Beweis für eine kausale 
Rolle dieses Pathomechanismus bei FTD/ALS. Die langsame Progression und unvollständige 
Penetranz  von CHCHD10-Mutationen hatten jedoch zu heftigen Debatten geführt. Darüber hinaus 
sind die molekularen Mechanismen der bisher bekannten CHCHD10-Mutationen unklar. 
In dieser Arbeit charakterisierte ich eine neue Mutation in CHCHD10 (Q108P), die bei einem 29 
Jahre alten ALS-Patienten mit sehr aggressiver Krankheitsprogression identifiziert wurde. Q108P 
befindet sich in der CHCH-Domäne und betrifft eine hoch konservierte Aminosäure. Meine in vitro 
Experimente zeigen, dass Q108P den mitochondrialen Import fast vollständig blockiert, was zu 
einer verringerten Proteinstabilität und einer diffusen zytoplasmatischen Lokalisierung führt. 
Zusätzlich analysierte ich alle bisher in FTD/ALS Patienten beschriebenen CHCHD10-Varianten 
und entdeckte, dass eine weitere Mutation in der CHCH-Domäne (C122R) auch zu 
zytoplasmatischer Mislokalisierung führt. Einige Mutationen (G66V und E127K) zeigten normalen 
mitochondrialen Import, führten jedoch zu mitochondrialer Cluster-Bildung. Somit können 
CHCHD10-Mutationen zu einem Funktionsverlust als auch zu einer toxischen Fehlfunktion des 
Proteins führen. CHCHD10 Trunkationen zeigten, dass die CHCH-Domäne für den 
mitochondrialen Import wichtig ist, und nicht die N-terminale Sequenz, welche bisher als 
mitochondriales Importsignal postuliert wurde. Entscheidend für den mitochondrialen Import vieler 
CHCH-Proteine ist eine Mia40-abhängige Bildung von Disulfidbrücken. Mit Hilfe von Knockdown-
Experimenten konnte ich in HeLa-Zellen belegen, dass Mia40 auch den mitochondrialen Import 
von CHCHD10 vermittelt. Durch Überexpression von Mia40 konnte der mitochondrialen Import 
von CHCHD10 Q108P aufgrund verstärkter Bildung von Disulfidbindungen wiederhergestellt 
werden. Reduzierte mRNA- und Proteinexpression in Patientenlymphoblasten mit Q108stop-
Mutation deuten zusätzlich auf Haploinsuffizienz hin. Tatsächlich fand ich eine reduzierte Reserve-
Atemkapazität in den Q108stop-Lymphoblasten und in CHCHD10-Knockdown-Zellen. Dies 
bestätigt, dass mitochondriale Dysfunktion wahrscheinlich zur FTD/ALS-Pathogenese beiträgt. Die 
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Entdeckung einer neuartigen CHCHD10-Mutation mit klarem Pathomechanismus unterstützt 
CHCHD10 als bona fide ALS-Gen. Ein möglicher neuer Therapieansatz für diesen FTD/ALS 
Subtypen wäre eine Steigerung der Mia40-Aktivität wodurch der CHCHD10-Import und dessen 
Stabilität erhöht wird (Publikation I). 
Zusammengefasst zeigen meine Daten, dass verschiedene Mechanismen wie chronische 
Beeinträchtigung der Mitochondrien oder des Proteasoms und die Übertragung von 
Aggregaten zwischen Zellen zur Entwicklung von FTD/ALS beitragen. Darüber hinaus ist 
Poly-GP ein geeigneter Biomarker für die C9orf72 FTD/ALS Diagnose und die Überwachung 
klinischer Therapiestudien. 
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III. Summary 
This thesis investigates protein-mediated pathomechanisms and biomarkers in two familial forms 
of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) in cell culture and 
patient material. I focused on the ubiquitin-proteasome system (UPS), spreading-mechanisms and 
mitochondrial dysfunction. 
The most frequent genetic cause of FTD and ALS is a GGGGCC-repeat expansion mutation in the 
intronic region of C9orf72. Patients harbor hundreds of repeats that are bi-directionally transcribed. 
Repeat-containing transcripts form nuclear RNA foci and are unconventionally translated in all 
reading frames into five dipeptide repeat (DPR) proteins (poly-GA, poly-GP, poly-GR, poly-PA and 
poly-PR). These DPR proteins coaggregate specifically in C9orf72 patient brains, but their 
pathogenic nature is still under intense debate.  
In C9orf72 FTD/ALS and other neurodegenerative diseases, dysfunction of the UPS has been 
discussed as cause or consequence of protein aggregation. To gain deeper insights into the 
ultrastructure of poly-GA aggregates, we conducted cryo-electron tomography in primary neurons. 
We found that poly-GA aggregates consist of densely packed twisted ribbons immobilizing 
numerous 26S proteasomes that are stalled in a rare transition state indicating an unsuccessful 
degradation attempt. I validated the colocalization of the proteasome with poly-GA and confirmed 
sequestration of the proteasome by biochemical fractionation. Altogether these results indicate 
that proteasomes are trapped in poly-GA aggregates and inhibit the UPS (Publication II).  
Cell-to-cell transmission of intracellular protein aggregates is emerging as a common feature in 
neurodegenerative diseases. As part of a study on transmission of DPR protein, I conducted co-
culture experiments in primary neurons revealing that poly-GA is released and taken up by other 
neurons. Unexpectedly, I observed that overexpression of poly-GA also induced RNA foci 
formation in C9orf72 fibroblasts suggesting a transcriptional feedback mechanism. Together these 
data suggest cell-to-cell transmission of poly-GA causes non-cell autonomous effects in C9orf72 
FTD/ALS (Publication IV).  
Despite ample evidence for DPR protein toxicity in cellular and animal models, the lack of 
correlation between DPR protein expression and neurodegeneration in end-stage tissue have cast 
doubt on the relevance of DPR proteins for C9orf72 pathogenesis. To study the temporal course 
of DPR expression in C9orf72 FTD/ALS, I established a novel poly-GP immunoassay using 
monoclonal antibodies. In a cross-sectional study in the CSF from C9orf72 mutation carrier poly-
GP was clearly detected, compared to controls with other neurodegenerative diseases or healthy 
individuals. Interestingly, poly-GP detection in a clinical AD case and subsequent genetic testing 
identified a misdiagnosed C9orf72 case, demonstrating the clinical utility of this immunoassay. 
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Importantly, I detected similar poly-GP levels in symptomatic and asymptomatic C9orf72 mutation 
carriers, suggesting chronic DPR expression in the prodromal stage may trigger subsequent steps 
in a disease cascade, e.g. by chronic overloading of the UPS, and non-cell autonomous effects 
through cell-to-cell transmission (Publication III). 
While DPR proteins have also been linked to mitochondrial dysfunction, mutations in the 
mitochondrial protein CHCHD10 are so far the strongest evidence for a causal role of this 
pathomechanism in FTD/ALS. However, most CHCHD10 mutations described in FTD/ALS 
patients are associated with late disease onset and slow progression. Incomplete penetrance has 
raised concerns by some geneticists about the pathogenicity. Moreover, the molecular 
mechanisms of known CHCHD10 mutations are unclear. 
Here, we identified a novel mutation in CHCHD10 (Q108P) in a 29-year old ALS patient with very 
aggressive disease progression. Q108P is located in the CHCH domain and affects a highly 
conserved residue. I discovered that Q108P blocked mitochondrial import nearly completely 
resulting in decreased protein stability and diffuse cytoplasmic localization in vitro. I analyzed all 
CHCH10 variants reported in FTD/ALS patients and discovered that another mutation in the 
CHCH domain (C122R) disrupted mitochondrial localization as well. In contrast, other mutations 
(G66V and E127K) showed normal mitochondrial import but resulted in mitochondrial clustering. 
Thus, both loss-of-function and toxic gain-of-function mechanisms might contribute to 
pathogenesis in CHCHD10 FTD/ALS. Truncation experiments show that the CHCH domain is 
critical for import, but not the N-terminal sequence, which has been commonly referred to as a 
mitochondrial import signal. For other CHCH containing proteins a Mia40-depependent formation 
of disulfide bonds is critical for mitochondrial import. Using knockdown experiments in HeLa cells, I 
showed that Mia40 mediates mitochondrial import of CHCHD10. Strikingly, Mia40 overexpression 
fully rescued mitochondrial import of CHCHD10 Q108P by enhancing disulfide-bond formation and 
protein stability. Reduced mRNA and protein levels in lymphoblasts froma FTD patient, carrying a 
Q108stop mutation, further support a loss-of-function mechanism. Interestingly, I also found 
reduced spare respiratory capacity in the patient Q108stop lymphoblasts and CHCHD10 
knockdown cells suggesting that mitochondrial dysfunction can contribute to FTD/ALS 
pathogenesis. The discovery of a novel CHCHD10 mutation with a clear pathomechanism strongly 
supports CHCHD10 as a bona-fide ALS gene. Enhancing Mia40 activity to boost CHCHD10 
import and stability may be a new treatment strategy for this subtype of ALS/FTD (Publication I).  
Together, my data show that diverse mechanisms such as chronic impairment of 
mitochondria or the proteasome, and cell-to-cell transmission of aggregating proteins 
contribute to the development of FTD/ALS. Furthermore, poly-GP is a suitable biomarker 
for C9orf72 FTD/ALS diagnosis and/or monitoring of clinical trials.  
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IV. Results 
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Abstract
CHCHD10 mutations are linked to amyotrophic lateral sclerosis, but
their mode of action is unclear. In a 29-year-old patient with rapid
disease progression, we discovered a novel mutation (Q108P) in a
conserved residue within the coiled-coil-helix-coiled-coil-helix
(CHCH) domain. The aggressive clinical phenotype prompted us to
probe its pathogenicity. Unlike the wild-type protein, mitochondrial
import of CHCHD10 Q108P was blocked nearly completely resulting
in diffuse cytoplasmic localization and reduced stability. Other
CHCHD10 variants reported in patients showed impaired mitochon-
drial import (C122R) or clustering within mitochondria (especially
G66V and E127K) often associated with reduced expression. Trunca-
tion experiments suggest mitochondrial import of CHCHD10 is
mediated by the CHCH domain rather than the proposed N-terminal
mitochondrial targeting signal. Knockdown of Mia40, which intro-
duces disulfide bonds into CHCH domain proteins, blocked mito-
chondrial import of CHCHD10. Overexpression of Mia40 rescued
mitochondrial import of CHCHD10 Q108P by enhancing disulfide-
bond formation. Since reduction in CHCHD10 inhibits respiration,
mutations in its CHCH domain may cause aggressive disease by
impairing mitochondrial import. Our data suggest Mia40 upregula-
tion as a potential therapeutic salvage pathway.
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Introduction
The recent identification of mutations in CHCHD10 implicates mito-
chondrial dysfunction in the pathogenesis of frontotemporal
dementia (FTD) and amyotrophic lateral sclerosis (ALS) (Bannwarth
et al, 2014). CHCHD10 is a small soluble protein with a positively
charged N-terminus commonly referred to as a mitochondrial
targeting signal (MTS), a central hydrophobic domain and a C-term-
inal CHCH domain (Perrone et al, 2017). Mutations have been
reported mainly in the N-terminus and the central hydrophobic
domain. However, the exact molecular function of the protein and
the effect of these mutations remain unknown. Electron microscopy
and biochemical studies suggest that CHCHD10 resides in the mito-
chondrial contact site and cristae organizing system (MICOS) in the
intermembrane space of mitochondria (Bannwarth et al, 2014)
although that has been recently disputed by others (Burstein et al,
2018). In the MICOS complex, CHCHD10 interacts with mitofusin,
CHCHD3, and CHCHD6 and it seems to be required for proper pack-
aging of mitochondrial DNA into the nucleoid structures (Genin
et al, 2016).
Several CHCHD10 mutations were identified in association studies
from ALS/FTD kindreds. The S59L mutation was found in an
extended family with variable clinical presentation including classic
motoneuron disease, cerebellar ataxia, and frontal lobar cognitive
symptoms (Bannwarth et al, 2014). Moreover, S59L patients also
show ragged-red fiber myopathy indicative of mitochondrial disease.
The subsequent identification of a R15L mutation as the causal muta-
tion in several pedigrees of familial ALS by three independent groups
corroborated the link to ALS (Johnson et al, 2014; Muller et al, 2014;
Kurzwelly et al, 2015), while a more cautious interpretation of these
association studies was put forward by others due to incomplete
penetrance (van Rheenen et al, 2014). Later, a G66V mutation was
associated with ALS (Muller et al, 2014), the Jokela type of spinal
muscular atrophy (Penttila et al, 2015), and Charcot-Marie-Tooth
disease type 2 (Auranen et al, 2015). The typical age-of-onset in these
families is in the fifties, and patients show variable clinical presenta-
tion and disease duration (1–12 years). Sequencing studies identified
several other CHCHD10 mutations in ALS/FTD cohorts, but lack func-
tional characterization to support pathogenicity (Chaussenot et al,
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2014; Dols-Icardo et al, 2015; Zhang et al, 2015; Jiao et al, 2016;
Zhou et al, 2017; Blauwendraat et al, 2018).
Functional studies of CHCHD10 variants are largely limited to
the S59L mutation and have so far not revealed a clear mode of
action. Patient fibroblasts with the S59L mutation show an altered
mitochondrial network structure, but as mitochondrial fusion is
normal, this may be secondary to instability of mitochondrial DNA
(Bannwarth et al, 2014). Overexpression of human wild-type but
not R15L or S59L CHCHD10 rescues the shorter lifespan of
Caenorhabditis elegans lacking the CHCHD10 homolog har-1 (Woo
et al, 2017). The reported inhibition of apoptosis by CHCHD10 S59L
(Genin et al, 2016) has not been replicated by others (Woo et al,
2017) and is difficult to reconcile with a neurodegenerative process.
The neuropathological features of CHCHD10 cases have not been
comprehensively characterized, but CHCHD10 was recently linked
to synaptic integrity and nuclear retention of TDP-43 (Woo et al,
2017), although the latter has not been replicated (Brockmann et al,
2018).
Here, we report a novel Q108P mutation in the CHCH domain of
CHCHD10 in a very young patient with rapidly progressing classical
ALS symptoms, which is in sharp contrast to the slow progression
in most CHCHD10 patients. We show that the Q108P mutation
blocks mitochondrial import nearly completely, and examine the
mechanism of CHCHD10 mitochondrial import in detail, including
rescue strategies. In addition, we analyzed the effect of all other
reported missense mutations on protein expression and localization.
Results
Identification of CHCHD10 Q108P in an early-onset ALS patient
A 29-year-old male presented with progressive spasticity, starting in
the right foot and spreading to the other extremities over 2 years. He
reported recurring painful cramps and had recently noticed atrophy
in the hand muscles. Neurologic exam revealed spastic tetraparesis,
diffuse fasciculations, muscle atrophy in all extremities, hyperactive
deep tendon reflexes, a positive Babinski on the right and equivocal
on the left. Motor abnormalities were most severe in the right arm.
Bulbar, sensory and coordination functions were normal.
The CSF showed slightly elevated proteins (530.2 mg/l) but was
otherwise unremarkable. The electrophysiological exam showed
chronic and acute neurogenic changes in the cervical, thoracic, and
lumbar region.
The family history was unremarkable for neurodegenerative
diseases. Both parents are alive and well at 56 and 55 years, respec-
tively. No DNA was available from the parents. Repeat primed PCR
detected no C9orf72 repeat expansion in the index case. Sequencing
using a custom panel with genes linked to ALS/FTD and Alzheimer
revealed a heterozygous Q108P mutation in CHCHD10, but no
mutations in APP, CSF1R, CHMP2B, FUS, GRN, HNRNPA1,
HNRNPA2B1, MAPT, MATR3, NEK1, OPTN, PSEN1, PSEN2, SOD1,
TARDBP, TBK1, TUBA4A, TREM2, or VCP (see Materials and Meth-
ods). Sanger sequencing confirmed a heterozygous Q108P mutation
(Fig 1A). Recently, a nonsense variant (Q108*) was reported at the
same position in a case with FTD and atypical Parkinson’s disease
(Perrone et al, 2017). The Q108P variant was not found in the
60,706 control exomes curated in the ExAc database, and the
residue is highly conserved between species (Lek et al, 2016).
Among the species in the ENSEMBL ortholog list, Q108 is fully
conserved apart from yeast (asparagine). While most other reported
CHCHD10 variants lie in the N-terminal region (e.g., R15L) and the
central hydrophobic domain (e.g., S59L and G66V), the novel
Q108P mutation is located in the CHCH domain (Fig 1B).
CHCHD10 Q108P inhibits mitochondrial import nearly completely
CHCHD10 is localized in the intermembrane space of mitochondria,
and several pathogenic mutations are near the putative MTS at the
N-terminus. Therefore, we asked, how the Q108P mutation affects
the localization and function of CHCHD10, and compared it to the
R15L mutation, which was independently discovered in several
ALS/FTD kindreds. In HeLa cells, the levels of R15L and especially
Q108P were reduced in whole cell lysate compared to HA-tagged
wild-type CHCHD10 (Fig EV1A). In immunofluorescence experi-
ments, the wild-type protein showed typical mitochondrial staining
and colocalization with the mitochondrial marker protein ATP5A1
(Fig 1C). In contrast, CHCHD10 Q108P was diffusely localized all
over the cell, without discernible mitochondrial localization,
suggesting that this mutation disrupts the mitochondrial import
and/or impairs protein folding/stability. While CHCHD10 R15L
levels were also reduced, the residual protein still colocalized with
mitochondria similar to the wild-type protein. Line scans confirmed
the lack of correlation of CHCHD10 Q108P and mitochondrial signal
(Fig EV1B).
In addition, biochemical fractionation showed strongly reduced
levels of CHCHD10 Q108P in mitochondria compared to wild-type
despite similar cytosolic levels in a quantitative analysis (Fig 1D and
E). The mitochondrial levels of CHCHD10 R15L consistently
appeared lower than for the wild-type protein without reaching
statistical significance. A C-terminal anti-CHCHD10 antibody showed
comparable expression of exogenous and endogenous CHCHD10,
but poorly detected the Q108P mutant protein. Moreover, transfec-
tion of the mutant and wild-type CHCHD10 had no effect on the
levels and localization of endogenous CHCHD10 arguing against
molecular replacement or dominant negative effects. Next, we trans-
duced primary rat hippocampal neurons with lentivirus expressing
CHCHD10 variants. Similar to the results in HeLa cells, wild-type
and R15L predominantly localized to mitochondria, while Q108P
showed diffuse expression in the soma and neurites (Fig 1F).
Next, we analyzed protein stability, because Q108P and R15L
showed reduced protein levels compared to wild-type CHCHD10.
Therefore, we treated CHCHD10 expressing cells with cyclohex-
imide (CHX) to block protein translation and analyzed the decay of
CHCHD10 over a time course of 24 h (Fig EV1C). Quantification
confirmed rapid degradation of CHCHD10 Q108P compared to the
wild-type (Fig EV1D), which is reflected in an almost fivefold lower
half-life time (Fig EV1E). CHCHD10 R15L showed intermediated
stability. Together, these data suggest that the Q108P mutation
strongly inhibits mitochondrial import leading to enhanced protein
degradation in the cytosol.
CHCHD10 knockdown impairs cellular respiration
Since mitochondrial CHCHD10 levels are likely reduced in the
ALS patient with CHCHD10 Q108P mutation, we addressed the
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functional role of CHCHD10 focusing on cellular respiration in
knockdown experiments using siRNA. CHCHD10 siRNA reduced
expression of CHCHD10 mRNA and protein detected by quantitative
RT–PCR and immunoblotting in HeLa cells compared to control
siRNA (Fig 2A). Using the Seahorse analyzer, we quantified cellular
respiration upon CHCHD10 knockdown in HeLa cells. CHCHD10
knockdown cells showed reduced basal respiration and also reduced
maximal respiration upon uncoupling with FCCP, resulting in a
lower spare respiratory capacity (Fig 2B and C).
Next, we used CRISPR/Cas9 to introduce a frameshift in
CHCHD10 in haploid HAP1 cells near Q108. Deletion of 11
base pairs led to a premature stop codon resulting in the dele-
tion of amino acids 110–142 (p.Leu110HisfsTer5, here called
D10 fs). The frame shift caused significant reduction in the
CHCHD10 mRNA through nonsense-mediated decay (Fig 2D).
While a C-terminal CHCHD10 antibody detected no full-length
protein in the edited cells, an N-terminal antibody still
detected low levels of truncated CHCHD10 (Fig 2D). D10 fs
cells showed reduced spare respiratory capacity (Fig 2E and
F), which is consistent with the knockdown data in HeLa cells
(Fig 2B and C).
Since primary cells of the Q108P patients were unfortunately not
available, we analyzed lymphoblasts from an FTD patient with a
heterozygous Q108* mutation (Perrone et al, 2017). Consistent with
the reported nonsense-mediated decay of the mutant allele and the
findings from the very similar CHCHD10 frame shift allele in HAP1
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Figure 1. CHCHD10 Q108P inhibits mitochondrial import.
A Genomic DNA of an ALS patient was PCR amplified and subjected to Sanger sequencing. The fluorogram revealed a heterozygous Q108P mutation in exon 3 of
CHCHD10.
B Domain structure and known mutations of CHCHD10. R15L is localized in the putative mitochondrial targeting signal (“MTS?”), S59L and G66V in the hydrophobic
region and Q108P in the CHCH domain.
C–F HeLa cells were transfected (C–E) and primary hippocampal neurons were transduced (F) with HA-tagged CHCHD10 (D10-HA) wild-type (WT), Q108P, or R15L. (C, F)
Mitochondrial localization of CHCHD10-HA (D10-HA) was analyzed by co-staining of a mitochondrial ATP synthase subunit (ATP5A1). Cells with similar expression
levels were selected for imaging. Scale bars represent 10 lm. (D) Biochemical fractionation of mitochondria and cytosol from transfected HeLa cells. Immunoblot
using antibodies against HA, CHCHD10 C-terminus (D10-CT), ATP5A1, and actin. (E) Protein quantification of CHCHD10-HA (D10-HA) in mitochondrial (normalized
to ATP5A1) and cytosolic (normalized to actin) fractions. Data are shown as mean  SD. One-way ANOVA (followed by Dunnett’s post hoc test against WT): n = 3
biological replicates, mitochondrial WT versus Q108P: *P = 0.0135.
Source data are available online for this figure.
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cells, Q108* lymphoblasts show reduced CHCHD10 mRNA and
protein levels compared to lymphoblasts from controls with wild-
type CHCHD10 (Fig 2G). Reduced CHCHD10 expression in these
cells is associated with a reduced spare respiratory capacity
compared to the three control lines with wild-type CHCHD10 coding
sequence (Fig 2H and I).
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Figure 2. Partial loss of CHCHD10 reduces spare respiratory capacity.
A–C HeLa cells were transfected with siRNA targeting CHCHD10 (siD10) or control (siCtrl). (A) Quantitative RT–PCR and immunoblotting (using a C-terminal antibody)
show CHCHD10 knockdown. mRNA levels were normalized to GAPDH and B2M mRNA. Data are shown as mean  SD. Welch’s t-test was used for statistical
analysis: n = 3 biological replicates, *P = 0.0102. (B, C) Mitochondrial respiration was quantified in real-time using the Seahorse extracellular flux analyzer. The
oxygen consumption rate was measured in pmol O2 per minute and normalized to total protein concentration. After measuring basal respiration, oligomycin was
added to inhibit ATP synthase (proton leak), followed by the uncoupling agent FCCP (maximal respiration) and antimycin A/rotenone (non-mitochondrial oxygen
consumption). Statistical analysis was done for the spare respiratory capacity (difference of maximal and basal respiration). Data are shown as mean  SD. T-test:
n = 11 biological replicates, ***P < 0.0001.
D–F CHCHD10 inactivation in haploid HAP1 cells using CRISPR/Cas9 leading to a premature stop codon (p.Leu110HisfsTer5, henceforth abbreviated as D10 fs). (D)
Quantitative RT–PCR and immunoblotting (using C- and N-terminal antibodies) show strong reduction of CHCHD10 mRNA expression and loss of full-length
protein in D10 fs cells. mRNA levels were normalized to GAPDH and B2M mRNA. Data are shown as mean  SD. Welch’s t-test was used for statistical analysis:
n = 3 technical replicates, *P = 0.0125. (E, F) Mitochondrial respiration was analyzed as in (B, C). Statistical analysis was done for spare respiratory capacity
(difference of maximal and basal respiration). Data are shown as mean  SD. T-Test: n = 7 technical replicates, **P = 0.0022. A representative experiment of
several experiments is shown.
G–I Lymphoblasts from an FTD patient with a Q108* mutation were compared to three control cases with wild-type CHCHD10. (G) Quantitative RT–PCR and
immunoblotting (using C- and N-terminal antibodies) show both reduced CHCHD10 mRNA expression and 50% CHCHD10 protein in Q108* patient cells. mRNA levels
were normalized to GAPDH and B2M mRNA. Data are shown as mean  SD. One-way ANOVA (followed by Dunnett’s post hoc test against Q108*) was used for
statistical analysis: n = 3 technical replicates, Q108* versus Ctrl1: ***P = 0.0004, Q108* versus Ctrl2: *P = 0.0338, Q108* versus Ctrl3: *P = 0.0105. (H, I) Mitochondrial
respiration was analyzed 1 h after plating an equal number of lymphoblasts. Statistical analysis was done for spare respiratory capacity (difference of maximal and
basal respiration). Data are shown as mean  SD. One of two independent experiments with similar results was analyzed by one-way ANOVA (followed by Dunnett’s
post hoc test against Q108*): n = 4 technical replicates, Q108* versus Ctrl1: ***P = 0.0001, Q108* versus Ctrl2: **P = 0.0017, Q108* versus Ctrl3: ***P = 0.0001.
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Thus, reduced mitochondrial import of CHCHD10 Q108P may
decrease mitochondrial function in the early-onset ALS case with
only one intact allele.
The CHCH domain is critical for mitochondrial import
In the current literature, the N-terminus of CHCHD10 is widely
referred to as a MTS due to the presence of four interspaced arginine
residues. To decipher the contribution of the respective domain to
the mitochondrial import mechanism of CHCHD10, we generated
truncated CHCHD10 expression constructs and analyzed the mutant
proteins by immunofluorescence and biochemical fractionation
(Fig 3A–C). Similar to the R15L mutation, truncation of the
predicted N-terminal MTS (DNT, aa 1–16) had little effect on the
mitochondrial import. Deleting the C-terminal CHCH domain
(DCHCH, aa D92–142) strongly reduced protein levels and
prevented mitochondrial import nearly completely. Importantly, the
Q108* patient variant inhibited mitochondrial import like the Q108P
mutation. Both CHCHD10 DCHCH and Q108* proteins were retained
in the cytosolic fraction, confirming that an intact CHCH domain is
necessary for mitochondrial import of CHCHD10 (Fig 3B and C).
Deleting the N-terminus from the Q108P did not further impair mito-
chondrial import arguing for a dominant role of the CHCH domain
(Fig 3B and C).
To determine which domains of CHCHD10 are sufficient for
mitochondrial import, we fused the N-terminus (NT-GFP, amino
acids 1–33) or the C-terminus (CHCH-GFP and GFP-CHCH, amino
acids 88–142) to GFP. While conventional MTS is widely used in flu-
orescent mitochondrial reporters, the predicted MTS of CHCHD10
was not sufficient for mitochondrial import when fused to GFP
(Fig 3D). Unexpectedly, the CHCH domain fused to either the N- or
C-terminus of GFP also failed to drive mitochondrial import.
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Figure 3. The CHCH domain is necessary for mitochondrial import of CHCHD10.
HeLa cells were transfected with the indicated CHCHD10 variants (D10-HA) and GFP-fusion proteins.
A–D (A, D) Double immunofluorescence using ATP5A1 as a mitochondrial marker protein. Cells with similar expression level are shown. Scale bars represent 10 lm.
(B, C) Representative immunoblot of biochemical fractionation of mitochondria and cytosol using antibodies against HA, ATP5A1, and actin followed by quantitative
analysis of the respective CHCHD10 truncation mutant. Levels of HA-tagged CHCHD10 (D10-HA) were either normalized to ATP5A1 (for mitochondria) or actin (for
cytosol). Data are shown as mean  SD. One-way ANOVA (followed by Dunnett’s post hoc test against WT): n = 3–4 biological replicates, mitochondrial: WT versus
DCHCH **P = 0.0013, WT versus Q108* **P = 0.0019, WT versus Q108P **P = 0.0030, WT versus DNT-Q108P **P = 0.0020; Cytosolic: WT versus Q108* *P = 0.0428.
Source data are available online for this figure.
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However, fusing GFP to the N- or C-terminus of full-length
CHCHD10 also blocked mitochondrial import of wild-type CHCHD10
(data not shown), indicating that the CHCH domain-mediated
import mechanism may not be compatible with large proteins,
which unfortunately precludes definite interpretation of this experi-
ment. The truncation experiments show that mitochondrial import
of CHCHD10 is predominantly driven by the CHCH domain.
Mutations in the hydrophobic region and the CHCH domain
affect subcellular CHCHD10 distribution
To test, whether impaired mitochondrial import is a common patho-
mechanism, we examined steady state protein levels and localiza-
tion of all reported missense CHCHD10 variants (Bannwarth et al,
2014; Ajroud-Driss et al, 2015; Dols-Icardo et al, 2015; Jiao et al,
2016; Perrone et al, 2017; Zhou et al, 2017). In public exome
sequencing data from ~ 2,000 ALS patients (ALSdb, Cirulli et al,
2015), we discovered two additional CHCHD10 mutations in the
CHCH domain that are rare in the ExAc database (Lek et al, 2016).
One case had a heterozygous mutation of an essential cysteine
(C122R), and one case had a charge-altering mutation in a highly
conserved residue (E127K) within the CHCH domain, suggesting
that such mutations significantly contribute to ALS pathogenesis. In
addition, this dataset contained novel R6G and G66S variants. To
facilitate site-directed mutagenesis of the highly GC-rich sequence,
we used a codon-optimized synthetic gene encoding human
CHCHD10 (Fig EV2A). The Q108P and R15L mutants had similar
effects on expression and localization, although the synthetic gene
allowed higher expression levels (Fig EV2B and C).
Importantly, the C122R mutant showed diffuse cytoplasmic local-
ization similar to Q108P (Figs 4A and EV2C). Consistent with previ-
ous reports (Woo et al, 2017), CHCHD10 S59L showed small
punctate staining in mitochondria in many transfected cells. Even
stronger clustering was observed for G66V and E127K in nearly all
cells. Other variants in the hydrophobic domain had little (G58R
and G66S) or no effect (V57E) on CHCHD10 localization but may
have subtle effects on mitochondrial morphology similar to reports
for S59L (Bannwarth et al, 2014; Woo et al, 2017). The other vari-
ants showed no gross abnormalities in expression level and localiza-
tion by immunofluorescence (Fig EV3), highlighting the importance
of the hydrophobic region and the CHCH domain.
For a more quantitative analysis, we analyzed CHCHD10 protein
levels 3 days after transfection (Fig 4B). CHCHD10 P23S, G58R,
G66V, Q108P, and C122R levels were significantly reduced
compared to wild-type. Surprisingly, expression of the common
P34S variant and R6G, R15S, A32D, and A35D was enhanced argu-
ing against pathogenicity. Biochemical fractionation confirmed that
C122R strongly inhibits mitochondrial import similarly to Q108P
suggesting that disulfide-bond formation in the CHCH domain is
critical for mitochondrial import (Fig 4C and D).
Mia40 mediates mitochondrial import of CHCHD10
To test whether CHCHD10 is imported into mitochondria via the
Mia40 redox system similar to other CHCH domain containing
proteins, we used siRNA to inhibit this pathway, also including the
FAD-linked sulfhydryl oxidase Erv1 and AIFM1. RT–qPCR and
immunoblotting confirmed the potency and specificity of all siRNAs
(Fig 5A–C). Strikingly, Mia40 knockdown strongly reduced the
levels of endogenous CHCHD10 protein despite unchanged mRNA
levels. Knockdown of AIFM1 and Erv1 also seemed to decrease
CHCHD10 protein levels slightly, however, without reaching statisti-
cal significance (Fig 5C). Immunofluorescence confirmed colocaliza-
tion of endogenous CHCHD10 with mitochondrial cytochrome c
oxidase II (MTCO2; Fig 5D). In contrast to control, Mia40 knock-
down strongly reduced overall CHCHD10 levels and prevented mito-
chondrial targeting. Due to the low CHCHD10 protein levels in
Mia40 knockdown, we speculate that CHCHD10 mislocalized to the
cytosol is degraded rapidly similar to our findings for Q108P
(Fig EV1C–E).
Mia40 mediates import of its substrates by direct binding and
disulfide-bond formation, which traps the target proteins in the
mitochondria (Peleh et al, 2016). Therefore, we analyzed interac-
tion of CHCHD10 with Mia40 in cotransfected HeLa cells. Co-
immunoprecipitation experiments showed interaction of wild-type,
Q108P, and R15L CHCHD10 with Mia40, but no interaction with the
DCHCH construct and only weak interaction with the Q108*
construct (Fig EV4A).
To directly probe Mia40-mediated disulfide-bond formation in
the CHCH domain, we treated cell extracts with 4-acetamido-40-
maleimidylstilbene-2,20-disulfonic acid (AMS), which is covalently
linked to free thiol-groups and thus leads to slower migration in
SDS–PAGE. AMS treatment of non-reduced extracts had no effect on
wild-type CHCHD10 migration indicating that all cysteine residues
are oxidized under basal conditions (Fig 5E). Prior reduction with
DTT increased the apparent molecular weight of wild-type
CHCHD10, particularly upon heating samples to 95°C, presumably
due to increased reduction efficiency. Similar results were obtained
for endogenous CHCHD10 (Fig EV4B). While CHCHD10 Q108P
levels were lower under all conditions, heating the CHCHD10
Q108P extracts during DTT treatment had no additional effect on
AMS accessibility in contrast to the wild-type. Thus, the Q108P
mutant is completely reduced by DTT already at room temperature
indicating that the CHCH domain in the Q108P mutant may be
misfolded. Moreover, treating CHCHD10 R15L extract with AMS
showed results similar to wild-type, suggesting normal formation of
disulfide bonds in the intermembrane space of mitochondria in this
mutant.
Mia40 overexpression restores mitochondrial import of
CHCHD10 Q108P
Since mitochondrial import of wild-type CHCHD10 depends on
the integrity of the Mia40 system, we asked how the patient-
derived variants are affected by this pathway. First, we analyzed
the impact of Mia40 overexpression on the localization of
CHCHD10 Q108P in HeLa cells. Strikingly, Mia40 promoted mito-
chondrial import of CHCHD10 Q108P (Fig 6A). The rescue of
mitochondrial import of CHCHD10 Q108P due to Mia40 overex-
pression was fully replicated in primary neurons (Fig 6B). Addi-
tionally, biochemical fractionation and quantification confirmed
that overexpression of Mia40 increased the levels of wild-type,
Q108P, and R15L CHCHD10 in isolated mitochondria from HeLa
cells (Fig 6C and D, also seen in input of Fig EV4A). Overex-
pressed Mia40 increased also wild-type and mutant CHCHD10 in
the cytosolic fraction, which may be explained by partial
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cytosolic localization of excess Mia40 (Fig EV4C). Importantly,
Mia40 expression also enhanced CHCHD10 Q108P stability
(Fig EV4D and E). Moreover, biochemical analysis of CHCHD10
disulfide-bond formation using AMS treatment confirmed Mia40-
induced oxidation and mitochondrial import of Q108P CHCHD10.
Without Mia40 overexpression, the CHCHD10 Q108P mutant was
poorly expressed (Fig 6E). However, co-expression of Mia40
resulted in higher protein expression and disulfide-bond forma-
tion comparable to wild-type CHCHD10, suggesting that oxida-
tion via Mia40 is crucial for the stability and mitochondrial
localization of CHCHD10 Q108P. Thus, Mia40 overexpression
likely restores mitochondrial import of CHCHD10 Q108P by
promoting disulfide-bond formation.
Discussion
Unusual phenotypes of genetically determined diseases offer an
opportunity to explore molecular pathomechanisms. The known
CHCHD10 mutations are usually associated with slow progress-
ing forms of late-onset motoneuron disease and frontotemporal
dementia. Here, we identified a novel CHCHD10 mutation in a
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B Quantification of CHCHD10 levels from immunoblots of whole cell lysates. Data are shown as mean  SD. One-way ANOVA (followed by Dunnett’s post hoc test
against WT): n = 3–6 biological replicates, WT versus R6G: *P = 0.0145, WT versus R15S: ***P = 0.0001, WT versus P23S: *P = 0.0189, WT versus A32D: ***P = 0.0001,
WT versus P34S: ***P = 0.0001, WT versus A35D: **P = 0.0044, WT versus G58R: **P = 0.0029, WT versus G66V: ***P = 0.0001, WT versus Q108P: ***P = 0.0001, WT
versus C122R *P = 0.0146.
C Immunoblot of biochemical fractionation of mitochondria and cytosol from transfected HeLa cells expressing different CHCHD10 patient variants using antibodies
against HA, ATP5A1, and actin.
D Quantification of CHCHD10-HA protein level normalized to mitochondrial ATP5A1. Data are shown as mean  SD. One-way ANOVA (with Dunnett’s post hoc test
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Source data are available online for this figure.
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young ALS patient with an aggressive disease course and
analyze the consequences for protein function. The Q108P muta-
tion inhibits mitochondrial import of CHCHD10 via the Mia40
system nearly completely. Rescue of mitochondrial import by
Mia40 overexpression suggests that Q108P reduces binding affin-
ity to Mia40 and can be compensated for by excess Mia40. In
contrast, the common R15L mutation had a much smaller effect
on protein levels and subcellular distribution, while several
mutations in the hydrophobic domain cause clustering of
CHCHD10 within mitochondria. Thus, the strong effect of
CHCHD10 Q108P on mitochondrial import may explain the
aggressive disease in the mutation carrier and suggests that
CHCHD10 is important for mitochondrial respiration in motoneu-
rons during healthy aging.
Mitochondrial import of CHCHD10 via Mia40
To address the pathogenicity of the novel Q108P variant in
CHCHD10, we expressed the mutant protein in HeLa cells and
primary hippocampal neurons and noticed diffuse localization all
over the cell compared to predominantly mitochondrial localization
of the wild-type. Our findings suggest that impaired mitochondrial
import is the main pathogenic mechanism for the CHCHD10 Q108P
variant and led us to investigate the mitochondrial import mecha-
nisms of wild-type and mutant CHCHD10 in more detail.
Apart from the 13 proteins encoded on the mitochondrial DNA,
all other ~ 1,500 mitochondrial proteins are synthesized in the
cytosol and require active transport into mitochondria (Wiedemann
& Pfanner, 2017). The vast majority of nuclear encoded proteins
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CHCHD10, Mia40, AIFM1, and Erv1. mRNA levels were normalized to GAPDH and B2M mRNA. Data are shown as mean  SD. One-way ANOVA (followed by
Dunnett’s multiple comparisons test against siCtrl) was used for statistical analysis: n = 4 biological replicates, siCtrl versus siD10 ***P = 0.0001, siCtrl versus
siMia40 ***P = 0.0001, siCtrl versus siAIFM1 ***P = 0.0001, siCtrl versus siErv1 ***P = 0.0001. (B) Immunoblots with indicated antibodies in siRNA transfected
cells. (C) CHCHD10 protein quantification of siRNA transfected cells normalized to actin. Data are shown as mean  SD. Kruskal–Wallis test: n = 4 biological
replicates, siCtrl versus siD10: **P = 0.0013, siCtrl versus siMia40: **P = 0.0136. (D) Immunostaining of Mia40 knockdown HeLa cells shows overall reduced
expression of CHCHD10 compared to control (siCtrl). An antibody against mitochondrially encoded cytochrome c oxidase II (MTCO2) labels mitochondria. Scale bar
represents 10 lm.
E AMS assay to assess disulfide-bond formation in whole cell extracts of HeLa cells transfected with CHCHD10-HA wild-type (WT) and mutants (Q108P, R15L).
Extracts were treated with the thiol-reactive cross-linker AMS (10 mM, 37°C, 60 min) with or without prior reduction with DTT and heat denaturation (95°C,
10 min), and subjected to immunoblotting to analyze AMS-induced gel shift from oxidized (ox) to reduced (red) forms of CHCHD10. Note that 95°C treatment has
no additional effect on AMS accessibility of CHCHD10 Q108P indicating impaired folding compared to wild-type and R15L. Upper and lower panel show short and
long exposure of the same blot, respectively. Asterisk denotes degradation product.
Source data are available online for this figure.
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have to pass through the translocator of the outer membrane
(TOM). Distinct machinery directs these proteins further to their
final destination in the outer membrane, the intermembrane space,
the inner membrane or the matrix, depending on additional
sequence motifs. The classical import pathway is triggered by an
amphipathic N-terminal MTS recognized by the TOM complex. For
CHCHD10, the NCBI annotation and bioinformatic predictions tools
(e.g., Psort2 and MitoProt II) suggest the presence of a classical N-
terminal MTS with interspaced conserved arginines (amino acids
1–16). So far, the N-terminal region has been interpreted as an
MTS in several papers without rigorous experimental validation
(e.g., Perrone et al, 2017). Disruption of this putative MTS could
potentially explain pathogenicity of the common N-terminal muta-
tions. However, the R15L mutant was still localized to mitochondria
and expression levels and stability of CHCHD10 were only slightly
reduced, which is consistent with previous colocalization data for
this mutant (Woo et al, 2017). Other tested N-terminal variants
(R6G, P12S) did not reduce expression levels noticeable or even
increased expression (R15S). The dramatic reduction of endogenous
CHCHD10 levels in Mia40 knockdown cells suggests that cytosolic
CHCHD10 lacking the characteristic disulfide bonds is misfolded
and rapidly degraded. We therefore cannot exclude that the reduced
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Figure 6. Mia40 overexpression rescues CHCHD10 mutants.
Co-transfection of HeLa cells (A, C, D, E) and co-transduction of primary hippocampal rat neurons (B) with the indicated HA-tagged CHCHD10 (D10-HA) variants and Mia40-
MYC or empty vector (Ctrl).
A, B Immunofluorescence shows colocalization of wild-type CHCHD10 with Mia40. Scale bars represent 10 lm. Overexpression of Mia40 promotes expression and
mitochondrial localization of CHCHD10 Q108P.
C, D Immunoblot and quantification of mitochondrial fraction confirms CHCHD10 stabilization and increased mitochondrial localization upon Mia40 expression
compared to empty vector. Quantification normalized to ATP5A1. Data are shown as mean  SD. Kruskal–Wallis test: n = 4 biological replicates. Q108P Ctrl versus
Q108P Mia40 *P = 0.0126.
E AMS treatment visualizes disulfide-bond formation in CHCHD10 Q108P upon Mia40 expression comparable to wild-type CHCHD10 (with endogenous Mia40
levels). Actin is used as loading control. Note that DTT treatment has no effect on AMS cross-linking of actin, because all its cysteines are reduced in the
cytoplasmic environment. Asterisk denotes degradation product.
Source data are available online for this figure.
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expression of R15L is due to slightly less efficient mitochondrial
import. Indeed, consistent with other recent reports, CHCHD10
R15L has a shorter half-life time than wild-type (Brockmann et al,
2018). The N-terminal arginine-rich sequence may enhance mito-
chondrial import although it is neither necessary nor sufficient for
mitochondrial import by itself. Truncation of the N-terminus did not
further impair mitochondrial import in Q108P. The more dramatic
effect of the Q108P mutation on mitochondrial import and half-life
time may explain the early age of onset in our patient.
Deletion of the whole CHCH domain completely abolished mito-
chondrial import of CHCHD10. The Mia40 redox system mediates
import of proteins with twin CX3C and CX9C motifs into the inter-
membrane space, including CHCH domain proteins (Mesecke et al,
2005). We show that mitochondrial import of CHCHD10 critically
depends on Mia40. Strikingly, overexpression of Mia40 promotes
import of not only wild-type CHCHD10 but also the Q108P and
R15L mutants. In yeast, Mia40 levels are rate limiting for mitochon-
drial import suggesting it acts as a trans-site receptor for import
(Peleh et al, 2016). In addition, disulfide-bond formation is impaired
in the Q108P mutant, which may be due to disturbed a-helix forma-
tion in the CHCH domain because proline is a strong helix breaker
(Darshi et al, 2012). Interestingly, exome sequencing of ~ 2,000
mostly sporadic ALS cases revealed a mutation (C122R) in one of
the critical cysteines in the CHCH domain that also impaired mito-
chondrial import (ALSdb, Cirulli et al, 2015).
Our analysis of all reported missense CHCHD10 variants suggests
that mutations within the hydrophobic region (G58R, S59L, G66V,
and G66S) might invoke additional pathomechanisms because they
still allow mitochondrial targeting but lead to intra-mitochondrial
clustering. Surprisingly, a similar localization pattern was observed
for the E127K variant, but not for other variants in the CHCH domain.
Recently, partial nuclear localization and transcriptional effects
of CHCHD10 and a homologous protein, CHCHD2, have been
reported (Aras et al, 2015, 2017; Woo et al, 2017), particularly
under stress conditions such as TDP-43 overexpression or oxidative
stress. We detected some nuclear staining (Figs 1B and 3A) for
CHCHD10 Q108P and other variants with strongly impaired mito-
chondrial import, suggesting they might additionally cause a gain of
toxic function.
Relevance of CHCHD10 impairment for ALS/FTD
Mitochondrial dysfunction has long been implicated in the patho-
genesis of ALS (Smith et al, 2017). ALS-causing mutations in SOD1
inhibit respiration and cause mitochondrial damages (Magrane et al,
2009), and poly-Gly-Arg/Pro-Arg translated from the expanded
C9orf72 hexanucleotide repeat induce oxidative stress and disrupt
mitochondrial architecture (Lopez-Gonzalez et al, 2016). Further-
more, pathogenic OPTN mutations impair mitochondrial clearance
by mitophagy (Wong & Holzbaur, 2014). Mitochondrial dysfunction
has been linked to other neurodegenerative diseases and may
explain the broad clinical symptoms associated with CHCHD10
mutations. Interestingly, we noticed reduced spare respiratory
capacity upon CHCHD10 knockdown or CRISPR/Cas9-mediated
truncation consistent with findings in patient fibroblasts with
CHCHD10 S59L (Genin et al, 2016). Importantly, spare respiratory
capacity was also reduced in lymphoblasts showing reduced
CHCHD10 expression due to nonsense-mediated decay caused by a
Q108* mutation in an FTD patient (Perrone et al, 2017). This may
impair ATP synthesis in patient motoneurons or muscle and may be
accompanied by enhanced formation of damaging reactive oxygen
species. Several previous reports of conflicting findings of respira-
tory function in CHCHD10 cellular models (mutant, knockdown,
and overexpression) and the recent finding of impaired respiration
in muscle but not in whole brain of homozygous CHCHD10 knock-
out mice suggest cell type-specific effects are at play (Burstein et al,
2018; Straub et al, 2018). Interestingly, CHCHD10 knockdown in
zebrafish also causes muscle pathology (Brockmann et al, 2018).
Altered metabolism in muscle may promote to ALS pathogenesis
(Loeffler et al, 2016). AIFM1, which is required for mitochondrial
targeting of Mia40, and thus indirectly of CHCHD10, has been linked
to mitochondrial encephalopathy and axonal neuropathy (Ghezzi
et al, 2010; Rinaldi et al, 2012). AIFM1 knockdown appeared to
reduced CHCHD10 levels after 3 days (without reaching statistical
significance), but longer knockdown may be required for a more
severe effect due to its indirect action via Mia40.
Together, our data demonstrate that the Q108P mutation almost
completely prevents mitochondrial import and perturbed mitochon-
drial function may ultimately lead to motoneuron degeneration. The
stronger effect of Q108P on mitochondrial import compared to
previously characterize pathogenic variants may explain the early
onset and aggressive course of ALS in our patient. Our findings have
implications for genetic counseling of novel CHCHD10 variants and
suggest future therapeutic approaches: (i) Variants in conserved
residues of the CHCH domain and nonsense mutations (e.g., the
previously reported Q108*) are likely pathogenic. Variants in the
hydrophobic region primarily alter CHCHD10 distribution within
mitochondria. Thus, analyzing mitochondrial import and clustering
within mitochondria may be used to assess pathogenicity of novel
variants. (ii) Unless the mutant CHCHD10 causes a toxic gain-of-
function phenotype, epigenetic boosting of CHCHD10 expression
may rescue haploinsufficiency by increasing expression of the wild-
type allele. (iii) It may be possible to pharmacologically activate the
Mia40/Erv1 disulfide relay system using small redox-compounds.
Boosting Mia40 activity or expression may promote import of
mutant and wild-type CHCHD10 and thus restore its function within
mitochondrial respiration. Most importantly, our report of a novel
aggressive mutation with clear functional consequences strongly
supports the genetic linkage of CHCHD10 to ALS/FTD pathogenesis.
Materials and Methods
Patient materials, clinical history, and sequencing
All procedures on human subjects were in accordance with the
WGA Declaration of Helsinki and the Department of Health and
Human Services Belmont Report. The Q108P patient consented to
diagnostic DNA testing for ALS mutations. All information was
obtained from the hospital files. No experiments were done on the
patient or using patient material. Genomic DNA was sequenced with
a TruSeq Custom Amplicon kit on a MiSeq (Illumina) according to
the protocol from the manufacturer. The custom gene panel covered
all exons of CHCHD10, CHMP2B, GRN, MAPT, NEK1, OPTN,
PSEN1, PSEN2, SOD1, TARDBP, TBK1, TUBA4A, TREM2 and the
exons with known pathogenic mutations of APP (exons 12–15),
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CSF1R (exon 13–21), FUS (exon 6, 14, 15), HNRNPA1 (exon 9),
HNRNPA2B1 (exon 10), MATR3 (exon 1), VCP (exons 3, 5, 6, 11).
The CHCHD10 Q108P mutation was confirmed by Sanger Sequenc-
ing of genomic DNA (primers GTGGCCCCAGGTTTGAAAC and
CAATCTGGTGTTGTGGTCTGG). Repeat primed PCR for C9orf72
repeat expansion was performed as described previously (van der
Zee et al, 2013).
Epstein–Barr virus (EBV)-transformed lymphoblast cell lines
were established according to standard procedures for previously
reported patients and controls (Perrone et al, 2017). All subjects
had given informed consent.
DNA constructs, siRNA, and transfection
CHCHD10 and Mia40/CHCHD4 were amplified from HEK293T
cDNA and cloned in the FUW3a lentiviral expression vector contain-
ing a C-terminal HA or myc epitope tag. As controls we used the
empty vectors containing only the epitope tag. The following
CHCHD10 truncations were generated: D1–16 (DNT), D108–142
(Q108*), D92–142 (DCHCH). Q108P and R15L were introduced by
standard mutagenesis. For Figs 4 and EV2, we introduced several
patient variants in a codon-optimized synthetic gene with reduced
GC-content encoding human CHCHD10. All constructs were
sequence verified. We used Silencer Select siRNA targeting human
Mia40/CHCHD4 (s43607, Thermo Fisher Scientific), human
CHCHD10 (s53406, Thermo Fisher Scientific), human Erv1/Gfer
(s5704, Thermo Fisher Scientific), human AIFM1 (s17440, Thermo
Fisher Scientific), and the Silencer Select Negative Control No. 1
(#4390844, Thermo Fisher Scientific). HeLa cells were transfected
using Lipofectamine 2000 (Thermo Fisher Scientific).
CRISPR/Cas9 genome editing
HAP1 cells (Horizon Discovery) were transfected with Cas9
(Addgene plasmid #52962) and sgRNA (TCTGAGTGGTGGAA
CAGTCC in Addgene plasmid #41824) using Lipofectamine 3000
(Thermo Fisher Scientific). After 12 h, medium was exchanged for
24 h before splitting into selection medium containing 8 lg/ml blas-
ticidin and 400 lg/ml Zeocin. After 3 days, selection medium was
removed and cultured for 10–14 days till single cell clones were visi-
ble. Individual clones were picked and cultured in 96 wells. For
screening, genomic DNA was extracted with the NucleoSpin Tissue
96 well kit (Macherey-Nagel) according to manufacturer’s instruc-
tions. The region of CHCHD10 targeted by the sgRNA was PCR
amplified (GGTTTGAAACGCACCTCCAG and AGGTGCAAGAGGA
GGGTTG) using the Q5 High-Fidelity Master Mix (New England
Biolabs) and analyzed by Sanger sequencing.
Antibodies
The following primary antibodies were used: anti-HA (clone 3F10,
Thermo Fisher - IF 1:10, WB 1:50), anti-myc (9E10 hybridoma
supernatant, WB 1:15, supernatant of clone 9E10, IF 1:200, puri-
fied), anti-ATP5A1 (WB 1:1,000, IF 1:250, clone 15H4C4, abcam
14748), anti-CHCHD10 (C-terminal WB 1:500, IF 1:100, abcam
121196), anti-CHCHD10 (N-terminal, WB 1:500, abcam ab124186),
anti-MTCO2 (IF 1:100, abcam 3298), anti-actin (WB 1:3,000, clone
A5316, Sigma), anti-calnexin (WB 1:7,000, clone SPA-860, Enzo Life
Sciences), anti-CHCHD4 (Mia40, WB: 1:1,000, Proteintech 21090-1-
AP) anti-AIF (AIFM1, WB 1:1,000, abcam ab32516), anti-Gfer (Erv1,
WB 1:200, Atlas Antibodies HPA041227).
Cell culture, mitochondrial fractionation
HeLa cells were transfected with plasmids and siRNA using Lipofec-
tamine 2000 (Thermo Fisher Scientific) according to the manufac-
turer’s instructions. Three days after transfection, mitochondria
were isolated using the Qproteome Mitochondria Isolation Kit (Qia-
gen). The cytosolic fraction was precipitated with four volumes of
ice-cold acetone and incubated for 15 min on ice. After centrifuga-
tion (10 min, 12,000 g, 4°C), the pellet was washed twice with
acetone and air dried. The cytosolic pellet and the highly purified
mitochondrial pellet were resuspended in RIPA buffer (137 mM
NaCl, 20 mM Tris pH 7.5, 0.1% SDS, 10% glycerol, 1% Triton X-
100, 0.5% deoxycholate, 2 mM EDTA) containing protease inhibitor
cocktails (1:100, Sigma), incubated for 20 min on ice, and sonicated
for 10s. Afterward, the protein concentration was determined using
BCA assay (Interchim). After adding 4× Laemmli buffer (Bio-Rad)
containing 2-mercaptoethanol, samples were denatured (95°C,
10 min) and loaded with the same protein amount on Novex
10–20% Tris-Tricine gels (Life Technologies).
Protein stability and immunoblotting
For protein stability analysis, HeLa cells were treated 2 days after
transfection with 150 lg/ml cycloheximide dissolved in DMSO or
DMSO only for 0, 4, 8, and 24 h.
For immunoblotting of the whole cell lysates, cells were lysed in
RIPA buffer (137 mM NaCl, 20 mM Tris pH 7.5, 0.1% SDS, 10%
glycerol, 1% Triton X-100, 0.5% deoxycholate, 2 mM EDTA) with
protease inhibitor cocktails (1:100, Sigma) and incubated on ice
(20 min). After centrifugation (18,000 g, 15 min), the supernatant
was transferred into a new tube, protein concentration was deter-
mined by BCA assay (Interchim), and 4× Laemmli buffer (Bio-Rad)
containing 2-mercaptoethanol was added. Samples were denatured
at 95°C for 10 min and loaded on Novex 10–20% Tris-Tricine gels
(Life Technologies) or 12.5% SDS–PAGE gels.
Immunoprecipitation
HeLa cells were lysed at 4°C for 20 min in lysis buffer (120 mM
NaCl, 1 mM EDTA, 0.5% NP-40, 20 mM Tris–HCL pH 8) supple-
mented with protease and phosphatase inhibitors and centrifuged at
13,000 g for 10 min. HA-labeled magnetic beads (Thermo Fischer
88836) were washed with 4°C lysis buffer; 5% of the cell lysate was
used as an input control and the rest of the cell lysate was incubated
at 4°C with HA-labeled beads overnight. Beads were washed
three times with 4°C lysis buffer supplemented with protease and
phosphatase inhibitors, boiled in 50 ll Laemmli buffer (Bio-Rad)
containing 2-mercaptoethanol, and analyzed by immunoblotting on
Novex 10–20% Tris-Tricine gels (Life Technologies).
Neuronal cell culture and lentivirus production
Primary hippocampal cultures were prepared from E19 rats as
described previously and plated on glass coverslips coated with
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poly-D-lysine (Guo et al, 2018). Lentivirus was packaged in
HEK293FT cells as described (Guo et al, 2018).
Immunofluorescence
After washing once with PBS, HeLa cells (2 days after transfec-
tion) and transduced primary hippocampal rat neurons (DIV3 + 4)
were fixed for 10 min at room temperature (4% paraformalde-
hyde and 4% sucrose in PBS). Primary and secondary antibodies
were diluted in GDB buffer (0.1% gelatin, 0.3% Triton X-100,
450 mM NaCl, 16 mM sodium phosphate pH 7.4). For visualizing
the nucleus, cells were stained with DAPI (1:5,000 in PBS,
10 min, RT). After mounting the coverslips with FluoromountTM
Aqueous Mounting medium (Sigma), images were taken with
LSM710 confocal microscope (Carl Zeiss, Jena) using a 63× oil
immersion objective (NA 1.4).
RNA isolation and quantitative RT–PCR
After 3 days of transfection, RNA isolation was conducted with the
RNeasy- and QIAshredder kit (Qiagen) following the manufacturer’s
instructions. cDNA was generated using the TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems) with random
hexamer primers according to the manufacturer’s instructions. RT–
qPCR was performed on the CFX384-Real-Time system (Bio-Rad)
using following primers: CHCHD10 (Hs01369775_g1, Thermo
Fisher), Mia40/CHCHD4 (Hs01027804_g1, Thermo Fisher), AIFM1
(Hs00377585_m1, Thermo Fisher), Erv1/GFER (Hs00193365_m1,
Thermo Fisher), B2M (4326319E, Thermo Fisher), GAPDH
(Hs02758991_g1, Thermo Fisher). Signals were normalized to
GAPDH and B2M with the CFX Manager program (Bio-Rad) accord-
ing to the DDCT method.
Analysis of disulfide-bond formation
We used thiol-reactive 4-acetamido-40-maleimidylstilbene-2,20-
disulfonic acid (AMS, Thermo Fisher) to analyze disulfide-bond
formation following the protocol by (Gross et al, 2011). HeLa
cells were lysed in RIPA buffer (137 mM NaCl, 20 mM Tris pH
7.5, 0.1% SDS, 10% glycerol, 1% Triton X-100, 0.5% deoxy-
cholate, 2 mM EDTA) for 20 min on ice. After centrifugation
(18,000 g, 15 min, 4°C), the supernatant was divided and incu-
bated at room temperature or 95°C for 10 min with or without
15 mM dithiothreitol (DTT). Afterwards, proteins were precipi-
tated with trichloroacetic acid (TCA). Here, one volume of a
8 M TCA stock solution was added to four volumes of protein
sample, incubated at 4°C for 10 min, and centrifuged (18,000 g,
5 min, 4°C). After removing the supernatant, the pellet was
washed with ice-cold acetone and again centrifuged (18,000 g,
5 min, 4°C). These washing steps were repeated twice, and the
remaining pellet was dried at 95°C for 5–10 min. After acetone
evaporation, the pellet was resolved in buffer (2% SDS,
100 mM Tris pH 8, 100 mM NaCl, 10 mM EDTA) and 10 mM
AMS or distilled water was added. The samples were incubated
for 60 min at 37°C in the dark. After adding 50 mM iodoacetic
acid (IAA), Laemmli buffer (Bio-Rad) was added and the
proteins were analyzed by immunoblotting using 12.5% SDS–
PAGE gels.
Quantitative analysis of respiration
Oxygen consumption rate (OCR) was measured using the Seahorse
XF96 extracellular flux analyzer (Agilent). The day before,
siCHCHD10 knockdown or control siRNA transfected HeLa cells
were plated in growth medium in 96-well plates (Agilent). For OCR
measurements, growth medium was replaced with pre-warmed XF
assay medium (Agilent) supplemented with 10 mM glucose and
10 mM pyruvate, and cells were incubated at 37°C without CO2 for
60 min. To measure OCR in patient lymphoblastoid cells, 96-well
plates (Agilent) were coated with 30 ll of poly-D-lysine (50 lg/ml)
in 0.1 M borate buffer (pH 8.5) for 2 h and washed twice with
cell culture-grade water. One hour before the measurement,
The paper explained
Problem
Several mutations in CHCHD10 have been reported in familial and
sporadic cases of amyotrophic lateral sclerosis (ALS), frontotemporal
dementia (FTD), spinal muscular atrophy, and mitochondrial myopa-
thy, but their mode of action is unclear. Since disease progression in
mutation carriers is usually slow and penetrance is incomplete, some
geneticists raised concerns, whether CHCHD10 mutations are truly
pathogenic. CHCHD10 is a small protein localized to the intramem-
brane space of mitochondria. It is involved in organizing cristae
morphology and has been linked to stability of mitochondrial DNA.
Loss-of-function and gain-of-function pathomechanisms have been
discussed. Several patient mutations, including R15L, are located in
the proposed N-terminal mitochondrial targeting signal (MTS), but
the mitochondrial import mechanism of CHCHD10 has not been care-
fully analyzed experimentally, although restoring mitochondrial
import of CHCHD10 may be a therapeutic strategy.
Results
We discovered a novel CHCHD10 mutation (Q108P) in a highly
conserved residue within the coiled-coil-helix-coiled-coil-helix (CHCH)
domain in a young ALS patient with aggressive disease progression
and analyzed its pathogenicity in transfected heterologous cells and
primary rat neurons. The Q108P mutation blocked mitochondrial
import nearly completely suggesting a loss-of-function mechanism.
Moreover, reduced CHCHD10 expression in heterologous and patient
cells inhibited mitochondrial respiration. The R15L mutation had only
a small effect on overall protein levels, but largely spared mitochon-
drial localization. Several other CHCHD10 variants reported in ALS/FTD
patients showed diffuse cytoplasmic localization (C122R) or dot-like
clustering within mitochondria (G58R, S59L, G66V, G66S, E127K) and
reduced stability and/or expression (R15L, P23S, G58R, G66V, Q108P,
Q108*, C122R). Mitochondrial import of CHCHD10 is predominantly
driven by Mia40-dependent disulfide-bond formation in the CHCH
domain rather than the putative N-terminal MTS. Overexpression of
Mia40 strikingly boosts mitochondrial import of CHCHD10 Q108P.
Impact
The identification of a novel CHCHD10 mutation resulting in aggres-
sive ALS and a clear loss-of-function phenotype in vitro strongly
supports the genetic role of CHCHD10 in ALS pathogenesis. This
unusual mutation revealed Mia40-dependent mitochondrial import of
CHCHD10 and suggests that activation of the Mia40-dependent mito-
chondrial import pathway could be a novel therapeutic strategy. Our
data supports the pathogenicity of several previously uncharacterized
CHCHD10 variants found in ALS/FTD patients via a loss-of-function
mechanism (R15L, P23S, G58R, G66V, Q108P, Q108*, C122R) and/or
gain-of-function mechanism (G58R, S59L, G66V, G66S, E127K).
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lymphoblasts were plated (1.1 × 105cells/well) in pre-warmed XF
assay medium (Agilent) and incubated at 37°C without CO2. Oligo-
mycin (final concentration 1 lM), FCCP (0.75 lM), and rotenone
and antimycin A (10 lM each) were diluted with pre-warmed assay
medium and loaded into injector ports. Assay cycles included 4 min
of mixing, followed by 4 min of measurement.
Expanded View for this article is available online.
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Figure EV1. CHCHD10 mutants are less stable.
A CHCHD10-HA (D10-HA) level in whole cell lysates of HeLa cells transfected with empty vector (Ctrl) or HA-tagged CHCHD10 variants (WT, Q108P, or R15L).
B Line scans of CHCHD10-HA (D10-HA) and ATP5A1 intensity in immunofluorescence pictures (right) of HeLa cells transfected with the indicated HA-tagged CHCHD10
constructs. Intensities of the red (ATP5A1, here shown in magenta) and the green (D10-HA) channels were measured along a 6.5-lm-long line (yellow), and diagrams
were generated with the plugin RGB-profiler in ImageJ. Scale bar represents 10 lm.
C Protein stability of HA-tagged CHCHD10 (WT, Q108P, or R15L) was measured in HeLa cells transfected for 2 days and then treated with cycloheximide (+CHX) or
vehicle (+DMSO) and harvested after 0, 4, 8, and 24 h. Note that steady state levels of CHCHD10 Q108 and R15L in DMSO-treated cells are also lower at 24 h, i.e.
3 days after transfection.
D Quantification of HA-tagged CHCHD10 (D10-HA) protein levels normalized to ATP5A1. Transfected HeLa cells were treated with cycloheximide for 0, 4, 8, and 24 h.
Data are shown as mean  SD. Two-way ANOVA (followed by Turkey’s multiple comparison): n = 3 biological replicates, t = 4 h WT versus Q108P: ***P < 0.0001,
t = 4 h WT versus R15L: **P = 0.002, t = 8 h WT versus Q108P: ***P < 0.0001, t = 8 h WT versus R15L: **P = 0.0076.
E Half-life analysis of the respective CHCHD10 variant was calculated by nonlinear regression analysis. Data are shown as mean  SD. n = 3 biological replicates.
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Figure EV2. Import deficit of CHCHD10 Q108P is replicated with a high-expressing synthetic gene.
A Sequence of the codon-optimized synthetic CHCHD10 gene used to reduce GC-content in order to facilitate cloning of many patient-derived variants.
B Comparison of HA-tagged CHCHD10 (D10-HA) protein levels in whole cell lysates of HeLa cells transfected with CHCHD10 constructs harboring either the original or
the codon-optimized synthetic cDNA.
C Mitochondrial localization of synthetic CHCHD10-HA (D10-HA) was analyzed in transfected HeLa cells by co-staining with a mitochondrial marker (ATP5A1). Scale bar
represents 10 lm.
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Figure EV3. Subcellular distribution of CHCHD10 patient variants.
A, B HeLa cells were transfected with HA-tagged CHCHD10 (D10-HA) patient variants in two sets (A and B). Immunofluorescence shows expression pattern of
CHCHD10-HA (D10-HA) variants compared to the mitochondrial marker ATP5A1. Scale bars represent 10 lm.
Carina Lehmer et al CHCHD10 Q108P blocks mitochondrial import EMBO Molecular Medicine
ª 2018 The Authors EMBO Molecular Medicine e8558 | 2018 EV3
54
A
D E
ATP5A1
ATP5A1
ATP5A1
CHX
D10-HA
D10-HA
55-
17-
55-
17-
55-
17-
W
T
Q
10
8P
R
15
L
C
trl
M
ia
40
C
trl
M
ia
40
C
trl
M
ia
40
C
trl
M
ia
40
0h 4h 8h 24h
2
0
4
M
ia
40C
trl
M
ia
40C
trl
M
ia
40C
trl
D
10
-H
A
/A
TP
5A
1
Q108P
**
**
C
Q108PWTCtrl R15L
C
trl
M
ia
40
C
trl
M
ia
40
C
trl
M
ia
40
C
trl
M
ia
40
Actin
D10
Cytosol
D10-HA
Mia40-MYC
45-
17-
17-
17-
Mia40
C
trl
W
T
R
15
L
Q
10
8P
D10-HA IPInput
17-
D10-HA
Δ
C
H
C
H
Q
10
8*
C
trl
W
T
R
15
L
Q
10
8P
Δ
C
H
C
H
Q
10
8*
17-
R15LWT
M
ia
40C
trl
M
ia
40C
trl
M
ia
40C
trl
M
ia
40C
trl
M
ia
40C
trl
M
ia
40C
trl
6
2
0
4
6
2
0
4
6
*
*
**
D
10
-H
A
/A
TP
5A
1
D
10
-H
A
/A
TP
5A
1
n.s. n.s. n.s.
n.s.
0h 4h 8h 0h 4h 8h 0h 4h 8h
D10-HA
B DTT
temp RT 95
AMS − + + +
− +
RT RT
22-
22-
D10-CT
D10-NT
ox
red
ox
red
Actin50-
Figure EV4. Mia40 binds and stabilizes CHCHD10.
A Co-immunoprecipitation of Mia40-MYC and CHCHD10-HA (D10-HA) wild-type (WT), variants (Q108P, R15L, DCHCH, Q108*), or empty vector (Ctrl) from transfected
HeLa cells. Input represents 5% of the whole cell lysate used for immunoprecipitation. Immunoblot of the co-immunoprecipitation was detected with antibodies
against Mia40 and HA. Low binding may be explained by the transient interaction of the oxidoreductase Mia40 with its substrate CHCHD10.
B AMS treatment shows disulfide-bond formation of endogenous CHCHD10 in HeLa cells. Note that endogenous CHCHD10, detected with an N-terminal antibody
(D10-NT), shows a similar pattern. The C-terminal CHCHD10 antibody poorly detects AMS coupled endogenous CHCHD10 indicating that the epitope overlaps with
the cysteine residues. Actin is used as loading control. Note that DTT treatment has no effect on AMS cross-linking of actin, because all its cysteines are reduced in
the cytoplasmic environment.
C Immunoblotting shows elevation of CHCHD10 upon Mia40 expression also in cytosolic fractions with indicated antibodies.
D, E Protein stability of HA-tagged CHCHD10 (WT, Q108P, or R15L) upon MIA40 overexpression was measured in HeLa cells treated with cycloheximide (+CHX) and
compared to empty vector co-transfection (Ctrl). Cells were harvested after 0, 4, 8, and 24 h. Quantification of CHCHD10-HA (D10-HA) protein levels normalized to
ATP5A1. Data are shown as mean  SD. Two-way ANOVA (with Sidak’s multiple comparisons test): n = 4 biological replicates, WT: t = 0 h Ctrl versus Mia40:
*P = 0.0146, t = 4 h Ctrl versus Mia40 *P = 0.0168; Q108P: t = 0 h Ctrl versus Mia40: **P = 0.0039, t = 4 h Ctrl versus Mia40 **P = 0.0089; R15L: t = 0 h Ctrl
versus Mia40: **P = 0.0014.
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Protein aggregation and dysfunction of the ubiquitin-
proteasome system are hallmarks of many neurode-
generative diseases. Here, we address the elusive
link between these phenomena by employing cryo-
electron tomography to dissect the molecular archi-
tecture of protein aggregates within intact neurons
at high resolution. We focus on the poly-Gly-Ala
(poly-GA) aggregates resulting from aberrant transla-
tion of an expanded GGGGCC repeat in C9orf72, the
most common genetic cause of amyotrophic lateral
sclerosis and frontotemporal dementia. We find
that poly-GA aggregates consist of densely packed
twisted ribbons that recruit numerous 26S protea-
some complexes, while other macromolecules are
largely excluded. Proximity to poly-GA ribbons stabi-
lizes a transient substrate-processing conformation
of the 26S proteasome, suggesting stalled degrada-
tion. Thus, poly-GA aggregates may compromise
neuronal proteostasis by driving the accumulation
and functional impairment of a large fraction of
cellular proteasomes.
INTRODUCTION
The ubiquitin-proteasome system (UPS) is the main cellular
pathway for targeted protein degradation (Collins and Goldberg,
2017; Hershko et al., 2000). UPS alterations have been impli-
cated in many human diseases, including multiple neurodegen-
erative disorders (Dantuma and Bott, 2014; Hipp et al., 2014;
Schmidt and Finley, 2014). In particular, frontotemporal demen-
tia (FTD) and amyotrophic lateral sclerosis (ALS) have been
associated with mutations in UPS components (Deng et al.,
2011; Johnson et al., 2010; Watts et al., 2004) and altered UPS696 Cell 172, 696–705, February 8, 2018 ª 2018 Elsevier Inc.function (Cheroni et al., 2009; Tashiro et al., 2012). However,
the contribution of UPS dysfunction to neurodegeneration and
its underlying mechanisms are not yet well understood.
UPS impairment also has been linked to C9orf72 mutations,
the most common genetic cause of ALS/FTD (Edbauer and
Haass, 2016; Freibaum and Taylor, 2017; Gendron and Petru-
celli, 2017; Lin et al., 2017). A massive expansion of a GGGGCC
(G4C2) repeat in a non-coding region of theC9orf72 gene to up to
several thousand copies is found in 10%–50% of familial
ALS/FTD cases and in 5%–7% of patients with sporadic disease
(DeJesus-Hernandez et al., 2011; Majounie et al., 2012; Renton
et al., 2011; van der Zee et al., 2013). Three non-mutually exclu-
sive mechanisms have been suggested tomediate the toxicity of
the G4C2 repeat expansion: (1) loss of native function of the
C9orf72 protein due to reduced transcription of themutant allele,
(2) aberrant RNA interactions, and (3) production of toxic
translation products and aggregates via repeat-associated
non-ATG (RAN) translation (Zu et al., 2011).
Although the G4C2 repeat is found in a non-coding region of
the C9orf72 gene, sense and anti-sense transcripts are
unconventionally translated in all reading frames into five
dipeptide-repeat proteins (Ash et al., 2013; Gendron et al.,
2013; Mori et al., 2013a, 2013b; Zu et al., 2013): poly-GA,
poly-GR, poly-GP, poly-PR, and poly-PA. While all five proteins
form TDP-43-negative, p62-positive inclusions in ALS/FTD
patient brain, the vast majority of these aggregates contain
poly-GA (Mackenzie et al., 2015; Mori et al., 2013b; Zhang
et al., 2014).
Poly-GA expression leads to toxicity in heterologous cells,
primary neuron cultures, and mice (Jovicic et al., 2015; May
et al., 2014; Schludi et al., 2017; Yamakawa et al., 2015; Zhang
et al., 2014, 2016). Similar to other toxic aggregating proteins
(Olzscha et al., 2011; Park et al., 2013), poly-GA aggregates
sequester critical cellular factors including Unc119 and multiple
UPS components (May et al., 2014; Zhang et al., 2016). UPS
impairment is critically involved in poly-GA-mediated toxicity
(Yamakawa et al., 2015; Zhang et al., 2014, 2016), but our59
Figure 1. In Situ Neuronal Poly-GA Aggre-
gates Form Twisted Ribbons
(A) Tomographic slice of an aggregate within a
(GA)175-GFP-transducedneuron (DIV5+5).Colored
boxes show macromolecules magnified in (C).
(B) 3D rendering of the aggregate shown in (A).
Selected poly-GA ribbons (red) magnified in (D) are
indicated.
(C) Series of higher magnification tomographic
slices of representative protein complexes de-
tected in the tomogram shown in (A). Yellow and
magenta boxes show the typical smaller (yellow)
and larger (magenta) ring-like structures found in
the aggregate region. Blue and orange boxes
show side views of single-capped (blue) and
double-capped (orange) 26S proteasomes.
(D) Selected ribbons from (B) rotated and magni-
fied for visualization. Note the variable width of the
ribbons (a-c). Some ribbons show bifurcations
(d and e).
(E and F) Higher magnification tomographic slices
of aggregates within neurons transduced with
(GA)175-GFP (DIV 5 + 5) (E) or untagged (GA)175
(DIV 5 + 5) (F). Yellow boxes mark similar small
ring-like structures like in (A). Note that (GA)175-
GFP ribbons (red arrowheads) are decorated by
additional densities (green arrowheads), which are
missing from untagged (GA)175 ribbons. Tomo-
graphic slices are 5 nm thick.
Scale bars, 200 (A and B) and 50 nm (C–F).
See also Figure S1.understanding of the underlying mechanisms remains incom-
plete. This is aggravated by the limited structural information
currently available on poly-GA aggregates, especially within
an unperturbed cellular context.
Here, we address these challenges using state-of-the-art
cryo-electron tomography (cryo-ET) technologies, which allow
3D imaging of the cell interior in close-to-native conditions and
at molecular resolution (Beck and Baumeister, 2016). We reveal
the structure and cellular interactions of poly-GA aggregates
within intact neurons to an unprecedented level of detail. Inter-
estingly, we find that poly-GA aggregates consist of densely
packed twisted ribbons that recruit large numbers of 26S
proteasome complexes. Structural analysis of these proteasome
complexes by subtomogram averaging and classification into
functional states provides mechanistic insights into proteasomal
dysfunction in C9orf72 ALS/FTD.
RESULTS
Poly-GA Aggregates Contain Densely Packed Twisted
Ribbons
To study neuronal poly-GA aggregates without interference
from C9orf72 loss-of-function and RNA-mediated toxicity, we
transduced primary rat neuronal cultures with a GFP-tagged
codon-modified synthetic construct expressing (GA)175-GFP
using an ATG start codon (May et al., 2014). We have
previously shown that lentiviral poly-GA expression results in
inclusions of similar size and poly-GA intensity as in C9orf72 pa-
tient tissue (May et al., 2014). Neurons were transduced at day
in vitro (DIV) 5 and allowed to express the protein for another5 days (DIV 5 + 5). The cultures were then vitrified and subse-
quently imaged by cryo-light microscopy to locate cellular
poly-GA inclusions (Figure S1A). Correlative microscopy al-
lowed the production of 100 to 200 nm-thick lamellas at the
location of these aggregates using cryo-focused ion beam
milling (Bauerlein et al., 2017; Rigort et al., 2012) (Figures
S1B–S1D). Lastly, the samples were transferred to a cryo-trans-
mission electron microscope for high-resolution 3D imaging by
cryo-ET (Figures S1E and S1F).
Poly-GA aggregate cross-sections were typically 3 mm in
diameter and consisted of a dense network of elongated poly-
morphic ribbons (Figures 1A and 1B). Whereas the thickness
of the ribbons was well defined (13–15 nm), their length
(100 nm–1 mm) and width (20–80 nm) varied considerably (Fig-
ure 1D, top). Our measurements likely underestimate ribbon
length, as the parts of ribbons oriented perpendicular to the
electron beam were not reliably detected because of missing
information along this direction (Lucic et al., 2005). The ribbons
were twisted along their axis with a variable helical pitch, and
often bifurcated and/or associated laterally with neighboring
ribbons (Figure 1D, bottom). This polymorphism contrasts
with the uniform fibrils forming polyQ-expanded huntingtin
exon 1 aggregates in mammalian cells (Bauerlein et al., 2017).
Poly-GA ribbons were also more densely packed than polyQ
fibrils, which occupied a lower fraction of the inclusion volume
(poly-GA,R 10%; polyQ,% 4%). Thus, different amyloids adopt
different morphologies in situ.
However, similarly to GFP-tagged polyQ fibrils, GFP-labeled
poly-GA ribbons were decorated by additional densities (Fig-
ure 1E). To investigate the nature of these densities, neuronsCell 172, 696–705, February 8, 2018 697
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Figure 2. Mapping Macromolecules within
Poly-GA Aggregates Shows a Substantial
Recruitment of 26S Proteasomes
(A) 3D rendering of an aggregate within a neuron
transduced with (GA)175-GFP (DIV 5 + 5) showing
different macromolecules found either within or at
the periphery of the aggregate. Red, poly-GA rib-
bons; green, 26S proteasomes; yellow, ribosomes;
purple, TRiC/CCT chaperonins. The macromole-
cules are mapped in their original locations and
orientations, computationally determined by tem-
plate matching and subtomogram averaging.
(B–E) Maximum intensity projection heatmaps of
the molecular species shown in (A). Note that the
proteasomes (C) aremostly found in between poly-
GA ribbons (B), whereas ribosomes (D) almost
exclusively occur outside of the aggregate. TRiC/
CCT molecules (E) mostly populate the aggregate
periphery, but some can also be found between
poly-GA ribbons.
See also Figures S2–S5 and Movie S1.were co-transduced with untagged poly-GA and tagRFP-p62,
as p62 co-localizes with poly-GA aggregates (May et al.,
2014; Mori et al., 2013b; Yamakawa et al., 2015; Zhang et al.,
2014) and allows targeting untagged poly-GA by correlative mi-
croscopy. As for polyQ fibrils (Bauerlein et al., 2017), the deco-
rating densities were absent from untagged poly-GA ribbons
(Figure 1F), demonstrating that these additional densities
require GFP for their formation and that the ribbons consisted
indeed of poly-GA aggregates. Thus, poly-GA forms amyloid-
like ribbons in neurons.
26S Proteasomes Are Recruited to Poly-GA Aggregates
Unlike polyQ fibrils (Bauerlein et al., 2017), poly-GA ribbons did
not visibly interact with cellular endomembranes. However,
both the aggregate interior and periphery were densely popu-
lated by macromolecular complexes (Figures 1A, 1C, 1E, and
1F). Ribosomes were abundant around poly-GA aggregates but
largely absent from their interior. In contrast, the space between
poly-GA ribbons was densely populated with macromolecules
that appeared as 10-nm rings in tomographic cross-sections.
Larger (20 nm) cross-sectioned rings were also found at the
aggregate periphery and occasionally in the interior. To investi-
gate the identity of these macromolecules, we performed unbi-
ased subtomogram averaging (Figure S2A). A small set of parti-
cles were hand-picked from the tomogram, aligned, and
averaged. The resultant average was used as a template to
computationally search the tomogram for additional occurrences
of the same structure. These additional particles were then visu-
ally inspected, aligned, classified, and averaged again to
produce a higher resolution average. The iterative application of
this procedure yielded an average structure unequivocally corre-698 Cell 172, 696–705, February 8, 2018sponding to the 26S proteasome (Chen
et al., 2016a; Huang et al., 2016; Schweit-
zer et al., 2016; Wehmer et al., 2017) for
the smaller ring-like structures, and to
the TRiC/CCT chaperonin (Leitner et al.,
2012; Zang et al., 2016) for the largerones (Figures 2, 3, and S3A–S3C; Movie S1). Other large UPS
components, such as p97/VCP, did not appear abundant at
poly-GA aggregates.
The abundance of TRiC/CCT complexes was not significantly
different around poly-GA aggregates compared to the cell body
of control neurons (untransduced or transduced with GFP only).
However, the estimated concentration of proteasomes within the
aggregate (7 mM) was approximately 30-fold higher than in the
cell body (Figure S4B) or the processes (Asano et al., 2015) of con-
trol cells. Given that poly-GA expression did not increase overall
proteasome expression levels (Figure S4C), these data suggest
that proteasomes are removed from other regions of the cell to
accumulate within poly-GA aggregates. This is consistent with
immunofluorescence staining (Figure S4A) and biochemical frac-
tionation experiments showing reduced levels of Triton-soluble
neuronal proteasomes (Figure S4C). Furthermore, our tomograms
showed that 26S proteasomes almost exclusively accumulated
within the aggregate interior (Figures 2 and S5A–S5D). Taken
together, these results show that a substantial fraction of neuronal
26S proteasomes is sequestered into poly-GA aggregates.
To test the influence of the poly-GA expression level on
proteasome recruitment, we analyzed aggregates formed in
neurons at an earlier time point after transduction (DIV 5 + 3).
Although these aggregates were smaller, they contained a
similar concentration of proteasomes in their interior (Fig-
ure S5E). Importantly, analogous observations were made for
poly-GA aggregates generated from a RAN-translated (G4C2)73
construct, which more closely mimics the C9orf72 patient situa-
tion (Figures S4E and S5F). Thus, poly-GA aggregate
morphology and proteasome recruitment were comparable in
all the experimental conditions tested.61
Figure 3. Subtomogram Classification of
26S Proteasomes Reveals Enrichment of
Substrate Processing Conformations
(A–C) To analyze the functional state of protea-
some regulatory particles, we cut single- and
double-capped proteasomes by the half of the CP.
The resultant half proteasomes were classified
according to RP conformation into ground- or
substrate-processing states (Asano et al., 2015),
yielding two ground states (GS1, GS2) and two
substrate-processing classes (SPS1, SPS2).
(A and B) The four density maps are displayed in
solid surface representation in two different views.
The positions of the Rpn1, Rpn5, and Rpn6 sub-
units are indicated. Prominent densities in the
substrate binding region of SPS1 and SPS2 are
colored in pink. For each class, the percentage of
the total number of classified particles and the
global resolution are indicated.
(C) Same view as (A), with semi-transparent maps
superimposed with the atomic models generated
by MDFF. The classes, respectively, represent the
s1 state with different Rpn1 positions (GS1, GS2),
the s2 state (SPS1), and the s4 state (SPS2). Atomic
models are colored by subunits: Rpn1 (brown),
Rpn2 (yellow), Rpn9/5/6/7/3/12 (different shades of
green), Rpn8/Rpn11 (light/dark magenta), Rpn10
and Rpn13 (purple), AAA-ATPase hexamer (blue),
and CP (red).
See also Figures S2 and S3 and Table S1.Poly-GA Aggregation Alters Proteasome Structure
The 26S proteasome consists of a barrel-shaped 20S core par-
ticle (CP) that harbors the catalytic activity, bound to one or two
19S regulatory particles (RP). Regulatory particles are respon-
sible for substrate recognition, unfolding, and translocation into
the CP for proteolysis. Recent single-particle cryoelectron
microscopy (cryo-EM) studies have revealed how RP conforma-
tional dynamics are coupled to the functional cycle of the 26S
complex (Chen et al., 2016a; Unverdorben et al., 2014; Wehmer
et al., 2017). Initial binding of substrates to the 26S proteasome
presumably occurs in a low-energy ground state (s1) (see also Lu
et al., 2015). Bound substrates are committed for degradation
(s2 state) and then translocated into the CP (s3-s4 states). In
the s4 state, the gate of the 20S CP is open, allowing the sub-
strates to access the proteolytic chamber. We took advantage
of the large number of proteasome complexes recruited to
poly-GA aggregates to investigate their functional states in situ
by subtomogram averaging and classification (Figure S2B).
We first sorted 26S proteasomes according to the number of
regulatory particles (one or two) bound per CP. Previous struc-
tural (Asano et al., 2015) and biochemical (Tai et al., 2010) data
indicated that in control neurons the largemajority of 26S protea-
somes contain only one RP (single-capped 26S). In striking
contrast, 76% of poly-GA-associated 26S proteasomes were
double-capped (Figures S3D and S3F). Therefore, the labileinteraction between the proteasome
core and regulatory particles (Kleijnen
et al., 2007) is apparently stabilized within
poly-GA aggregates.We further classified 26S proteasomes by RP conformation
(Asano et al., 2015; Unverdorben et al., 2014). This yielded four
well-defined classes, two of which (GS1, GS2) were consistent
with the RP ground state conformation (s1), whereas the other
two (SPS1, SPS2) corresponded to substrate processing states
(s2-s4) (Figure 3). Interestingly, 37% of all 26S proteasomes
belonged to substrate processing classes, almost twice the
number than in control neurons (Asano et al., 2015) (Figures
S3E and S3G). Thus, poly-GA aggregates recruit a large number
of 26S proteasome regulatory particles, a substantial fraction of
which adopts substrate processing conformations.
The relatively high resolution of the classes (11.8–15.4 Å) (Fig-
ures 3 and S3H) enabled us to assign each class to a functional
state. To this end we employed molecular dynamics flexible
fitting (MDFF) (Trabuco et al., 2009) initiated through the atomic
models of the s1–s4 states of the yeast 26S proteasome (Fig-
ure 3C) (Wehmer et al., 2017). The s1 state was clearly the
best fit for the GS1 and GS2 classes (Table S1). The yeast s1
structure fitted GS1 (49% of the total number of particles)
without large discrepancies except for the position of the Rpn1
subunit, which in GS1 was similar to that observed in the human
26S proteasome (Chen et al., 2016a; Huang et al., 2016;
Schweitzer et al., 2016). Also, in agreement with these studies,
no prominent density was visible in our data for the Rpn13 sub-
unit. The GS2 class (13.7% of particles) was overall similar toCell 172, 696–705, February 8, 2018 699
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Figure 4. Detailed Structural Differences be-
tween 26S Proteasome Conformations
Highlight Its In Situ Structural Dynamics
and Interactions
(A) Superimposition of GS1 (green) and GS2 (cyan)
density maps aligned by their CP. Both classes are
consistent with the s1 state and differ only in the
position of Rpn1.
(B) Magnified view of the region boxed in (A)
showing a 25 rotation of the Rpn1 subunit in the
GS2 map.
(C) Atomic model of the GS2 class colored ac-
cording to the root-mean-square deviation (RMSD)
from the GS1 model. Note that the only substantial
differences are found in the Rpn1 region.
(D) Two views of the SPS1map (consistent with the
s2 state) shown in surface representation super-
imposedwith its atomicmodel. A prominent density
in the substrate binding region is colored in pink.
(E and F) Magnified view of the regions boxed in
(D). The atomic models of Rpn1 (E), Rpn2, and
Rpn10 (F) are shown in brown, yellow, and purple,
respectively. Parts of the additional density de-
noted by asterisks may correspond to protea-
some-bound ubiquitin or UBL domain proteins.
(G) Two views of the SPS2map (consistent with the
s4 state) shown in surface representation super-
imposed with its atomic model. A prominent
density in the substrate binding region is colored in
pink.
(H and I) Magnified view of the regions boxed in (G).
Note that the density in the Rpn2/10 region is
similar in the SPS1 and SPS2 class averages (I),
whereas no additional density was found on the
Rpn1 region of the SPS2 map (H).GS1, but the Rpn1 subunit pivoted 25 on its N-terminal region to
shift its C terminus toward the CP with respect to GS1 (Figures
4A–4C). This is a novel conformation of Rpn1, a particularly dy-
namic subunit (Asano et al., 2015; Huang et al., 2016; Schweitzer
et al., 2016; Wehmer et al., 2017) that serves as binding hub for
26S regulatory cofactors containing ubiquitin-like (UBL) domains
(Elsasser et al., 2002; Leggett et al., 2002) and was recently iden-
tified as an ubiquitin receptor (Shi et al., 2016).
SPS1 proteasomes (14.2% of particles) were most similar to
the substrate commitment state s2 (Table S1). In contrast, the
SPS2 class (23.1% of particles) was best fitted by the s4 model
of actively translocating proteasomes (Table S1). This is remark-
able because, in vitro, the s4 state was only recently discovered
in proteasomes incubated with non-hydrolyzable nucleotide an-
alogs (Wehmer et al., 2017), suggesting that it is normally a highly
transient conformation. Thus, the interaction of poly-GA aggre-
gates with the proteasome appears to stall its s4 conformation.
Both substrate processing classes showed prominent addi-
tional densities in the substrate binding region of the protea-
some, in contact with the ATPase ring (Figure 3). In SPS1 the
density was well defined (Figure 3), indicating a relatively stable
interaction with the 26S complex that may in part correspond to
bound UBL domain proteins (Aufderheide et al., 2015; Bashore
et al., 2015). The density contacted Rpn1 (Figures 3, 4D, and
4E), consistent with the bound UBL domains of Rad23 or the
ubiquitin C-terminal hydrolase 6 (Ubp6)/USP14 (Chen et al.,700 Cell 172, 696–705, February 8, 20182016b; Shi et al., 2016), and extended to another binding site
of Rad23 at the Rpn10 subunit (Hiyama et al., 1999; Mueller
and Feigon, 2003;Walters et al., 2002) (Figures 4D and 4F). Inter-
estingly, similar to our SPS1 class, Ubp6-bound proteasomes
have been shown to mainly adopt the s2 conformation (Aufder-
heide et al., 2015). Because the Rpn1 and Rpn10 UBL binding
sites also interact with ubiquitin, proteasome-bound ubiquiti-
nated substrates may also contribute to the extra density.
Consistent with this notion, the estimated molecular mass of
the density (70 kDa) was larger than Ubp6 (56 kDa) or Rad23
(40/44 kDa for Rad23A/B). For the SPS2 class, the additional
density contacted the Rpn10 subunit but not Rpn1 (Figures
4G–4I). The density was overall less well defined than for
SPS1, indicating a more dynamic interaction, perhaps involving
a more extensive participation of substrates (see below). There-
fore, both substrates and cofactors may contribute to the addi-
tional densities found on substrate processing proteasomes.
Direct Interactions with Poly-GA Aggregates Impair
Proteasome Function
To address the physiological role of the different proteasome
conformations observed, we investigated their cellular distribu-
tion bymapping the particles back into the tomograms (Figure 5).
We found that proteasome conformation correlated with the
distance to poly-GA ribbons (Figures 5B–5E, p < 0.001, chi-
square test, n = 6,080 regulatory particles from 4 tomograms).63
Figure 5. Spatial Mapping of Proteasomes within Poly-GA Aggregates Reveals Poly-GA Influence on Proteasome Conformation
(A) 3D rendering of an aggregate within a neuron transduced with (GA)175-GFP (DIV 5 + 5). Poly-GA ribbons (red), proteasomes in ground state (green), and
proteasomes in substrate processing states (blue). Proteasome location and orientation were determined by template matching and subtomogram averaging.
(B and C) Magnification of the region boxed in (A) showing only proteasomes less than 15 nm away from poly-GA ribbons (B) or 30–45 nm away (C). Poly-GA
ribbons are shown as a transparent red surface. Note that substrate processing proteasomes are more abundant close to poly-GA ribbons.
(D) Examples of SPS2 proteasomes directly touching poly-GA ribbons in the tomogram shown in (A). The additional density in the substrate binding region
overlaps with the poly-GA ribbons.
(E) Plot of proteasome conformation versus distance to poly-GA ribbons. The influence of the distance to poly-GA ribbons in proteasome conformation was
statistically significant (p < 0.001, chi-square test, n = 6,080 regulatory particles from 4 tomograms).
Scale bars, 200 nm (A) and 100 nm (B and C).
See also Figure S4.For proteasomes directly touching (Figure 5D) or very close to
ribbons, the SPS2 class was overrepresented (36% versus
23% of the total proteasomes (Figure 5E), whereas the fraction
of GS1 proteasomes was smaller than within the total (40%
versus 49%) (Figure 5E). The fraction of GS1 proteasomes
increased with their distance to ribbons, whereas SPS2 protea-
somes followed the opposite trend. For SPS2 proteasomes
associated with poly-GA ribbons, the contact interface was
consistent with the location of the additional density observed
in this class (Figures 3 and 4G–4I). Only small variations were
found in the fractions of GS2 and SPS1 particles with respect
to the distance to poly-GA ribbons (Figure 5E). These results indi-
cate that association with poly-GA aggregates modifies the
functional state of the 26S proteasome.
In agreement with this notion, functional measurements show
that poly-GA expression impairs proteasome function (Fig-
ure S4D) (Yamakawa et al., 2015; Zhang et al., 2014). Interest-
ingly, GA-rich sequences have been reported to slow or even
stall proteasomal substrate processing in the context of the Ep-
stein-Barr virus-encoded nuclear antigen 1 protein (Hoyt et al.,
2006; Kraut, 2013; Levitskaya et al., 1997). Whereas in vitro the
s4 state was only observed in the presence of non-hydrolysable
nucleotide analogs (Wehmer et al., 2017), 23% of all protea-
somes within neuronal poly-GA aggregates, and 36% of the pro-
teasomes located in the immediate vicinity of poly-GA ribbons
adopted the s4 conformation in situ (SPS2 class). Therefore,
our results suggest that proteasomal degradation is sloweddown by poly-GA-mediated stalling of the otherwise highly
transient s4 state. This may play an important role in the proteo-
stasis impairment observed in poly-GA models.
DISCUSSION
Previous studiesusingclassical EMreported that cellular poly-GA
inclusions consist of a network of filaments 15–17 nm in diameter
(Zhang et al., 2014, 2016). Our 3D imaging of unstained fully hy-
drated neurons shows that rather than filaments, poly-GA forms
twisted ribbonssimilar to thoseobserved in vitro for (GA)15 (Chang
et al., 2016).Whereasmostamyloids arebelieved tobe largely un-
branched (Knowles et al., 2014), poly-GA ribbons bifurcated
extensively. Together with their variable width, this suggests
that in situ poly-GA ribbons are formed by different numbers of
laterally stacked protofilaments. Furthermore, the similar
morphology of (GA)15 (Chang et al., 2016) and (GA)175 (this study)
ribbons is consistent with a molecular arrangement in which
stackedGA-repeats give rise to the long axis of the protofilament.
Poly-GA aggregates recruited striking numbers of 26S protea-
somes, whereas other macromolecules were excluded from the
aggregate interior. This is remarkably different from our recent
observations on polyQ inclusions, which interact with and may
disrupt the membranes of the endoplasmic reticulum (ER) and
other organelles, but do not harbor substantial numbers of 26S
proteasomes or other large macromolecules (Bauerlein et al.,
2017). This difference is surprising as proteasomes were alsoCell 172, 696–705, February 8, 2018 701
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reported to colocalize with polyQ aggregates (Bennett et al.,
2005; Waelter et al., 2001). Thus, different aggregating proteins
may trigger UPS dysfunction and cellular toxicity by distinct
mechanisms, and how proteasomes associate with other dis-
ease-related aggregates remains to be elucidated (Deriziotis
et al., 2011; Myeku et al., 2016). Future work should also address
the extent of proteasome recruitment by aggregates of poly-GA
proteins expressed at endogenous levels, as well as by other
C9orf72 dipeptide-repeat proteins.
UPS impairment is known to play an important role in poly-GA
induced toxicity (Yamakawa et al., 2015; Zhang et al., 2014,
2016). The proteasome and other UPS components are major
poly-GA interactors in neurons (May et al., 2014), and poly-GA
expression leads to reduced proteasome activity (Yamakawa
et al., 2015; Zhang et al., 2014; our results). Our data provide
mechanistic insights into these phenomena. First, poly-GA ag-
gregates sequester a large fraction of cellular proteasomes,
depleting them from other cellular functions critical for proteo-
stasis maintenance, such as ER-associated degradation (Zhang
et al., 2014). This may be particularly damaging to neurons given
their extended morphology. Second, many of the poly-GA asso-
ciated proteasomes may be functionally impaired. The fraction
of double-capped proteasomes and proteasome RPs in sub-
strate processing conformations was much higher within poly-
GA aggregates than in control cells. Given that CP/RP interac-
tions are stabilized during substrate degradation (Kleijnen
et al., 2007), these data suggest that many poly-GA-associated
proteasomes are processing substrates or stalled in the process.
Consistently, our analysis shows that contact with poly-GA
ribbons causes the proteasomes to adopt the s4 conformation,
an otherwise highly transient intermediate state of substrate
translocation (Wehmer et al., 2017). This is in line with previous
reports that GA-rich sequences slow proteasomal translocation
or even stall it (Kraut, 2013; Levitskaya et al., 1997). Interestingly,
despite the strong association between proteasomes and poly-
GA aggregates observed here, inhibiting proteasomal degrada-
tion does not affect poly-GA levels (Yamakawa et al., 2015).
Therefore, the recruitment of proteasomes to poly-GA aggre-
gates may be unproductive and may not lead to poly-GA degra-
dation. The mechanisms driving such recruitment, which may
involve ubiquitination of poly-GA and/or of associated factors,
require further investigation.
Our data may also provide insights into the cellular mecha-
nisms of proteasome regulation in the presence of protein aggre-
gates. Poly-GA-associated proteasomes in substrate process-
ing states showed additional densities that may correspond to
bound ubiquitin and/or UBL domain-containing cofactors such
as the deubiquitinating enzyme Ubp6/USP14 or the substrate
shuttle factor Rad23 (Aufderheide et al., 2015; Bashore et al.,
2015; Chen et al., 2016b; Shi et al., 2016). Although the binding
of these factors to poly-GA-associated proteasomes remains
to be conclusively demonstrated, several UBL domain proteins
(Rad23, ubiquilin2, or Bag6) were highly enriched in the poly-
GA interactome (May et al., 2014), and Rad23 is an important
regulator of poly-GA induced toxicity (Zhang et al., 2016). UBL
domain proteins strongly modulate proteasome activity (Finley
et al., 2016) and have recently been implicated in neurodegener-
ation and aggregate clearance (Deng et al., 2011; Hjerpe et al.,702 Cell 172, 696–705, February 8, 20182016). Our results are consistent with the notion that UBL domain
cofactors regulate the interactions of the proteasome with
protein aggregates.STAR+METHODS
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Cryo-EM model of the S. cerevisiae 26S proteasome (s3 state) Wehmer et al., 2017 PDB: 5MPB
Cryo-EM model of the S. cerevisiae 26S proteasome (s4 state) Wehmer et al., 2017 PDB: 5MPC
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Hybrid model of the S. cerevisiae TRiC/CCT Leitner et al., 2012 PDB: 4V94
Cryo-EM map of the human 80S ribosome Khatter et al., 2015 EMDB: 2938
In situ subtomogram average of the GS1 conformation of
the 26S proteasome from rat neurons
This paper EMDB: EMD-3916
Fitted model of the GS1 conformation of the 26S
proteasome from rat neurons
This paper PDB: 6EPF
In situ subtomogram average of the GS2 conformation of
the 26S proteasome from rat neurons
This paper EMDB: EMD-3913
Fitted model of the GS2 conformation of the 26S
proteasome from rat neurons
This paper PDB: 6EPC
In situ subtomogram average of the SPS1 conformation of
the 26S proteasome from rat neurons
This paper EMDB: EMD-3914
Fitted model of the SPS1 conformation of the 26S
proteasome from rat neurons
This paper PDB: 6EPD
In situ subtomogram average of the SPS2 conformation of
the 26S proteasome from rat neurons
This paper EMDB: EMD-3915
Fitted model of the SPS2 conformation of the 26S
proteasome from rat neurons
This paper PDB: 6EPE
In situ subtomogram average of TRiC from rat neurons This paper EMDB: EMD-3917
In situ cryo-electron tomogram of C9ORF72 poly-GA
aggregates within a rat neuron
This paper EMDB: EMD-4191
Experimental Models: Cell Lines
HEK293FT Thermo Fisher Scientific Cat# R70007
UbG76V-GFP HEK293 stable cell line De Smet et al., 2017 N/A
Experimental Models: Organisms/Strains
Primary neuronal cultures from CD (SD) IGS rats Charles River CD-SIFA; RRID: RGD_734476
Recombinant DNA
Plasmid: FhSynW-GFP May et al., 2014 N/A
Plasmid: FhSynW-175xGA-GFP May et al., 2014 N/A
Plasmid: FU3a-tagRFP-T2 human p62 This paper N/A
Plasmid: FhSynW -GA149stop This paper N/A
Plasmid: pcDNA3.1-VSVG Kuhn et al., 2010 N/A
Plasmid: psPAX2 Gift from Didier Trono
(unpublished data)
Addgene Cat# 12260
Plasmid: pcDNA3.1-STOP-GA(G4C2)73-GFP This paper N/A
Software and Algorithms
SerialEM Mastronarde, 2005 http://bio3d.colorado.edu/SerialEM/
TomSegMemTV Martinez-Sanchez
et al., 2014
https://sites.google.com/site/
3demimageprocessing/tomosegmemtv
MaskTomRec Fernandez et al., 2016 https://sites.google.com/site/
3demimageprocessing/masktomrec
K2Align Dimitry Tegunov https://github.com/dtegunov/k2align
Pytom Hrabe et al., 2012 http://pytom.org/
RELION Bharat and
Scheres, 2016
http://www2.mrc-lmb.cam.ac.uk/relion/
index.php/Main_Page
UCSF CHIMERA Pettersen et al., 2004 http://www.cgl.ucsf.edu/chimera
OriginPro OriginLab https://www.originlab.com/
index.aspx?go=Products/Origin
MATLAB MathWorks https://www.mathworks.com/
IMOD Kremer et al., 1996 http://bio3d.colorado.edu/imod/
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
VTK N/A https://www.vtk.org; RRID: SCR_015013
Python scripts used to measure the distance between
proteasomes and poly-GA aggregates
This paper https://github.com/anmartinezs/poly-GA
QwikMD Ribeiro et al., 2016 http://www.ks.uiuc.edu/Research/qwikmd/
VMD Humphrey et al., 1996 http://www.ks.uiuc.edu/Research/vmd/
NAMD Phillips et al., 2005 http://www.ks.uiuc.edu/Research/namd/
TOM toolbox Nickell et al., 2005 https://www.biochem.mpg.de/tom
Amira Thermo Fisher Scientific https://www.fei.com/software/amira-
3d-for-life-sciences/; RRID: SCR_014305
Other
Quantifoil grids 200 mesh Gold R2/1 Quantifoil Micro Tools N/A
Whatman filter paper #1 Whatman Cat# 1001090
Nunc 12 well plates Thermo Fisher Cat# 150628
Glass coverslips VWR Cat# 631-1581CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Wolfgang
Baumeister (baumeist@biochem.mpg.de).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Culture
HEK293 cells (female) stably expressing UbG76V-GFP (Dantuma et al., 2000; De Smet et al., 2017) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Biochrom) supplemented with 10% (v/v) fetal bovine serum (GIBCO), 2 mM L-glutamine (GIBCO),
penicillin-streptomycin (Thermo Fisher) and non-essential amino acids (GIBCO). Transfection was carried out using FuGENE 6
(Promega).
Rats (IGS background, Charles River; RRID:RGD_734476) were housed in a pathogen-free facility with 12:12 h light/dark cycle and
food/water available ad libitum. All animal experiments were performed in compliance with institutional policies approved by the gov-
ernment of Upper Bavaria following x11 Ab.1 TierSchG for the DZNE animal facility (Inst.-Nr. 04-26). Primary cortical neurons were
prepared from embryonic day 19 animals of both sexes. Neocortex and hippocampus were dissected in ice-cold dissection media
(HBBS, penicillin-streptomycin, 10mMHEPES pH 7.3). The tissue was enzymatically dissociated at 37C (for cortices 20min in 0.2%
trypsin, 0.7 mg/ml DNase I; for hippocampi 15 min in 0.25% trypsin in dissection media) followed by gentle trituration.
For EM analysis, 250,000 cells/ml cortical neuronswere plated on EMgrids and cultured in Neurobasal medium containing 2%B27
(Thermo Fisher), penicillin-streptomycin, 0.5 mM L-glutamine (Thermo Fisher). For biochemical analysis, 250,000 cells/ml cortical
neurons were plated on 12-well plates (Thermo Fisher) and cultured in Neurobasal medium. For immunofluorescence experiments,
85,000 cells/ml hippocampal neurons were plated on 12-well plates containing glass coverslips (VWR) coated with poly-D-lysine and
cultured in Neurobasal medium supplemented with 12.5 mM glutamate.
METHOD DETAILS
Lentivirus Packaging
HEK293FT cells (female; from Thermo Fisher) of low passage number were plated in three 10 cm dishes (5,000,000 cells/dish) and
cultured in DMEM (Thermo Fisher), penicillin-streptomycin, 1% non-essential amino acids (Thermo Fisher) and 10% fetal bovine
serum (Sigma). A transfection mix was set up as follows: 18.6 mg transfer vector (FhSynW-(GA)175-GFP, FhSynW (GA)149, FU3a-
tagRFP-p62 or FhSynW-GFP), 11 mg pSPAX2 and 6.4 mg pVSVg in 4.5 mL Opti-MEM were combined with 108 ml Lipofectamine
2000 in 4,5 mL Opti-MEM (Thermo Fisher) and incubated for 20 minutes. Cell media was replaced with 5 mL Opti-MEM and 3 mL
of transfection mix were added per dish. The transfection media was replaced after 6 h by plating media supplemented with
13 mg/ml bovine serum albumin, and the supernatant was collected after additional 24 h. Lentiviral particles were harvested by
ultracentrifugation using a Sw28 rotor (22,000 rpm, 2 h), resuspended in 150 ml Neurobasal media on a rocking platform overnight
and stored in aliquots at 80C.e3 Cell 172, 696–705.e1–e7, February 8, 2018
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Generation of pcDNA3.1 – STOP-GA(G4C2)73-GFP
The method to generate the construct was adapted from Lee et al. (2013). Complementary G4C2 repeat oligonucleotides with phos-
phorylated ends (50-PHOS-(G4C2)5-30 and 50-PHOS-CC(G2C4)4GGCC-30) were energetically optimized to maximize heterodimer
formation. After initial denaturation for 5 min at 95C in T4 ligase buffer (New England Biolabs), the complementary oligonucleotides
were allowed to anneal by slow cool down to room temperature during 2 h. Hybridized oligonucleotides were then self-ligated for 1 h
to extend the G4C2 DNA sequence. Adaptor oligonucleotides containing NheI (5
0) and BamHI (30) restriction sites (50 adaptor oligo-
nucleotides containing NheI: 50-GCCGTCAAGGCCGCATCTAGTAGCTAGC-30 and 50-PHOS-CCGCTAGCTACTAGATGCGGCCTT
GACGGC-30; 30 adaptor oligonucleotides containing BamHI: 50-PHOS-GGGATCCCTAGTACTGGGCCTCATGGGC-30 and 50-GCC
CATGAGGCCCAGTACTAGGGATC-30) were separately hybridized and sequentially added in excess to the ligation reaction mix
to stop G4C2 elongation. Ligation products were separated in a 1.25% agarose gel, and bands running at the desired molecular
size were excised. The DNA was then purified with the Zymolclean Gel DNA recovery kit (Zymo Research) according to the manu-
facturer’s guidelines. The resulting blunt-end fragments were phosphorylated and cloned into a dephosphorylated SmaI-restricted
pUC18 plasmid for amplification. Colonies were screened for G4C2 repeat length, and a construct with 73 G4C2 repeats was chosen
for further experiments. The selected sequence was subcloned into the mammalian expression vector pcDNA3.1(+)/myc-His be-
tween NheI and BamHI in front of a GFP-encoding region. Finally, multiple stop codons were added by site-directed mutagenesis
in every reading frame at the 50 of the sequence of interest, thereby removing all initiator codons between the T7 promoter and
the sequence of interest. The sequence was verified by multiple sequencing reactions as well as restriction digest.
Immunofluorescence and Cellular Fractionation
Immunofluorescence stainings were performed on primary hippocampal neurons 5 days after infection with (GA)175-GFP or GFP
lentivirus on day 5, or 3 days upon transfection with G4C2 on day 3 using Lipfectamine 2000 (Thermo Fisher). Cells were fixed for
10 min at room temperature (4% paraformaldehyde, 4% sucrose in PBS). Anti-PSMC4 (Bethyl Laboratories, 1:250, RRI-
D:AB_2620201) or anti-GA (Mackenzie et al., 2013, 1:200) primary antibodies as well as secondary antibodies (Alexa 555, Alexa
647, Thermo Fisher, 1:400, RRID:AB_2535850, RRID:AB_141780, RRID:AB_2535813) were diluted in staining buffer (0.1% gelatin,
0.3% Triton X-100, 450 mM NaCl, 16 mM sodium phosphate pH 7.4). After mounting the coverslips, images were taken using a
LSM710 confocal microscope (Carl Zeiss, Jena) with a 63 3 oil immersion objective.
Biochemical experiments were performed on primary cortical neurons 10 days after infection with either (GA)175-GFP or GFP lenti-
virus on day 3. Cells were lysed (PBS with 1% Triton X-100, 15 mMMgCl2, 0.2 mg/ml DNase with protease inhibitor cocktail). Upon
centrifugation (18,000 xg, 4C for 30min) the soluble fraction was collected from the supernatant. The pellets were washed twice with
lysis buffer yielding the insoluble fraction. After adding 4x Laemmli buffer (Bio-Rad), samples were denaturated (95C for 10 min) and
loaded on Tricine gradient gels (Thermo Fisher). The following antibodies were used: Anti-PSMC4 (Bethyl Laboratories, 1:1000), anti-
GFP (NeuroMab, 1:5000, RRID:AB_10671445) and anti-Calnexin (Enzo Life Sciences, 1:7000, RRID:AB_10616095). The data in Fig-
ure S4C was normalized to the total proteasome levels in GFP-transduced control neurons.
Flow Cytometry
HEK293 cells stably expressing UbG76V-GFP were harvested 72 h after transient transfection with (GA)175-tagRFP or tagRFP as
control and analyzed with a BD FACSAriaIII flow cytometer, as described previously (Hipp et al., 2012a, 2012b). In brief, to ensure
a sufficient number of cells with elevated levels of the transfected proteins > 100,000 events were analyzed per condition. To plot
the level of the reporter protein versus the level of the transfected protein, a set of gates was established in the tagRFP
channel. HEK293 cells transfected with tagRFP were used as single-color control to compensate the bleed-through between
GFP and tag-RFP individually for each gate, and to correct for effects due to high expression of tagRFP. The compensated
mean fluorescence of the reporter protein UbG76V-GFP in each of these gates was plotted on the y axis and the gate number
(corresponding to the log of fluorescence intensity of the transfected protein) was plotted on the x axis. The data shown in Figure S4D
are from a single representative experiment out of three independent repeats. Cells expressing low levels of tagRFP (gates 1-9) and
gates with < 1000 events were not included in the analysis. Raw flow cytometry data were analyzed using FlowJo software
(version 9.9; Tree Star).
Cryo-EM Sample Preparation
Quantifoil grids (R2/1, Au 200mesh grid, Quantifoil Micro Tools, Germany) were coatedwith an additional carbon layer (20 nm thick)
using a carbon evaporator (MED 020, BAL-TEC). Before use, the grids were glow discharged using a plasma cleaner (PDC-3XG, Har-
rick) for 20 s and neurons were seeded as described above. Neurons were vitrified 5 days after transduction with GFP or tagRFP-
p62/untagged (GA)175 on day 5, 3 or 5 days after transduction with (GA)175-GFP on day 5, and 3 days after transfection with
(G4C2)73 on day 3. Untransduced and untransfected control neurons were vitrified on DIV 10.
For vitrification, the grids were blotted for 10 s from the back side using filter paper and immediately plunged into a liquid ethane/
propanemixture (Tivol et al., 2008) using amanual plunge freezer. Grids were transferred to sealed boxes and stored in liquid nitrogen
until usage.Cell 172, 696–705.e1–e7, February 8, 2018 e4
72
Cryo-Fluorescent Light Microscopy and Cryo-FIB Microscopy
EM grids were mounted onto modified Autogrid (FEI, Hillsboro, OR, USA) sample carriers, allowing subsequent FIB milling with a
shallow incident ion beam (Rigort et al., 2012), and then transferred to the cryo-stage of an FEI CorrSight microscope for cryo-light
microscopy. Overview images of the grid and poly-GA-GFP/tagRFP-p62 signal were respectively acquired in transmitted light and
the spinning disk confocal modes using a 20x lens (air, N.A. 0.8). Image acquisition was done with FEI MAPS software. The samples
were then transferred into a FEI Scios dual beam cryo-FIB/scanning electron microscope (SEM) using a cryo-transfer system.
To improve the sample conductivity, a layer of organometallic platinum was deposited onto the grid using the in situ gas injection
system with the following parameters: 10 mm working distance, 26C pre-heating temperature, and 8 s gas injection time. MAPS
software allowed correlation between cryo-light microscopy and SEM images via the 3-point alignment method. Thin lamellas
were prepared in the regions of poly-GA-GFP/tagRFP-p62 fluorescence signal using the Ga2+ ion beam at 30 kV under a 20 stage
tilt angle. 0.5 nA beam current was used for rough milling, followed by sequentially lower currents during the thinning procedure.
A current of 30 pA was used for the final polishing step to reach a final lamella thickness of 150-200 nm. SEM imaging was used
to monitor the milling progress.
Cryo-Electron Tomography and Reconstruction
The specimens were examined at liquid nitrogen temperature in an FEI Titan Krios cryo-electron microscope operated at 300 kV and
equipped with a field emission gun and a Gatan post column energy filter. Lamellas were loaded vertical to the tilt axis, and were
precisely aligned by adjusting the b angle of the cryo-stage. Imageswere collected using a 4 k x 4 k K2 Summit (Gatan) direct detector
camera operated in dose fractionation mode (0.4 s, 0.3 electrons/Å2 per frame). Tilt series were recorded using SerialEM software
(Mastronarde, 2005) at a nominal magnification of 42,000 X, resulting in a pixel size of 3.42 Å at the specimen level. Unidirectional
tomographic tilt series were recorded from50 to +70 with an increment of 2. On average, 6 frameswere collected for each image
resulting in a total dose between 100 e-/Å2 to 110 e-/Å2 per tilt series. K2 frames were aligned using in house software (K2Align) based
on previous work (Li et al., 2013). Tilt series were aligned using fiducial-less patch tracking, and the tomograms were reconstructed
byweighted back projection using the IMOD software package (Kremer et al., 1996). For tomograms of lamellas superficially contam-
inated by ice crystals, a surface cleaning procedure was employed after alignment (Fernandez et al., 2016). The resulting tilt series
were then aligned and reconstructed again to obtain the final reconstructions.
Template Matching and Subtomogram Averaging
To identify the macromolecules found in the tomograms, a de novo subtomogram averaging procedure without any external
structural information was developed (Figure S2A). TheMATLAB (Mathworks) TOM toolbox (Nickell et al., 2005) was used as general
platform for image processing. First, all the tomograms were binned twice (13.68 Å3 per voxel) for processing. In one tomogram,
several identical small ring-like structures were hand-picked, aligned and averaged to obtain a first tube-like average structure.
This was used as an initial template for templatematching in all the binned tomograms using PyTom (Hrabe et al., 2012). The resulting
subtomograms were cropped, CTF-corrected and classified using Relion (Bharat and Scheres, 2016). The resulting structure clearly
showed a 20S proteasome core complex, but because of the missing wedge and the preferred orientation induced by the initial
template, the 19S regulatory particles (RP) were not well resolved. This structure was used to perform a new round of template
matching and classification, which clearly resolved proteasomes either single- or doubled-capped. The single-capped proteasome
were low-pass filtered to 40 Å and used as a reference for template matching again to produce the final dataset. In total, 10,367
proteasome subtomograms of 1803 pixel volume were picked for further analysis from 9 tomograms containing large (GA)175-GFP
aggregates (DIV 5 + 5). The same template matching procedure was applied to tomograms of control neurons, either untransduced
(16 tomograms) or transduced with GFP only (17 tomograms).
The subtomograms were then 3D classified using Relion (Figure S2B). They were first divided into single-capped and double-cap-
ped proteasomes. To further rule out reference bias, a single-capped proteasome, a double-capped proteasome and a mirrored
single-capped proteasome were used as references for classification. The results were similar, indicating negligible reference
bias during classification. To further analyze the conformational status of the 19S regulatory particles, all subtomograms were cut
in silico between the b-rings of the 20S, resulting in two independent particles for the double-capped proteasomes (Asano et al.,
2015). All cut-out half proteasomes were merged into a new dataset for another round of classification. Ground state and substrate
processing state structures were distinguished by the relative orientation of the Rpn5 and Rpn6 subunits (Asano et al., 2015; Unver-
dorben et al., 2014). Ground state and substrate processing state structures were further classified by applying a soft sphere mask in
the RP region only. Identical subclasses were merged resulting in two ground state and two substrate processing state classes,
which were further refined to achieve the final structures. A similar analysis could not be applied to control neurons (GFP-transduced
or untransduced) due to the low numbers of proteasomes found in these samples. Therefore, the results from untransduced neurons
from a previous study (Asano et al., 2015) were used as reference. Visualization of the subtomogram averages was performed in
UCSF Chimera (Pettersen et al., 2004). Resolution was determined using the 0.143 criterion according to the gold standard Fourier
Shell Correlation (Scheres and Chen, 2012).
To identify the larger ring-like structures found in the tomograms, a similar template matching procedure was employed. A spher-
ical structure was generated after processing, which showed a clear eight-fold symmetry by rotational correlation coefficient analysis
(Figure S3B). Furthermore, the size of the average fitted well with the crystal structure of TRiC/CCT (PDB: 4V94) (Leitner et al., 2012),e5 Cell 172, 696–705.e1–e7, February 8, 2018
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indicating that these larger rings correspond to the TRiC/CCT chaperonin. A total of 1,366 TRiC subtomograms were used for aver-
aging. For ribosome template matching, a human 80S ribosome structure (EMDB 2938) (Khatter et al., 2015) was filtered to 40 Å and
used as a template.
Atomic Model Fitting
The S. cerevisiae proteasome models of the states s1 (PDB: 5MP9, 5MPD), s2 (PDB: 5MPA, 5MPE), s3 (PDB: 5MPB), and s4 (PDB:
5MPC) (Wehmer et al., 2017) were used as initial models. The core particles of themodels were fitted into each of the groups obtained
by classification of the poly-GA proteasome dataset using rigid body docking within UCSF Chimera. For each class, MDFF was per-
formed to refine the s1-4 models according to the density maps. Then, the RMSD between the best fitting atomic models and the
initial s1-4 state models was calculated (Table S1). This showed that the GS1 class reflected the s1 state with the Rpn1 positioning
of the human s1 state (PDB: 5L5K) (Schweitzer et al., 2016), GS2 reflected the s1 state with a rotated Rpn1 position, SPS1 reflected
the s2 state and SPS2 reflected the s4 state. To obtain the final atomic rat models, the best fitting yeast structures for each class were
used as templates for comparativemodeling and real-space structure refinement (Goh et al., 2016).MDFF simulations were prepared
using QwikMD (Ribeiro et al., 2016), analyzed with VMD (Humphrey et al., 1996), and carried out with NAMD (Phillips et al., 2005).
Segmentation of Poly-GA Aggregates and Distance Measurement
Poly-GA ribbons are locally planar and were consequently segmented using a filter based on tensor voting, which distinguishes
planar-like from line- and blob-like structures (Martinez-Sanchez et al., 2014). The filter outputs a scalar map, where voxel intensity
value is proportional to the local similarity with a plane. The final segmentation was generated by thresholding the filter output
combined with a manually generated mask to discard other locally planar structures like membranes and correct minor artifacts.
Due to the missing information along the electron beam direction (Lucic et al., 2005), poly-GA ribbons were not clearly visible
when oriented within the xy plane. Segmentations were visualized using Amira (Thermo Fischer, RRID:SCR_014305).
For Figure 5, proteasome regulatory particles and poly-GA ribbons were represented by an isosurface, properly placed and
oriented in their original tomogram. For regulatory particles, surfaces were obtained by applying the marching cubes algorithm, im-
plemented in the VTK Open Source library (https://www.vtk.org/; RRID:SCR_015013; Schroeder et al., 2006), on the corresponding
subtomogram average. Isosurface threshold was set manually for every case with the criterion of choosing theminimum value avoid-
ing noisy features. For poly-GA ribbons, isosurfaces were generated from the output of the planar filter using the marching cubes
algorithm. The final ribbon surfaces were obtained by masking the isosurface with the corresponding ribbon segmentation from
the tomogram. To calculate the fraction of the volume of poly-GA inclusions occupied by poly-GA ribbons, total ribbon volume
was measured from the segmentations and divided by the total tomogram volume. For this calculation, tomograms (n = 4,
(GA)175-GFP transduced neurons at DIV 5 + 5) were selected in which the largemajority of the volume contained poly-GA aggregates.
RP to poly-GA ribbon distance was defined as the shortest Euclidean distance between the center of the RP to any surface point of
any ribbon in the same tomogram. A custom Python software package was developed to measure RP-to-ribbon distance for every
RP in all tomograms. The results were grouped by particle class to facilitate statistical analysis. The shortest distance among surfaces
was computed with the help of a VTK library (Schroeder et al., 2006).
QUANTIFICATION AND STATISTICAL ANALYSES
To measure proteasome concentration, for each tomogram (n = 9, (GA)175-GFP transduced neurons, DIV 5 + 5; n = 17, GFP trans-
duced neurons; n = 16, untransduced neurons) the number of proteasomes found by template matching and subtomogram
averaging was divided by the total tomogram volume. Because other cellular structures (such as poly-GA aggregates, other macro-
molecules or cellular organelles) were also present in the tomogram volume, this calculation underestimates the cytosolic concen-
tration of proteasomes. For poly-GA aggregates, only tomograms with more than half volume occupied by aggregates were consid-
ered for the concentration calculation. In Figure S4B, the top and bottom boundaries of the boxes indicate ± 2x standard error, and
whiskers extend to themaximum andminimum values. Statistical analysis was performed by the non-parametric Mann-Whitney test,
as not all data was normally distributed according to the Shapiro-Wilk test.
For the analysis of proteasome conformation as a function of the distance to poly-GA ribbons (Figures 5B, 5C, and 5E), 6080 reg-
ulatory particles from 4 tomograms of (GA)175-GFP transduced neurons (DIV 5 + 5) were analyzed. The data were divided in a 4x4
Table (4 RP states x 4 distance bins) resulting in 9 degrees of freedom. Statistical analysis was performed by Chi-square test.
The proteasome levels in the total, soluble and insoluble fractions of (GA)175-GFP transduced neurons were quantified from west-
ern blots by measuring the gray levels using Fiji (Schindelin et al., 2012). Error bars in Figure S4C indicate standard error. All data was
normally distributed according to the Shapiro-Wilk test (95% confidence level). Statistical analysis was performed by two-sided
paired t test (n = 6 replicates from 4 independent experiments). All graphs were plotted using OriginPro (OriginLab).
DATA AND SOFTWARE AVAILABILITY
The Python scripts used to calculate the distance between proteasomes and poly-GA ribbons are available at https://github.com/
anmartinezs/poly-GA.Cell 172, 696–705.e1–e7, February 8, 2018 e6
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The tomogram analyzed in Figure 2 has been deposited at the Electron Microscopy Data Base with accession number EMDB:
EMD-4191. The structures of the proteasome and TRiC/CCT obtained by in situ subtomogram averaging have been deposited at
EMDB with the following accession numbers: EMDB: EMD-3916 (GS1 proteasome), EMD-3913 (GS2 proteasome), EMD-3914
(SPS1 proteasome), EMD-3915 (SPS2 proteasome), EMD-3917 (TRiC/CCT). The fitted atomic models of the different proteasome
states have been deposited at the Protein Data Base with the following accession numbers: PDB: 6EPF (GS1), 6EPC (GS2),
6EPD (SPS1), 6EPE (SPS2).e7 Cell 172, 696–705.e1–e7, February 8, 2018
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Supplemental Figures
Figure S1. Correlative Cryo-light and Cryoelectron Microscopy Workflow, Related to Figure 1
(A) Rat cortical neurons were cultured on EM grids and transduced with (GA)175-GFP on day 5. Upon vitrification by plunge freezing 5 days after transfection, the
grids were imaged by cryo-light microscopy. (A) shows an overlay of phase and GFP channels.
(B) EMgrids were transferred to a cryo-FIB/SEMmicroscope. To locate cells of interest (boxed), SEM images were aligned and superimposedwith the GFP signal
from the cryo-LM image.
(C) FIB-induced secondary electron image of the cell shown in (B), superimposedwith theGFP signal. Yellow boxesmark the regions of the cell removed by FIB to
produce a lamella containing the GFP-positive region.
(D) SEM image of the lamella resulting from FIB milling, with a final thickness of 200 nm, superimposed with the GFP signal.
(E) Cryo-TEM low magnification image of the lamella shown in (D).
(F) 5 nm-thick tomographic slice of a tomogram recorded in the areamarked by a white square in (E), containing the GFP signal. A dense network of poly-GA-GFP
ribbons (red arrowheads) is visible. The inset shows a high magnification of a poly-GA-GFP ribbon decorated by GFP-associated additional densities (green
arrowheads). Scale bar: 20 nm.
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Figure S2. Subtomogram Averaging and Classification Workflow, Related to Figures 2 and 3
(A) Unbiased template matching procedure. Several identical structures were first hand-picked from one tomogram, aligned and averaged. The resulting average
was used as a template to search more tomograms for additional occurrences of the same structure. These additional particles were then visually inspected,
aligned, classified and averaged again to produce a higher resolution average. This average was low-pass filtered and used as a template to search all the
tomograms to produce the final subtomogram dataset.
(B) All proteasome subtomograms were first classified into single-capped or double-capped. To further analyze the conformational status of the regulatory
particles, all the subtomograms were cut in silico between the b-rings of the core particle (Asano et al., 2015), resulting in two independent particles for double-
capped proteasomes. Cut out caps from all proteasomes were merged and subjected to a further round of classification.
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Figure S3. Subtomogram Averaging and Classification for TRiC/CCT and the 26S Proteasome, Related to Figures 2 and 3
(A) Unsymmetrized average structure of TRiC/CCT at a resolution of 20.5 Å superimposed on its atomic model (purple; PDB: 4V94).
(B) Rotational correlation coefficient analysis of (A) indicating 8-fold symmetry.
(C) Average structure of TRiC/CCT at a resolution of 17.1 Å upon application of D8 symmetry to (A) superimposed on its atomic model. Resolutions were
estimated by gold-standard Fourier shell correlation using the 0.143 criterion.
(D and F) Overall distribution of single-capped and double-capped 26S proteasomeswithin aggregates in (GA)175-GFP transduced neurons (D) and untransduced
neurons (Asano et al., 2015) (F).
(E and G) Distribution of the ground and substrate processing states for all regulatory particles within aggregates in neurons transduced with (GA)175-GFP (E) and
untransduced (Asano et al., 2015) (G).
(H) Gold-standard Fourier shell correlation curves of the four proteasome structures, yielding the following resolution estimations: 11.8 Å (GS1), 12.3 Å (GS2),
15.4 Å (SPS1) and 12.8 Å (SPS2).
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Figure S4. Proteasome Abundance and Function at Poly-GA Aggregates, Related to Figures 2 and 5
(A) Poly-GA-GFP aggregates (green) in primary neurons expressing a synthetic (GA)175-GFP construct with a start codon colocalize with proteasomes detected
with a PSMC4/Rpt3 antibody (red). Proteasome staining is diffuse in GFP-expressing control cells. Nuclei are labeled with DAPI (blue). Scale bar: 50 mm.
(B) Proteasome concentration for (GA)175-GFP aggregates (DIV 5 + 5), control neurons transduced with GFP only (DIV 5 + 5) or untransduced (DIV 10) (n = 9
tomograms, (GA)175-GFP; n = 17, GFP; n = 16, untransduced). For poly-GA aggregates, only tomograms with more than half volume occupied by aggregates
were considered for the concentration calculation. The top and bottom boundaries of the boxes indicate ± 2x standard error, and whiskers extend to the
maximum and minimum values. Proteasome concentration within poly-GA aggregates was significantly higher than in control conditions (***p < 0.001 by Mann-
Whitney test), whereas the difference between GFP-transfected and untransfected control neurons was not significant (n. s.).
(C) Quantification of proteasome levels in the soluble and insoluble fractions as well as total, analyzed by immunoblotting. The data was normalized to the total
proteasome levels in GFP-transduced control neurons. Error bars indicate standard error. * and ** indicate respectively p < 0.05 and p < 0.01 by paired t test (n = 6
replicates from 4 independent experiments). Proteasomes are enriched in the insoluble fraction in the presence of poly-GA aggregates.
(D) Poly-GA expression leads to the stabilization of a reporter for the ubiquitin-proteasome system. HEK293 cells stably expressing an unstable green fluorescent
reporter for the ubiquitin-proteasome system (UbG76V-GFP) were transfected with the indicated constructs. After 72 h, UbG76V-GFP levels were analyzed by
flow cytometry. The relationship between poly-GA-tagRFP levels on the x axis and of UbG76V-GFP on the y axis shows a concentration-dependent accumulation
of UbG76V-GFP in the presence of poly-GA. The data shown are from a single representative experiment out of three independent repeats.
(E) Poly-GA-GFP aggregates (green) in primary neurons expressing a non-ATG (G4C2)73 construct containing a downstream GFP in the poly-GA reading frame.
RAN translation-derived poly-GA-GFP aggregates are stained by a poly-GA antibody (red) and colocalize with proteasomes detected with a PSMC4/Rpt3
antibody (white). Nuclei are labeled with DAPI (blue). Scale bar: 10 mm.
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Figure S5. Macromolecule Mapping in Different Poly-GA Aggregates, Related to Figure 2
(A–C) Tomographic slices of aggregates within neurons transduced with (GA)175-GFP (main panels) and analyzed at DIV 5 + 5. Regions containing poly-GA
ribbons are outlined in red. For the whole tomogram, proteasomes (green) and ribosomes (yellow) are mapped to their original positions and orientations by
template matching and subtomogram averaging. For each tomogram, maximum intensity projection heatmaps of poly-GA ribbons, proteasomes and ribosomes
were generated (right column of each panel).
(D–F) Numbers of proteasomes and ribosomes detected in the tomograms shown in (A)–(C) plotted versus the volume of the region containing poly-GA ag-
gregates. The number of proteasomes detected shows a positive correlation with poly-GA aggregate volume. (E and F) Tomographic slices and mapped 26S
proteasomes of aggregates within neurons transduced with (GA)175-GFP at an earlier time point (DIV 5 + 3) (E), or transfected with a RAN-translated (G4C2)73
construct with GFP in the poly-GA reading frame (F). Note that despite the smaller size compared to DIV 5 + 5 (GA)175-GFP aggregates, similar concentrations of
proteasomes accumulatedwithin these aggregates (7 mM for (GA)175-GFP, DIV 5 + 3;5 mM for G4C2). Due to the lower thickness of the cryo-FIB lamella (70 nm
versus 100-200 nm in all other cases) fewer proteasomes are visible in (F). The inset in (F) shows a high magnification of a poly-GA ribbon (red arrowhead)
decorated by GFP-associated additional densities (green arrowheads). Note that the morphology of RAN-translated poly-GA ribbons is indistinguishable from
aggregates formed by the (GA)175-GFP construct. Tomographic slices are 7 nm thick. Scale bars: 200 nm in main panels, 20 nm in inset.
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Abstract
The C9orf72 GGGGCC repeat expansion is a major cause of amyo-
trophic lateral sclerosis and frontotemporal dementia (c9ALS/FTD).
Non-conventional repeat translation results in five dipeptide
repeat proteins (DPRs), but their clinical utility, overall significance,
and temporal course in the pathogenesis of c9ALS/FTD are unclear,
although animal models support a gain-of-function mechanism.
Here, we established a poly-GP immunoassay from cerebrospinal
fluid (CSF) to identify and characterize C9orf72 patients. Signifi-
cant poly-GP levels were already detectable in asymptomatic
C9orf72 mutation carriers compared to healthy controls and
patients with other neurodegenerative diseases. The poly-GP levels
in asymptomatic carriers were similar to symptomatic c9ALS/FTD
cases. Poly-GP levels were not correlated with disease onset, clini-
cal scores, and CSF levels of neurofilaments as a marker for axonal
damage. Poly-GP determination in CSF revealed a C9orf72 muta-
tion carrier in our cohort and may thus be used as a diagnostic
marker in addition to genetic testing to screen patients. Presymp-
tomatic expression of poly-GP and likely other DPR species may
contribute to disease onset and thus represents an alluring
therapeutic target.
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Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia
(FTD) are neurodegenerative diseases with similar neuropathologi-
cal features and overlapping clinical symptoms and pathomecha-
nisms (Ling et al, 2013). To date, a genetic cause can be identified in
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around two-thirds of familial and 10% of sporadic ALS (Renton et al,
2014). Similarly, a genetic cause is described in about 25% of famil-
ial and 10% of sporadic FTD (Belzil et al, 2016). The most frequent
genetic cause of ALS, FTD, or a combination of both is a large
GGGGCC repeat expansion in the C9orf72 gene (c9ALS/FTD). Three
non-mutually exclusive mechanisms are discussed to mediate the
effects of the hexanucleotide expansion. The C9orf72 protein has
been linked to autophagy and its expression is reduced in ALS/FTD
patients (Sellier et al, 2016). While C9orf72 knockout mice show no
neurodegeneration, repeat expressing mice develop neuron loss and
TDP-43 pathology depending on the expression levels (Hayes &
Rothstein, 2016; Jiang et al, 2016; O’Rourke et al, 2016). Formation
of repeat RNA foci in the nucleus and the accompanying sequestra-
tion of RNA-binding proteins are thought to alter RNA processing
(DeJesus-Hernandez et al, 2011). The expanded repeat is translated
into aggregating dipeptide repeat proteins (DPRs) by a non-conven-
tional mechanism termed repeat-associated non-ATG (RAN) transla-
tion (Ash et al, 2013; Mori et al, 2013b; Zu et al, 2013), which was
first discovered for expanded CAG repeats (Zu et al, 2011).
Five DPR species result from the translation from sense (poly-GA,
poly-GP, poly-GR) and antisense RNA (poly-PA, poly-PR, and further
poly-GP) in all reading frames (Gendron et al, 2013; Mori et al,
2013a; Zu et al, 2013). DPRs accumulate in p62-positive but TDP-43-
negative neuronal inclusions in the brain, a pathognomonic feature
of c9ALS/FTD (Al-Sarraj et al, 2011; Mori et al, 2013b). In vitro and
in vivo studies showed toxicity of the different DPR species by inhibi-
tion of gene expression, nucleocytoplasmic transport, and the ubiq-
uitin-proteasome system (May et al, 2014; Zhang et al, 2014; Jovicic
et al, 2015). Poly-GA is the most abundant DPR species in the brain
whereas overexpression of the arginine-containing species (poly-
GR/-PR) causes the most severe toxicity in cellular and fly models
(Mizielinska et al, 2014; Schludi et al, 2015).
However, in end-stage brains DPR pathology does not correlate
with the degree of neurodegeneration, which challenges the
concept of DPRs as the driving force of acute neurodegeneration
as overly simplistic (Mackenzie et al, 2013), although mouse
models strongly support a gain-of-function mechanism (Chew
et al, 2015; Jiang et al, 2016; Liu et al, 2016). However, post-
mortem studies cannot provide conclusions on the temporal
sequence of events (DPR/TDP-43 deposition and neurodegenera-
tion). Neuropathological reports from rare cases suggest that DPRs
accumulate in the brain prior to TDP-43 pathology early in disease
or even prior its onset (Baborie et al, 2014; Proudfoot et al, 2014;
Vatsavayai et al, 2016). Thus, the study of DPR expression in the
asymptomatic phase of C9orf72 mutation carriers is essential to
clarify the role of DPRs in the pathogenesis of c9ALS/FTD. So far
only poly-GP has been detected in cerebrospinal fluid (CSF) in a
small case series of symptomatic c9ALS patients (Su et al, 2014).
It is unclear how accurately CSF levels of poly-GP reflect the over-
all DPR load, but it is currently the only way to analyze RAN
translation in living patients.
Therefore, we performed a cross-sectional study of CSF samples
of patients in different stages of the disease, even before onset of
either dementia or motor symptoms to elucidate the temporal course
of poly-GP expression in c9ALS/FTD pathogenesis. In addition, we
correlated poly-GP levels with clinical scores (ALSFRS-R, FTLD-
CDR), markers of neurodegeneration/axonal damage (neurofilament
light chain, NfL; phosphorylated neurofilament heavy chain, pNfH),
age at disease onset, disease duration at CSF collection, and
estimated repeat length to assess the interaction between DPR load
and disease severity.
Results
Monoclonal antibodies specifically detect poly-GP
To develop an anti-GP sandwich immunoassay with optimal sensi-
tivity, we rescreened all our monoclonal anti-GP clones from rat for
affinity as a capture antibody (Schludi et al, 2015). As expected, the
two best anti-GP clones 18H8 and 3F9 specifically detected neuronal
cytoplasmic poly-GP inclusions by immunohistochemistry in a
c9ALS/FTD patient, but not in a C9orf72-negative ALS/FTD case
(Fig 1A). An optimized immunoassay using these antibodies reliably
detected GST-GP15 down to a concentration of 0.03 ng/ml (Figs 1B
and EV1). No cross-reactivity with other GST-DPR fusion proteins
was observed even at 1 lg/ml (Fig 1C). Due to the different number
of epitopes in the GST-GP15 and endogenous poly-GP from patients
with variable repeat length, we present only background-corrected
raw values of CSF samples. To confirm assay stability, we repeat-
edly measured the concentration of four recombinant GST-GP15
calibration samples ranging from 0.0064 to 0.8 ng/ml (Fig EV1).
The coefficient of variance was between 1.59 and 9.41% for intra-
plate replicates, between 7.36 and 15.95% for inter-plates replicates,
and between 4.77 and 14.53% for day-to-day replicates, suggesting
the assay is sufficiently accurate for diagnostic use.
Poly-GP is detectable in the CSF of asymptomatic and
symptomatic c9ALS/FTD
Poly-GP levels were measured in CSF in a group of 125 clinically
well-characterized patients and controls from the German FTLD
Consortium. The demographic characteristics of the participants are
listed in Table 1. The sample includes 30 subjects with evidence of
a repeat C9orf72 expansion (C9-F1, n = 10; c9ALS, n = 9; c9FTD,
n = 11) in the peripheral blood. The median response in the poly-
GP immunoassay in the CSF of all 30 C9orf72 patients was > 35-fold
higher than in ND-CON and NonC9-F1 controls (median 140.3,
interquartile range 66.5 to 335.3 vs. median 4.0, interquartile range
1.25 to 24.9), which indicates a specific response (Fig 2A). We
performed receiver operating characteristic (ROC) curve analysis of
all C9orf72 mutation carriers vs. all other samples. The area under
the curve (AUC) was 0.95 (95% CI: 0.92–0.99) (Fig 2B) and at a
cutoff of 43.5 the sensitivity was 93.3% (95% CI: 77.9–99.2%) and
the specificity was 91.6% (95% CI: 84.1–96.3%).
Of note, we detected poly-GP signal in eight out of 95 from
patients in the C9orf72-negative groups. One patient who eventually
received the clinical diagnosis of sporadic ALS and was initially seen
under the differential diagnosis of hereditary spastic paraplegia
(HSP) showed elevated poly-GP levels in CSF. One ND-CON patient
with very high poly-GP signal had undergone a lumbar puncture in
order to exclude a chronic inflammatory process. This patient
presented with dysaesthesia of the lower limbs, a small spinal lesion
in MRI, but without oligoclonal bands or motor and frontal signs.
The other patients included four patients with a clinical diagnosis of
AD and two control patients with the clinical diagnosis of a
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vestibular neuritis and a polyneuritis. However, for the latter two
patients, the poly-GP levels were just above the calculated cutoff
level. In these patients, there was no clinical sign for a neurodegen-
erative disease. The genetic C9orf72 status of these patients was
(re)analyzed except for the two control patients with vestibular
neuritis and polyneuritis, where no DNA was available. We did not
detect a C9orf72 repeat expansion in peripheral blood, but cannot
rule out a somatic mosaicism in the brain as autopsy samples were
not available for a definitive diagnosis. In an additional poly-GP-
positive AD case, genotyping indeed revealed a C9orf72 mutation,
which led to reclassification as c9FTD (Fig 2A, red dot).
Importantly, there was no significant difference in the poly-GP
levels of asymptomatic and symptomatic C9orf72 mutation carriers
and also not between c9ALS and c9FTD cases. In contrast, only
c9ALS and sALS patients, but not C9-F1 cases, showed increased
CSF concentrations of pNfH and NfL (Fig 2C and D). Thus, poly-GP
in CSF is a biomarker for the identification of both symptomatic and
asymptomatic C9orf72 mutation carriers, while neurofilament levels
in CSF are associated with the symptomatic but not the premanifest
phase of the disease.
Association of poly-GP with other CSF biomarkers and
clinical scales
Next, we analyzed the correlation of poly-GP levels in the CSF of
c9ALS/FTD cases with different markers of neurodegeneration and
disease severity (Fig 3). There was no significant correlation of
poly-GP levels with the axonal damage markers NfL (r = 0.02,
P = 0.98 in c9ALS; r = 0.04, P = 0.92 in c9FTD) and pNfH (r = 0.13,
P = 0.74 in c9ALS; r = 0.41, P = 0.21 in c9FTD) (Fig 3A and B).
Furthermore, no significant correlation was observed with clinical
scores (r = 0.12, P = 0.79 for ALSFRS-R in c9ALS; r = 0.10,
P = 0.81 for FTLD-CDR in c9FTD), disease duration at the time of
CSF collection (r = 0.67, P = 0.06 in c9ALS; r = 0.18, P = 0.63 in
c9FTD) (Fig 3C and D), and age at disease onset (r = 0.29, P = 0.44
in c9ALS; r = 0.38, P = 0.28 in c9FTD) (Fig 3E and F). Current
technologies allow only a rough estimate of the repeat length,
because the expanded allele presents as a smear rather than a distinct
band in Southern blots and somatic variability between blood and
brain DNA is well described (Nordin et al, 2015). Given these limita-
tions, no significant correlation of poly-GP levels with the estimated
repeat length from blood (available for 11 patients) was identified
(r = 0.58, P = 0.07 for c9ALS and c9FTD combined) (Fig 3G).
Despite being a cross-sectional study, we used a similar approach
as that used in the GENFI study (Rohrer et al, 2015) in order to
determine the changes of CSF poly-GP throughout the evolution of
the disease. That is, we used parental age of onset as a proxy to
calculate the estimated years to disease onset. We did not find any
association between the estimated years to disease onset and CSF
poly-GP (r = 0.28, P = 0.46) (Fig 3H). Thus, poly-GP expression
starts at least several years prior to clinical disease onset and
remains unchanged in late stages.
Discussion
Using a novel immunoassay, we measured poly-GP in the CSF from
C9orf72 ALS and bvFTD cases and carefully selected control groups.
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Figure 1. Validation of a novel poly-GP-specific immunoassay.
A Immunohistochemistry of frontal cortex from ALS/FTD cases with or without C9orf72 repeat expansion using poly-GP antibodies 18H8 and 3F9. Both antibodies
detect neuronal cytoplasmic inclusions specifically in the C9orf72 case (arrows). Hybridoma supernatants were used at 1:250 dilution as described previously
(Schludi et al, 2015). Scale bar 20 lm.
B, C Poly-GP sandwich immunoassay with anti-GP antibodies 18H8 and 3F9 detects purified GST-GP15 below 0.03 ng/ml (B), but no other 15-mer DPRs fused to GST at
1 lg/ml. Data are shown as mean  SD (n = 2) (C). A four-parameter logistic curve was used to fit the dose–response using Prism 7.01 software.
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Our main results were as follows: (i) Significant poly-GP levels are
detectable in the CSF of 93.3% of the C9orf72 ALS and bvFTD cases
but not in 91.6% of the control cases; (ii) rapid poly-GP immunoas-
say is useful to detect individuals with a C9orf72 expansion misdiag-
nosed with other diseases (e.g. AD); and (iii) poly-GP levels are
already increased in asymptomatic stages of the disease, suggesting
DPRs may be most important for the early pathogenic events in
C9orf72 ALS/FTD rather than driving acute neurodegeneration in
late-stage patients.
Poly-GP immunoassay from CSF
Previously, poly-GP had been detected in CSF of c9ALS cases by
immunoassay using polyclonal antibodies (Su et al, 2014). Here, we
developed an analogous immunoassay using two monoclonal anti-
GP antibodies. The monoclonal antibodies allow standardized
analysis and are not vulnerable to limited antibody availability or
batch-to-batch variation, which will be critical for the use as a
therapeutic biomarker for repeat-directed clinical trials (Jiang et al,
2016). The repeat expansion in C9orf72 patients seems to vary
mostly between 400 and > 5,000 (GGGGCC)n repeats (Beck et al,
2013; Fratta et al, 2013) and is notoriously difficult to determine
precisely (Akimoto et al, 2014). We present raw responses instead
of absolute poly-GP concentrations, because the repeat length
affects epitope numbers and thus likely capture and detection of
poly-GP antigens in the immunoassay (compare Fig 3G). While low-
level release and intercellular transmission of all five DPR species
have been reported in cell culture systems (Westergard et al, 2016),
we have so far not been able to detect the other DPR species in
patient CSF using a similar approach suggesting that these species
might be released into the CSF at lower levels.
Poly-GP signal in apparently C9orf72-negative cases
Using ROC analysis, we established a cutoff that allows sensitive
and specific discrimination of most C9orf72 cases from controls.
Table 1. Patient characteristics.
Characteristic
ND-CON
(n = 20)
NonC9-F1
(n = 8)
AD
(n = 24)
PD
(n = 14)
sALS
(n = 18)
sFTD
(n = 11)
C9-F1
(n = 10)
c9ALS
(n = 9)
c9FTD
(n = 11)
Age (years)a 63.5 (52.8 to
70.0)
42.3 (34.6
to 48.0)b
67.5 (56.6 to
70.2)
72.5 (67.0 to
77.0)
60.0 (52.0
to 67.5)
64.0 (53.0
to 68.0)
44.8
(39.4 to
51.2)b
65.1 (54.4
to 71.1)
56.3 (44.9
to 61.1)
Gender (F/M) 11/9 3/5 14/10 5/9 6/12 4/7 8/2 3/6 4/7
ALSFRS-Ra n.a. n.a. n.a. n.a. 41.0 (32.0
to 44.0)
n.a. n.a. 39.0 (36.3
to 44.0)
n.a.
FTLD-CDRa n.a. n.a. n.a. n.a. n.a. 4.5 (1.0 to
5.5)
n.a. n.a. 7.0 (3.8
to 11.8)
Disease duration
at LP (months)a
n.a. n.a. n.a. n.a. 14.5 (8.8
to 26.0)
21.0 (15.0
to 39.0)
n.a. 11.3 (4.8
to 29.9)
56.0 (23.4
to 163)c
Poly-GP in CSF
(arbitrary units)a
4.0 (1.3 to
24.9)
1.8 (5.5
to 7.0)
6.0 (3.6 to
16.3)d
10.5 (18.9 to
3.6)
1.3 (9.6
to 5.3)
13.5 (16.0
to 7.0)
129 (68.0
to 393)e
113 (80.0
to 279)f
151
(51.5 to
333)e
NfL in CSF
(pg/ml)a
909 (759 to
2,297)
720 (581
to 1,093)
2,232 (1,768 to
2,655)
2,911 (2,185 to
5,907)g
6,319 (3,000
to 27,013)h
4,455 (2,515
to 8,397)i
716 (620
to 1,043)
13,644
(9,313 to
29,818)j
2,614
(1,903 to
3,771)
pNfH in CSF
(pg/ml)a
264 (188 to
474)
188 (188
to 188)
353 (254 to
495)k
499 (343 to
675)l
1,593 (790
to 5,325)m
309 (241
to 768)
188 (188
to 188)
3,740
(2,028 to
5,487)n
303 (246
to 485)
AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale—revised; bvFTD, behavioral variant of frontotemporal dementia;
C9-F1, asymptomatic C9orf72 mutation carriers; c9ALS, symptomatic ALS C9orf72 mutation carriers; c9FTD, symptomatic bvFTD C9orf72 mutation carriers; CSF,
cerebrospinal fluid; F, female; FTLD-CDR, Frontotemporal Lobar Degeneration-specific Clinical Dementia Rating; LP, lumbar puncture; M, male; n.a., not available;
ND-CON, age-matched control population without signs of a neurodegenerative disease; NfL, neurofilament light chain; NonC9-F1, C9orf72-negative offspring of
a C9orf72 mutation carrier; PD, Parkinson’s disease; pNfH, phosphorylated neurofilament heavy chain; sALS, sporadic ALS; sFTD, sporadic bvFTD.
aValues are median and interquartile range.
bP < 0.05 vs. ND-CON, P < 0.01 vs. AD, P < 0.001 vs. PD.
cP < 0.05 vs. sFTD.
dP < 0.01 vs. PD.
eP < 0.05 vs. ND-CON, NonC9-F1, P < 0.001 vs. sFTD, PD, sALS.
fP < 0.05 vs. ND-CON, NonC9-F1, P < 0.001 vs. sALS, sFTD, PD.
gP < 0.05 vs. NonC9-F1, P < 0.01 vs. C9-F1.
hP < 0.01 vs. ND-CON, P < 0.001 vs. NonC9-F1, C9-F1.
iP < 0.001 vs. C9-F1, NonC9-F1.
jP < 0.01 vs. AD, P < 0.001 vs. ND-CON, NonC9-F1, C9-F1.
kP < 0.05 vs. C9-F1.
lP < 0.05 vs. NonC9-F1, P < 0.01 vs. C9-F1.
mP < 0.01 vs. ND-CON, P < 0.001 vs. NonC9-F1, C9-F1.
nP < 0.05 vs. ND-CON, P < 0.001 vs. NonC9-F1, C9-F1.
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Figure 2. Poly-GP expression is increased in CSF of asymptomatic and symptomatic C9orf72 mutation carriers.
A Poly-GP was measured using immunoassay in an age-matched control population without signs of a neurodegenerative disease (ND-CON, n = 18–20), C9orf72-
negative offspring of C9orf72 mutation carriers (NonC9-F1, n = 8) in patients with other neurodegenerative diseases, that is, Alzheimer’s (AD, n = 24) and
Parkinson’s disease (PD, n = 14), sporadic ALS (sALS, n = 18) and FTD (sFTD, n = 11) patients, and asymptomatic (C9-F1, n = 10) and symptomatic C9orf72 mutation
carriers with ALS (c9ALS, n = 9) and FTD (c9FTD, n = 11). The c9FTD patient indicated by the filled, red circle was initially seen under the differential diagnosis of AD,
but after poly-GP measurement followed by C9orf72 genotyping reclassified as c9FTD.
B Receiver operating characteristic (ROC) curve analysis of poly-GP levels for the discrimination of C9orf72 mutation carriers vs. non-carriers. The cutoff (43.5) was
calculated using the Youden index and is shown as a dotted line in (A). AUC, area under the curve; Sens, sensitivity; Spec, specificity.
C, D (C) Phosphorylated neurofilament heavy chain (pNfH) and (D) neurofilament light chain (NfL) were measured using an established ELISA.
Data information: Groups were compared by Kruskal–Wallis test and Dunn’s post hoc test. Bars and whiskers are median and interquartile range, and circles are
individual values. Exact P-values poly-GP (A): ND-CON vs. c9FTD: P = 0.0477; PD vs. AD: P = 0.0053; ND-CON vs. c9ALS: P = 0.0483; ND-CON vs. C9-F1: P = 0.0236;
NonC9-F1 vs. c9FTD: P = 0.0365; NonC9-F1 vs. c9ALS: P = 0.0334; NonC9-F1 vs. C9-F1: P = 0.0194; sALS vs. c9FTD: P = 0.0006; sALS vs. c9ALS: P = 0.0007; sALS vs. C9-F1:
P = 0.0003; sFTD vs. c9FTD, sFTD vs. c9ALS, sFTD vs. C9-F1, PD vs. c9FTD, PD vs. c9ALS, and PD vs. C9-F1: P < 0.0001. Exact P-values pNfH (C): PD vs. C9-F1: P = 0.0121;
PD vs. NonC9-F1: P = 0.0261; sALS vs. ND-CON: P = 0.0103; C9-F1 vs. AD: P = 0.0334; ND-CON vs. c9ALS: P = 0.0142; NonC9-F1 vs. c9ALS, C9-F1 vs. c9ALS, sALS vs. C9-F1,
and sALS vs. NonC9-F1: P < 0.0001. Exact P-values NfL (D): sFTD vs. C9-F1: P = 0.0013; sFTD vs. NonC9-F1: P = 0.0038; PD vs. C9-F1: P = 0.0122; PD vs. NonC9-F1:
P = 0.0245; c9ALS vs. AD: P = 0.0107; sALS vs. ND-CON: P = 0.0017; sALS vs. NonC9-F1: P = 0.0001; sALS vs. C9-F1, ND-CON vs. c9ALS, NonC9-F1 vs. c9ALS, and C9-F1 vs.
c9ALS: P < 0.0001.
ª 2017 The Authors EMBO Molecular Medicine Vol 9 | No 7 | 2017
Carina Lehmer et al Poly-GP in CSF of presymptomatic C9orf72 EMBO Molecular Medicine
863
Published online: April 13, 2017 
87
Only two of our genetically verified c9ALS/FTD cases had low
poly-GP levels in CSF. In contrast, some of the non-mutation
carriers (one sALS, four AD, and one ND-CON) showed strongly
elevated poly-GP signals. We offer three potential explanations.
First, the repeat length in C9orf72 patients is known to vary
widely between different tissues (Nordin et al, 2015) and it is
possible that the repeat length is normal in blood lymphocytes,
but pathological in the central nervous system. Thus, somatic
mosaicism could prevent detection of bona fide C9orf72 cases
using genotyping from peripheral blood. Emerging single-cell
A C
B
G H
D
E
F
Figure 3. Poly-GP expression in CSF correlates neither with markers of neurodegeneration nor with clinical disease severity.
A–F Correlation analysis of poly-GP levels in CSF of c9ALS (A, C, E) and c9FTD cases (B, D, F). Correlation with phosphorylated neurofilament heavy chain (pNfH) and
neurofilament light chain (NfL) (A, B), with disease duration at lumbar puncture (LP) and the ALSFRS-R or FTLD-CDR score (C, D) and with age at disease onset (E, F).
G Correlation of poly-GP levels in CSF with the largest repeat length estimated by Southern blotting.
H Association of poly-GP levels in CSF with disease duration at LP in c9ALS/FTD patients and with time to expected disease onset in C9-F1 cases. Time to expected
disease onset was calculated using parental age at disease onset.
Data information: Correlation analysis was performed using Spearman’s rank correlation coefficient.
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genome data show an unexpected degree of mosaicism in health
and disease (Forsberg et al, 2016). Second, other pathologically
expanded repeats in the genome, for example, the intronic
(GGCCTG)n repeat expansion in the gene for the nucleolar protein
NOP56 causing spinocerebellar ataxia type 36 (SCA36), could
result in poly-GP expression (Kobayashi et al, 2011). Third, other
CSF proteins with short poly-GP stretches that are upregulated
preferentially in a subgroup of AD patients may cross-react in the
immunoassay.
High poly-GP levels in presymptomatic C9orf72 carriers
Animal models support a predominant gain-of-function mechanism
for C9orf72 pathogenesis, but the role of DPR proteins in disease
initiation and progression in human ALS and FTD patients remains
unresolved. Here, we show that poly-GP is already elevated in CSF
of asymptomatic C9orf72 mutation carriers ~14 years younger than
the symptomatic group, suggesting that DPR expression is present
in the earliest disease phase (compare Table 1). This is in agreement
with the neuropathological detection of DPRs in presymptomatic
C9orf72 cases at young age (Baborie et al, 2014; Proudfoot et al,
2014; Vatsavayai et al, 2016). Interestingly, cross-sectional data
from the GENFI cohort show subtle brain volume loss and behavioral
changes in C9orf72 carriers already 20 years prior to the expected
disease onset, while MAPT (microtubule-associated protein tau) and
GRN (granulin) mutation carriers show the first significant differences
much closer to the disease onset (Rohrer et al, 2015). Presymp-
tomatic DPR expression suggests that DPRs may be most critical for
initially triggering the disease, while progression may largely depend
on TDP-43 pathology (Edbauer & Haass, 2016).
Moreover, poly-GP levels are similar in c9ALS and c9FTD
although disease duration is much shorter in ALS. Poly-GP levels in
CSF of c9ALS/FTD cases did not correlate with markers of neurode-
generation such as the axonal damage markers NfL and pNfH and
with markers of disease severity (clinical scores, disease duration,
and onset). This is consistent with neuropathological findings show-
ing no spatial correlation of DPR pathology with neurodegeneration
(Mackenzie et al, 2013; Schludi et al, 2015). It is unclear how CSF
levels of poly-GP correlate the amounts of poly-GP and the other
DPR species within the neuronal inclusions. Although the total DPR
levels vary between patients, we are not aware of cases with vastly
different ratios of the different DPR species (Mackenzie et al, 2015;
Schludi et al, 2015).
Since poly-GR/PR and poly-GA are by far more toxic than poly-
GP in cellular and animal models (Mizielinska et al, 2014), it will be
critical to determine their levels during disease progression to better
address the role of DPRs in c9ALS/FTD pathogenesis.
In conclusion, poly-GP determination in CSF may be used as an
alternative or addition to genetic testing to identify C9orf72 mutation
carriers. Our data indicate that poly-GP expression is already present
in the presymptomatic phase of c9ALS/FTD, and thus, DPRs may
predominantly contribute to triggering the disease rather than
driving acute neurodegeneration in late-stage patients. This has
implications for developing drugs and designing clinical trials. A
standardized monoclonal-based anti-GP immunoassay will be criti-
cal to determine whether antisense oligonucleotide treatment in
patients reduces DPR expression in patients similar to the preclinical
trials in mice (Su et al, 2014).
Materials and Methods
Patients
We investigated nine different patient groups: (i) symptomatic ALS
C9orf72 mutation carriers (c9ALS), (ii) symptomatic patients of the
behavioral variant of FTD (bvFTD) C9orf72 mutation carriers
(c9FTD), (iii) asymptomatic C9orf72 mutation carriers (C9-F1), (iv)
C9orf72-negative offspring of a C9orf72 mutation carrier (NonC9-
F1), (v) sporadic ALS patients (sALS), (vi) sporadic FTD patients
(sFTD), two groups of other neurodegenerative diseases, namely
(vii) Parkinson’s disease (PD) and (viii) Alzheimer’s disease (AD),
and (ix) an age-matched control population without clinical signs of
a neurodegenerative disease (non-neurodegenerative control, ND-
CON). Diagnosis was made according to standard criteria.
C9orf72 ALS cases and NonC9-F1 cases were recruited from the
German Presymptomatic (GPS)-ALS cohort (Weydt et al, 2016). AD
and bvFTD patients (including C9orf72 cases) were enrolled at dif-
ferent clinical centers coordinated by the German FTLD consortium
(Erlangen, Leipzig, Munich, Ulm, Würzburg). All other patients
were recruited at the Department of Neurology, Ulm University
Hospital, Germany. Group size for the groups ND-CON, PD, sALS,
and sFTD was estimated by experience because no preliminary data
were available. For the groups NonC9-F1, AD, C9-F1, c9ALS, and
c9FTD, all samples available from the cohorts of the GPS-ALS and
FTLD consortium were used. All patients gave written informed
consent. All procedures were in accordance with the WGA Declara-
tion of Helsinki and the Department of Health and Human Services
Belmont Report. The ethics committees of the participating centers
approved the study (Otto et al, 2011).
All patients underwent neuropsychological testing using stan-
dard procedures. Disease severity in ALS patients was assessed
using the ALS Functional Rating Scale—revised (ALSFRS-R) and in
bvFTD patients using the FTLD-specific Clinical Dementia Rating
(FTLD-CDR) score. PCR-based screening methods were used for
the detection of C9orf72 repeat expansion. If enough DNA was
available, Southern blot analyses were conducted (Akimoto
et al, 2014).
Cerebrospinal fluid was collected by lumbar puncture, centri-
fuged, and stored within 2 h at 80°C following standard operating
procedures at all sites.
Poly-GP sandwich immunoassay from CSF
By immunizing Lou/c rats with synthetic GP10 peptides, the poly-
GP-specific monoclonal antibodies 18H8 (IgG1/j) and 3F9 (IgG2a/j)
were raised using previously described protocols (Mackenzie et al,
2013). These new monoclonal antibodies against poly-GP had
higher affinity than the previously described clone 7A5 (Schludi
et al, 2015). An immunoassay was performed using the Meso
Scale Discovery platform (MSD). Streptavidin plates (MSD Gold
96-well Streptavidin) were coated with biotinylated 18H8 antibody
(capture antibody, 1:8,000) in PBS, washed three times (0.05%
Tween-20, PBS) using a Biotek 405US Microplate washer, and
blocked for 1 h at room temperature (0.05% Tween-20, 1% BSA
in PBS). Plates were incubated with 80 ll/well of CSF samples
diluted with one volume of RIPA buffer (137 mM NaCl, 20 mM
Tris pH = 7.5, 10% glycerol, 1% Triton X-100, 0.5% sodium
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deoxycholate, 0.1% SDS, 2 mM EDTA) and supplemented with a
protease inhibitor cocktail (Sigma) for 2 h at room temperature on
a shaking platform. Pseudonymized samples were randomly
distributed on the plate and measured blindly in two replicates.
After three washing steps, the plates were incubated with MSD
sulfo-tag-labeled 3F9 antibody (detection antibody, 1:1,000) for 2 h
at room temperature on a shaking platform followed by three final
washing steps. Upon adding 100 ll MSD Read Buffer T, the plates
were immediately measured. The electrochemical signal was
detected using a MSD SECTOR Imager 2400. 15-mer GST-DPR
fusion proteins were purified from Escherichia coli as described
(Mori et al, 2013b). After background correction, data are
presented in arbitrary units.
Measurement of neurofilament levels
Neurofilament, that is, NfL and pNfH, levels were measured using
commercial ELISA kits from Quanterix, Lexington (NfL), and
BioVendor (pNfH) (Steinacker et al, 2016a,b). Values of pNfH below
the detection limit (188 pg/ml) were set to 188 pg/ml to permit
statistical analysis.
Statistics
Statistical analysis was performed using GraphPad Prism 5.0 and
JMP software 11.1.1. The data did not follow a normal distribution,
and therefore, non-parametric tests were used. Groups were
compared by Kruskal–Wallis test and Dunn’s post hoc test
(> 2 groups) or Mann–Whitney test. Correlation analysis was
performed with Spearman’s rank correlation coefficient. ROC curve
analysis was used to calculate sensitivity and specificity of poly-GP
expression, and a threshold to separate C9orf72 mutation carriers
and non-carriers was selected using the Youden index. A P-value
< 0.05 was regarded as statistically significant.
Expanded View for this article is available online.
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Figure EV1. The poly-GP immunoassay is reproducible.
A–D Poly-GP sandwich immunoassay with anti-GP antibodies 18H8 and 3F9 was used to analyze the GST-GP15 standard at four concentrations. Background-corrected
absolute values, mean, and standard deviation (SD) for n = 4 GST-GP15 intra-plate replicates (A), n = 3 inter-plate replicates (B), and n = 3 day-to-day replicates
(C). Mean, SD, and the coefficient of variance (CV) for all conditions are listed in (D).
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C9orf72 poly-GA dipeptide repeat proteins
Qihui Zhou1,2, Carina Lehmer1, Meike Michaelsen1, Kohji Mori3,4 , Dominik Alterauge5,
Dirk Baumjohann5 , Martin H Schludi1,2, Johanna Greiling1, Daniel Farny1, Andrew Flatley6,
Regina Feederle1,2,6, Stephanie May1, Franziska Schreiber1, Thomas Arzberger1,7,8, Christoph Kuhm1,2,9,
Thomas Klopstock1,2,9, Andreas Hermann10, Christian Haass1,2,3 & Dieter Edbauer1,2,3,*
Abstract
Cell-to-cell transmission of protein aggregates is an emerging
theme in neurodegenerative disease. Here, we analyze the dipep-
tide repeat (DPR) proteins that form neuronal inclusions in
patients with hexanucleotide repeat expansion C9orf72, the most
common known cause of amyotrophic lateral sclerosis (ALS) and
frontotemporal lobar degeneration (FTLD). Sense and antisense
transcripts of the (G4C2)n repeat are translated by repeat-asso-
ciated non-ATG (RAN) translation in all reading frames into five
aggregating DPR proteins. We show that the hydrophobic DPR
proteins poly-GA, poly-GP, and poly-PA are transmitted between
cells using co-culture assays and cell extracts. Moreover, uptake or
expression of poly-GA induces nuclear RNA foci in (G4C2)80-expres-
sing cells and patient fibroblasts, suggesting an unexpected
positive feedback loop. Exposure to recombinant poly-GA and cere-
bellar extracts of C9orf72 patients increases repeat RNA levels and
seeds aggregation of all DPR proteins in receiver cells expressing
(G4C2)80. Treatment with anti-GA antibodies inhibits intracellular
poly-GA aggregation and blocks the seeding activity of C9orf72
brain extracts. Poly-GA-directed immunotherapy may thus reduce
DPR aggregation and disease progression in C9orf72 ALS/FTD.
Keywords amyotrophic lateral sclerosis; C9orf72; immunotherapy;
RAN translation; seeding
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Introduction
Intracellular protein aggregation is a common feature of Alzheimer’s
disease and many other neurodegenerative disorders. Cell-to-cell
transmission of intracellular protein aggregates has been described
for intracellular tau and a-synuclein aggregates forming amyloid fib-
rils (Chai et al, 2012; Sanders et al, 2014). The secretion and reup-
take mechanisms are largely unknown, but the transmitted small
aggregates seem to act as nucleation seeds that template further
aggregation in the receiving cell (Jucker & Walker, 2011). The
spreading of aggregates between cells is thought to cause the stereo-
typic progression of tau pathology through synaptically connected
brain regions during disease progression (Braak et al, 2006; Iba
et al, 2015; Takeda et al, 2015). Ongoing preclinical and clinical
trials aim to interrupt the spreading of intraneuronal pathology
using mostly passive vaccination (Yanamandra et al, 2013).
In 2011, a (G4C2)n repeat expansion upstream of the coding
region of C9orf72 was found to cause frontotemporal lobar degener-
ation (FTLD) and/or amyotrophic lateral sclerosis (ALS) in about
10% of all Caucasian patients with these related fatal neurodegener-
ative conditions (DeJesus-Hernandez et al, 2011; Renton et al,
2011; Gijselinck et al, 2012). C9orf72 haploinsufficiency, toxic
nuclear RNA foci, and translation into toxic dipeptide repeat (DPR)
proteins have been suggested as drivers of pathogenesis (Edbauer &
Haass, 2016). Animal models expressing the repeat expansion
strongly support a gain-of-function mechanism (Mizielinska et al,
2014; Chew et al, 2015; Jiang et al, 2016; Liu et al, 2016). Repeat
RNA accumulates in nuclear foci and sequesters several RNA-
binding proteins (Mori et al, 2013b), but even high level expression
of the repeat RNA from an intron is not toxic in Drosophila models
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(Tran et al, 2015). Sense and antisense repeat transcripts are trans-
lated in all reading frames into five aggregating DPR proteins (Ash
et al, 2013; Mori et al, 2013a,c) by an unconventional mechanism.
This so-called repeat-associated non-ATG (RAN) translation was
first described for expanded CAG repeats and seems to require
formation of RNA hairpins (Zu et al, 2011). Poly-GA is abundantly
expressed in the C9orf72 brains, followed by poly-GP and poly-GR,
while poly-PA and poly-PR resulting from translation of the anti-
sense transcript are rare. In addition to RNA foci and DPR pathol-
ogy, C9orf72 patients also develop TDP-43 pathology that correlates
well with neurodegeneration like in other forms of FTLD/ALS
(Mackenzie et al, 2013), but it is still unclear how the C9orf72
repeat expansion triggers TDP-43 pathology. In contrast, several
neuropathology studies failed to detect a strong correlation of the
different DPR species (or RNA foci) with the region-specific
neurodegeneration seen in C9orf72 ALS and FTLD patients
(Mackenzie et al, 2013; Schludi et al, 2015), suggesting an interplay
of several factors and/or non-cell autonomous effects such as
spreading and seeding may be crucial for pathogenesis. Interest-
ingly, GA15 peptides form amyloid-like fibrils that are taken up by
N2a cells (Chang et al, 2016).
Thus, we asked whether poly-GA and the other DPR species are
transmitted between cells and how DPR uptake affects the receiving
cells. We detected cell-to-cell transmission of all hydrophobic DPR
species and show that poly-GA boosts repeat RNA levels and DPR
expression, suggesting DPR transmission may trigger a vicious
cycle. Treating cells with anti-GA antibodies reduced intracellular
aggregation of DPRs. Poly-GA antibodies blocked the seeding activ-
ity of C9orf72 brain extracts which further supports the therapeutic
potential of our discovery.
Results
Poly-GA and poly-PR differentially affect repeat RNA expression
and translation
To allow better interpretation of DPR seeding experiments, we first
analyzed DPR protein co-localization in cell lines co-expressing
repeat RNA and synthetic DPR constructs. Thus, we cotransfected
ATG-initiated synthetic DPR expression plasmids with GFP tag
together with a (G4C2)80 expression vector driven by the strong
CMV promoter (Mori et al, 2016). As expected, RAN translation
leads to GA80-flag aggregation under all conditions. We observed
co-aggregation of GA80-flag with GA175-GFP, but little specific
co-localization with the other DPR proteins, which were mainly dif-
fusely localized in the cytoplasm as reported previously (May et al,
2014; Zhang et al, 2014). Compared to the GFP co-expression, GA80-
flag aggregates appeared larger particularly in GA175-GFP- and
PR175-GFP-expressing cells and to a lesser extent also with the other
DPR proteins (Fig 1A). Quantification confirmed the increased size
of GA80-flag aggregates in GA175-GFP- and PR175-GFP-expressing
cells and showed no significant effects on the number of aggregates
upon co-expression of any DPR species (Fig 1B and C). Similarly, fil-
ter-trap analysis showed enhanced aggregation of GA80-flag particu-
larly in GA175-GFP- and PR175-GFP-expressing cells (Fig 1D and E).
Since poly-PR binds RNA and RNA-binding proteins (Kwon et al,
2014; Kanekura et al, 2016) and thus might affect mRNA
expression, we quantified the expression levels of the repeat mRNA
(Fig 1F). Poly-PR had no significant effect on the repeat RNA,
suggesting it may mainly induce RAN translation. In contrast, poly-
GA expression unexpectedly also increased the levels of the (G4C2)n
RNA.
Together, these data indicate that especially poly-GA and poly-
PR proteins promote repeat transcription and/or RAN translation. In
contrast to patient tissue, poly-GA did not specifically co-aggregate
with the other DPR species under our conditions. Thus, uptake of
poly-GA may affect both expression and nucleation in receiver cells.
Poly-GA, poly-GP, and poly-PA are transmitted between cells
To address whether large DPR proteins are transmitted between
cells, we performed co-culture experiments. HEK293 cells were first
transfected separately with either DPR-GFP, GFP, or RFP expression
vectors. After 24 h, RFP-transfected cells were resuspended and
mixed with GFP- or DPR-GFP-transfected cells. Double-positive cells
were quantified using flow cytometry analysis immediately after
mixing or after 24 h of co-culture (Fig 2A and B). In mixtures of
GFP- and RFP-transfected cells, double-positive cells were extremely
rare (~0.3%) at both time points. In contrast, GA175-GFP was
detected in 1–2% of RFP-positive cells after 24 h of co-culture indi-
cating transmission of GA175-GFP to RFP-transfected neighboring
cells (Fig 2C and D). Furthermore, double-positive cells were sorted
to image GFP-tagged DPR proteins in RFP-positive receiver cells
(Fig EV1), thus implying secretion and uptake of poly-GA by neigh-
boring cells. We detected even higher intercellular transmission of
GP47-GFP and PA175-GFP, which show mostly diffuse cytoplasmic
expression (May et al, 2014; Zhang et al, 2014).
In contrast, positively charged GFP-GR149 and PR175-GFP, which
localize to cytoplasm and nucleus, were not detected in the RFP-
positive receiving cells above background levels. To compensate for
the different transfection and expression levels of the GFP-DPR
proteins, we also normalized the double-positive cells to the total
population of GFP-positive cells (Fig 2D), which showed a similar
result compared to the absolute fraction of double-positive cells
(Fig 2C). Thus, the hydrophobic cytoplasmic DPR proteins are
transmitted between cells regardless of their aggregation properties.
GA175 aggregates seed further poly-GA aggregates in
repeat RNA-expressing cells
To test whether transmitted DPR proteins act as a seed for further
aggregation, we next used (G4C2)80-transfected cells as receiving
cells in co-culture experiments. We first confirmed that (G4C2)80-
transfected cells also take up GA175-GFP by co-staining of GA80-flag
and GA-GFP for analysis by flow cytometry after 3 days of co-
culture to allow sufficient levels of RAN translation (Fig 3A and B).
We detected a similar fraction of double-positive cells for co-culture
of (G4C2)80 and GA175-GFP-, GP47-GFP-, or PA175-GFP-expressing
cells as with RFP-positive receiver cells (compare Figs 2 and 3B).
Since (G4C2)80 drives mainly poly-GA expression (Mori et al, 2016),
we focused on this DPR species for the following experiments.
To further increase the load of transmissible DPR proteins, we
incubated (G4C2)80-transfected cells for 3 days with GA175-RFP
aggregates (Fig 3C). Immunofluorescence confirmed intracellular
uptake of GA175-RFP aggregates (Fig 3D). The exogenous aggregates
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co-localized with GA80-flag derived from the (G4C2)80 vector
(Fig 3D, arrow), indicating that transmitted poly-GA can seed
further aggregation. Importantly, even cells without prominent
GA175-RFP staining showed increased GA80-flag levels compared to
cells treated with RFP extracts, suggesting that even trace amounts
of GA175-RFP can accelerate poly-GA aggregation in the receiving
cells (Fig 3D, arrowhead). Importantly, also the fraction of GA80-
flag-positive cells increased significantly, suggesting that genuine
seeding occurred (Fig 3E).
Filter-trap experiments and flow cytometry analysis confirmed
increased expression/aggregation of RAN translation-derived GA80-
flag and to a lesser extent also of GR80-HA and GP80-myc in GA-
RFP-treated cells on a biochemical level (Fig 3F and G). Similar to
direct poly-GA expression (Fig 1F), exposure to GA175-RFP lysates
also increased the levels of the (G4C2)80 mRNA transcripts (Fig 3H),
indicating that poly-GA may affect transcription or stability of the
expanded C9orf72 repeat RNA. Taken together, uptake of poly-GA
promotes further aggregation of poly-GA, poly-GR, and poly-GP in
cells expressing the C9orf72 repeat expansion.
Dipeptide repeat proteins promote repeat RNA foci formation
To corroborate the effect of poly-GA on repeat RNA levels, we
analyzed nuclear RNA foci, which are another disease hallmark of
C9orf72 FTLD/ALS. We switched from HEK293 to HeLa cells,
because they attach better to glass coverslips and can sustain the
harsh washing steps for in situ hybridization. As (G4C2)80 expres-
sion resulted in many coalescing RNA foci, which made counting
their number unreliable, we analyzed the size of RNA foci. Cotrans-
fection of GA175-GFP, PA175-GFP, and GFP-GR149 significantly
increased foci size compared to GFP control, while GP47-GFP and
PR175-GFP expression had no effect (Fig 4A and B). The effects of
DPR proteins on RNA foci in HeLa cells are comparable to their effects
on repeat RNA levels in HEK293 cells (compare Figs 4B and 1F).
To verify the effects of DPR proteins on the repeat RNA under
physiological conditions, we used primary fibroblasts derived from
patients with expanded G4C2 repeats and transduced them with
individual DPR-GFP-expressing lentiviruses. Since DPR expression
in primary patient-derived cells (including induced pluripotent stem
cells) is extremely low, we investigated the effect on RNA foci
formation. Consistent with the effects of DPR proteins on RNA foci
in HeLa cells (Fig 4B), expression of poly-GA, poly-PA, and poly-GR
increased the number of foci per cell (Fig 4C and D), whereas poly-
PR had no effect on foci formation. Thus, poly-GA, poly-PA, and
poly-GR seem to promote transcription or stability of the expanded
repeat RNA.
Poly-GA is transmitted between neurons
To replicate our data in primary neurons, we transduced donor
and receiver cells on separate coverslips for 3 days and co-
cultured both coverslips with spacers from paraffin dots for
another 4 days. We focused on poly-GA and used both (G4C2)80
and empty vector-transduced receiver cells. Unfortunately, repeat-
transduced neurons show only low GA80-flag expression, presum-
ably due to poor packaging efficiency of the repeat RNA (Fig 5A).
In contrast, lentiviral transduction of primary neurons with GA175-
GFP results in inclusions of size and intensity comparable to the
aggregates in cortex of C9orf72 patients (May et al, 2014).
Consistent with Figs 2 and 3, we did not detect transmission
from the GFP control donor to the receiver cells (Fig 5A, first row).
In contrast, we detect GA175-GFP inclusions in several receiver
neurons after 4 days of co-culture (Fig 5A, second row), suggesting
that neurons can release and take up poly-GA similar to HEK293
cells. In addition, we noticed co-localization of transmitted GA175-
GFP and RAN-translated GA80-flag in some receiver cells expressing
(G4C2)80 (Fig 5A, fourth row).
To directly assess poly-GA release from neurons, we collected
conditioned media every 24 h and performed a poly-GA immuno-
assay. We first detected poly-GA levels in GA175-GFP-transduced
cells compared to GFP controls 48 h after transduction (Fig 5B), but
poly-GA release was significantly higher on the third and fourth
day. Thus, neurons are able to release and take up low levels of
poly-GA similar to tau and other intracellular aggregates.
Brain lysates from C9orf72 mutation carriers seed poly-GA
aggregates in repeat RNA-expressing cells
Next, we asked whether patient-derived DPR aggregates can
induce seeding. Therefore, we homogenized cerebella of FTLD
patients with or without C9orf72 mutation, because in this brain
region, DPR levels are very high and TDP-43 aggregation is virtu-
ally absent (Mackenzie et al, 2013). Similar to established proto-
cols for tau seeding, we used liposome-mediated transfection to
promote aggregate uptake in (G4C2)80-expressing cells (Nonaka
et al, 2010; Sanders et al, 2014).
Cerebellar extracts from C9orf72 patients increased the number
of GA80-flag-positive cells compared to C9orf72-negative controls as
quantified by flow cytometry (Fig 6A and B). Filter trap confirmed
the enhanced GA80-flag aggregate levels in cells treated with extracts
from a C9orf72 patient compared to a C9orf72-negative control
(Fig 6C and D). Cerebellar extracts from a C9orf72 patient also
increased the levels of GR80-HA and GP80-myc (Fig 6C and D).
◀ Figure 1. DPR expression promotes RAN translation from (G4C2)80.HEK293 cells cotransfected with (G4C2)80 containing a flag-tag in the poly-GA reading frame and GFP or DPR-GFP for 3 days to analyze effects on RAN translation.
A Immunofluorescence for the GFP-tagged proteins and RAN translation-derived GA80-flag. DAPI labels nuclei. Scale bar 20 lm.
B, C Quantification of GA80-flag aggregate area and number from n = 4 independent experiments with five images each (containing 60–90 cells per image). Aggregate
and cell number were counted manually, and aggregate size was determined by thresholding. Data are shown as mean  SD. One-way ANOVA with Dunnett’s
multiple comparisons test; GFP vs. GA-GFP P = 0.0025; GFP vs. PR-GFP P = 0.0095; **P < 0.01.
D Filter-trap analysis of GA80-flag in two dilutions. A representative of four experiments is shown.
E Quantification of GA80-flag from four independent experiments. Data are shown as mean  SD. Statistics were performed by one-way ANOVA with Dunnett’s
multiple comparisons test; GFP vs. GA-GFP P = 0.0009; GFP vs. PR-GFP P = 0.0325; *P < 0.05, ***P < 0.001.
F Expression of the G4C280 RNA was measured by qPCR targeting the 30 region of the repeat sequence. RNA levels were normalized to GAPDH mRNA. Data are shown
as mean  SD (n = 3). Statistics were performed by one-way ANOVA with Dunnett’s multiple comparisons test; GFP vs. GA-GFP P = 0.0241; *P < 0.05.
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Figure 2. Hydrophobic DPR proteins are transmitted between cells in co-culture assays.
HEK293 cells were transfected with RFP, GFP, or DPR-GFP for 24 h and mixed in the indicated combinations. Co-cultures were analyzed by flow cytometry immediately after
mixing or 24 h later. Gating was performed on RFP-expressing cells compared to mixture of all green fluorescent cells.
A Schematic overview of experimental flow.
B The fraction of double-positive cells is indicated in percent. A representative of three experiments is shown.
C Absolute frequency of double-positive cells after 24 h of co-culture. Data are shown as mean  SD (n = 4). GFP vs. GA-GFP P = 0.0482; GFP vs. GP-GFP P = 0.0019;
GFP vs. PA-GFP P = 0.0012; *P < 0.05, **P < 0.01 by one-way ANOVA with Dunnett’s multiple comparisons test.
D Relative frequency of double-positive cells to total GFP-expressing cells after 24 h of co-culture. Data are shown as mean  SD (n = 4). GFP vs. GA-GFP P = 0.0473;
GFP vs. GP-GFP P = 0.0327; GFP vs. PA-GFP P = 0.0166; *P < 0.05 by one-way ANOVA with Dunnett’s multiple comparisons test.
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Similar to the experiments with cell lysates, this was associated with
an upregulation of (G4C2)80 mRNA expression in the cells receiving
extracts from different C9orf72 mutant patients (Fig 6E). Thus,
uptake of patient-derived DPR proteins induces DPR aggregation in
(G4C2)-repeat-expressing cells by seeding aggregation and increas-
ing repeat RNA levels.
Treatment with specific antibodies blocks poly-GA aggregation
and seeding
Since antibody treatment has been shown to reduce intracellular
aggregation of tau and a-synuclein, which are also known to be
transmitted between cells (Boutajangout et al, 2011; Chai et al,
2011, 2012; Yanamandra et al, 2013), we tested whether anti-GA
antibodies could inhibit aggregation in our cell culture model.
Treating GA175-GFP-transfected HEK293 cells with anti-GA reduced
GA175-GFP aggregation compared to isotype control (Fig 7A and
B). Filter-trap assays using a stable cell line expressing GA149-GFP
confirmed that anti-GA reduced poly-GA aggregate levels
compared to isotype control antibodies (Fig 7C). To analyze the
efficacy of anti-GA antibodies in neurons, we transduced primary
neurons with GA175-GFP and treated with antibodies for 6 days
(Fig 7D). Treatment with anti-GA significantly reduced poly-GA
levels compared to an isotype control (Fig 7E).
We next assessed the ability of anti-GA antibodies to block the
seeding activity of brain extracts from C9orf72 patients on repeat-
expressing cells. Brain lysates were pre-incubated with anti-GA or
IgG2a control for 16 h and then added to (G4C2)80-expressing
HEK293 cells for 48 h before measurement. We detected increased
expression of GA80-flag in cells receiving cerebellar extracts from a
C9orf72 patient (compare Figs 7F and G, and 6A–D). Pre-incubation
with anti-GA antibodies reduced the GA80-flag expression to control
levels, without affecting expression of GR80-HA or the repeat RNA
levels (Fig EV2), indicating that poly-GA is crucial for the seeding
activity of C9orf72 brains.
Together, these data suggest that anti-GA immunotherapy may
prevent seeding and spreading of poly-GA in C9orf72 disease.
Discussion
We demonstrate intercellular spreading and seeding of the
hydrophobic DPR species poly-GA, poly-GP, and poly-PA. Uptake
of poly-GA from transfected cells or from brain homogenates
promotes expression of the expanded repeat RNA and RAN
translation products, suggesting a vicious cycle of DPR expres-
sion and repeat RNA expression. Anti-GA antibodies block the
seeding activity of C9orf72 brain extracts and reduce poly-GA
aggregation in cell lines, suggesting immunotherapy may be a
useful therapeutic option to treat the DPR component of C9orf72
disease.
Hydrophobic DPR proteins are transmitted between cells
Using co-culture assays, we show intercellular transmission of the
hydrophobic DPR species poly-GA, poly-GP, and poly-PA in cell
lines (Fig 1) and we confirmed poly-GA release and uptake in rat
primary neurons (Fig 5). Moreover, cells treated with poly-GA-
containing cell extract or C9orf72 brain homogenates show induced
aggregation of RAN-translated GA80-flag (Figs 3, 6, and 7).
Our data add to previous reports that fibrillar GA15 peptides are
taken up by N2a cells and promote intracellular poly-GA aggrega-
tion (Chang et al, 2016), because we show intercellular transmis-
sion of much larger synthetic poly-GA and even patient-derived
poly-GA. In contrast to Ab seeding, which is very inefficient with
synthetic peptides and seems to require an elusive cofactor from
patient brain (Stohr et al, 2012), at least poly-GA seeding seems to
work with synthetic peptides and lysates from cell culture or cere-
bellum. In addition, we detected intercellular spreading of poly-GP
and poly-PA. Poly-GP is readily detectable in CSF of C9orf72 patients
(Su et al, 2014), but whether extracellular poly-GP in the CSF origi-
nates from active secretion or cellular debris is unclear. Our co-
culture data rather point to unconventional secretion or passive
release of small amounts of hydrophobic DPR proteins as it has been
shown for intracellular tau or a-synuclein (Chai et al, 2012),
because DPR expression is not toxic in HEK293 cells under our
conditions (May et al, 2014). We did not find significant transmis-
sion of arginine-rich DPRs at physiological levels, although synthetic
GR20 and PR20 peptides are taken up by cells and cause toxicity by
interfering with RNA expression and splicing when applied at
10 lM (Kwon et al, 2014).
While this manuscript was under review, Westergard et al
reported cell-to-cell transmission of the hydrophobic DPR 50-mers,
GR50-GFP, and in case of direct cell contact also of PR50-GFP
(Westergard et al, 2016). Even low-level transmission of these
species might be relevant due to their high toxicity (Mizielinska
et al, 2014). The different results between our studies may be due to
different repeat length or expression levels, as the arginine-rich
Figure 3. Poly-GA uptake seeds DPR aggregation and induces repeat RNA expression.
A, B Co-culture assay in HEK293 cells. 24 h after transfection with either (G4C2)80, GFP, or DPR-GFP, cells were mixed in the indicated combination. After 72 h of co-
culture, cells were fixed, permeabilized, and stained with anti-flag to detect GA80-flag for flow cytometry analysis. Flow cytometry dot plots are shown based on
levels of GA80-flag (x-axis) and GFP (y-axis) expression. The fraction of indicated populations is indicated in percent. Graphs shows mean  SD fraction of double-
positive cells from three independent experiments. Statistics were performed by one-way ANOVA with Dunnett’s multiple comparisons test; GFP vs. GA-GFP
P = 0.0316; GFP vs. GP-GFP P = 0.0331; GFP vs. PA-GFP P = 0.0513; *P < 0.05.
C–H HEK293 cells transfected with (G4C2)80 for 48 h were treated for 72 h with cell lysates from HEK293 transfected with RFP or GA175-RFP as depicted in (C). The RAN-
translated GA80-flag, GR80-HA, GP80-myc are detected by anti-flag immunofluorescence (D) and quantified (E). Arrowheads indicate GA80-flag aggregates in cells
without prominent GA175-RFP uptake, arrows indicate co-localization of exogenous GA175-RFP with GA80-flag. Results from n = 4 independent experiments with
five images each quantified and analyzed by two-tailed unpaired t-test. Data are shown as mean  SD. P = 0.0061; *P < 0.05. Scale bar 20 lm. Filter trap (F) and
flow cytometry analysis (G) confirmed the increased levels of GA80-flag in GA175-RFP-treated cells. The percentage of DPR-positive cells in GA-RFP-treated cells
compared to the RFP control is indicated. A representative of three independent experiments is shown. (H) Expression of the (G4C2)80 RNA in DPR-treated cells was
measured by qPCR targeting the tag region downstream of the repeat sequence. RNA levels were normalized to GAPDH mRNA. Data are shown as mean  SD
(n = 3). Statistics were performed by one-way ANOVA with Dunnett’s multiple comparisons test; (G4C2)80 + RFP vs. (G4C2)80 + GA-RFP P = 0.007; **P < 0.01.
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DPRs show lower expression in our system (Fig 1 and May et al,
2014).
Dipeptide repeat proteins affect repeat RNA expression
and/or stability
Surprisingly, poly-GA uptake did not only promote GA80-flag levels,
but also increased expression of the other two RAN products
poly-GP and poly-GR (Fig 3F and G). These findings complicate
interpretation of the data, but two lines of evidence support seeding
of poly-GA. First, poly-GA uptake in recipient cells increased the
number of GA80-flag inclusions. Second, poly-GA antibody treatment
reduced GA80-flag aggregation without affecting its mRNA levels.
Moreover, treating cells with poly-GA extracts induced repeat
RNA levels (Fig 3H), suggesting an effect on repeat transcription
and/or translation. To exclude variable uptake, we transfected DPR
expression constructs and analyzed the repeat RNA. In heterologous
cells and in patient fibroblasts, poly-GA and poly-PA expression
promoted RNA foci formation and poly-GA increased the levels of
repeat RNA (Figs 3H and 4). Since neither of the hydrophobic DPR
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Figure 4. DPR expression promotes formation of repeat RNA foci in HeLa cells and C9orf72 fibroblasts.
A, B In situ hybridization of RNA foci (red) in HeLa cells cotransfected with (G4C2)80 and GFP or DPR-GFP for 3 days. Representative images (A) and quantification
(B) of foci size from three experiments (at least 30 cells per condition per experiment) are shown. DAPI labels nuclei. Scale bar 10 lm. Summary indicated the
means  SD. GFP vs. GA-GFP P = 0.0210; GFP vs. PA-GFP P = 0.0163; GFP vs. GR-GFP P = 0.0413; *P < 0.05 by one-way ANOVA with Dunnett’s multiple
comparisons test.
C, D In situ hybridization of (G4C2)n RNA foci in fibroblast of C9orf72 patients transduced with GFP or DPR-GFP lentivirus for 8–9 days. Note that we could not analyze
poly-GP, because we failed to generate a codon-modified lentivirus. Representative images (C) and quantification of foci number (D) are shown. Brightness and
contrast were digitally enhanced for better visibility for the presentation only. Scale bar 40 lm. Summary indicated the means  SEM of n = 7 experiments for
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proteins is known to bind RNA or RNA-binding proteins directly,
we speculate that the DPR proteins trigger a stress response (Zhang
et al, 2014) leading to transcriptional upregulation of repeat
transcription. Moreover, about 10% of DPR inclusions are found in
the nucleus in patients, where they mainly co-localize with hete-
rochromatin next to the nucleolus, which may support a direct effect
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Figure 5. Release and uptake of poly-GA by neurons.
A Co-culture assay in rat primary neurons. Cortical neurons (400,000/well) on coverslips were transduced with GFP or GA175-GFP as donor. Hippocampal neurons
(85,000/well) on coverslips were transduced with (G4C2)80 or empty vector as receiver cells. Three days later, the washed coverslips were put into well with paraffin
spacers. GFP and GA80-flag expression was analyzed 4 days later in the receiver cells by immunofluorescence. Arrows indicate co-localization of GA175-RFP with
GA80-flag. Scale bar 10 lm.
B Cortical neurons transduced with GFP or GA175-GFP. Conditioned media were exchanged 24 h prior to transduction and collected right before and every 24 h after
infection. Poly-GA levels in media were determined by immunoassay. Data are shown as mean  SEM. Two-way ANOVA with Sidak’s multiple comparisons test
(n = 4). t = 72 h: GA-GFP vs. GFP ***P < 0.0001; t = 96 h: GA-GFP vs. GFP ***P < 0.0001.
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Analysis of RAN translation products in HEK293 cells transfected with (G4C2)80 (for 24 h) and incubated with cerebellar extracts of C9orf72 patients and controls.
A, B Flow cytometry analysis of GA80-flag-positive cells using n = 5 C9orf72-positive and n = 6 C9orf72-negative cases (three healthy controls, two ALS, one FTLD)
P = 0.0124; *P < 0.05 by two-tailed unpaired t-test.
C, D Filter-trap analysis of DPR products in all three reading frames using the indicated antibodies. Results from n = 3 independent experiments using one patient and
one control were quantified and analyzed by two-tailed unpaired t-test. Data are shown as mean  SD. Anti-flag (GA) P = 0.0079; anti-HA (GR) P = 0.0043;
anti-myc (GP) P = 0.0128; *P < 0.05, **P < 0.01.
E Quantitative RT–PCR shows upregulation of repeat RNA transcripts upon incubation with C9orf72 extracts as in Fig 3H. Data are shown as mean  SD from n = 3
patients and controls in independent experiments. Statistics were performed by one-way ANOVA with Dunnett’s multiple comparisons test; (G4C2)80 + non-C9 vs.
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on gene expression (Schludi et al, 2015). Surprisingly, poly-PR
expression induced poly-GA by RAN translation with little effect on
repeat RNA levels or foci formation (Figs 1 and 4). Poly-PR binds
directly to RNA and many RNA-binding proteins (Kwon et al, 2014;
Kanekura et al, 2016). Sequestration of certain RNA-binding
proteins might impair the tight control of ATG-mediated transla-
tional initiation and thus promote RAN translation. Interestingly,
antisense oligonucleotides consistently reduce DPR levels stronger
than repeat RNA levels independently supporting a feedback mecha-
nism (Jiang et al, 2016). Thus, DPR expression may trigger a vicious
cycle of increasing repeat RNA and DPR expression ultimately lead-
ing to neurodegeneration.
Poly-GA immunotherapy
Poly-GA, the most abundant DPR protein in patients, could be at the
center of C9orf72 gain-of-function toxicity, because it forms amyloid-
like fibrils capable of spreading between cells to seed further DPR
aggregation and enhance RNA foci formation. Therefore, we tested
whether we could reduce poly-GA aggregation using specific antibod-
ies. Anti-GA antibodies lowered poly-GA levels in both transiently and
stably transfected HEK293 cells and also in primary neurons (Fig 7).
Moreover, pre-incubation with anti-GA antibodies also prevented
uptake from C9orf72 brain extracts into HEK293 cells (Fig 7).
Immunotherapy targeting extracellular Ab aggregates has
finally shown promising results in patients with Alzheimer’s disease
in its early stages (Sevigny et al, 2016). Surprisingly, anti-tau
immunotherapy lowers intracellular tau aggregation and neurologi-
cal deficits in mouse models (Boutajangout et al, 2011; Chai et al,
2011, 2012; Yanamandra et al, 2013). Even for intracellular aggre-
gates, the antibodies are thought to act on extracellular proteins in
transit between two cells. Antibody binding may induce phagocyto-
sis through microglia via Fc receptors or inhibit neuronal uptake
(Yanamandra et al, 2013). Given our results for cell-to-cell transmis-
sion of the different DPR species, only the hydrophobic poly-GA/GP/
PA would be accessible for antibodies. Thus, anti-GA immunother-
apy may be a future treatment option for C9orf72 ALS/FTLD. Consid-
ering the long prodromal DPR accumulation accompanied by subtle
brain atrophy in C9orf72 patients (Proudfoot et al, 2014; Rohrer
et al, 2015; Edbauer & Haass, 2016), mutation carriers may require
very early treatment as proposed for Alzheimer’s disease.
Taken together, our work shows an unexpected link between
RNA and DPR toxicity and suggests a vicious cycle that may ulti-
mately lead to neuron loss after a prodromal phase. Non-cell auton-
omous effects due to spreading and seeding of poly-GA, poly-GP,
and poly-PA could explain the poor correlation of DPR proteins and
RNA foci with neurodegeneration in C9orf72 patients and suggest a
novel therapeutic approach through passive vaccination.
Materials and Methods
Antibodies
The following antibodies were used: anti-DYKDDDDK/flag (filter
trap 1:1,000, FACS 1:250, Cell Signaling), anti-myc (1:1,000, clone
9E10, Santa Cruz), anti-HA (1:1,000, clone 3F10, Roche), anti-GFP
(1:1,000, clone N86/8, NeuroMab), anti-GA clone 5F2 (1 lg/ml)
(Mackenzie et al, 2013), mouse IgG2a (1 lg/ml, Sigma), and rabbit
IgG (1:250, Sigma).
Plasmids and lentivirus production
ATG-initiated epitope-tagged synthetic expression constructs for
GA175-GFP, PA175-GFP, GFP-GR149, and PR175-GFP in pEF6 or
lentiviral backbone (FhSynW2) were described previously (May
et al, 2014; Schludi et al, 2015). pEGFP-GP47 was a kind gift from
Dr. Leonard Petrucelli (Zhang et al, 2014) and was for some experi-
ments subcloned into pEF6 vector. The triple-tagged (G4C2)80
construct to analyze RAN translation was recently reported (Mori
et al, 2016). Lentivirus was produced in HEK293FT cells (Life Tech-
nologies) as described previously (Fleck et al, 2013).
Cell lines and cell culture
HEK293-T-REx GA149-GFP stable cells were generated using T-REx
system (Thermo Scientific) according to the manufacturer’s instruc-
tion. Briefly, GA149-GFP was cloned into the pcDNA 5/FRT/TO under
the control of CMV promoter and two tetracycline operator 2 (TetO2)
sites and transfected in T-REx 293 cells containing the tet-repressor
protein. The stable cell line was maintained in high-glucose DMEM
medium supplemented with 5 lg/ml blasticidin, 10% FCS, 1% pen/
strep, and 2 mM L-glutamine. Expression of GA149-GFP was induced
with 10 ng/ml tetracycline. HEK293FT cells were cultured with
DMEM containing 10% FCS and penicillin/streptomycin.
Neuron culture
Primary cortical and hippocampal cultures were prepared from
E19 rats as described previously (May et al, 2014) and plated on
Figure 7. Anti-GA antibodies inhibit poly-GA aggregation and prevent seeding from brain tissue.
A, B HEK293 cells transfected with GA175-GFP were treated with anti-GA antibodies or mouse IgG2a isotype control (in the indicated concentration) for 3 days.
Fluorescence microscopy image of GA-GFP aggregation (scale bar 100 lm). (B) The percentage of poly-GA-positive cells was quantified semi-automatically using
BioTek Gen5 software. Data are shown as mean  SD. IgG2a vs. anti-GA 0.5 lg/ml P = 0.0109; IgG2a vs. anti-GA 1.0 lg/ml P = 0.0113; *P < 0.05 by one-way
ANOVA with Dunnett’s multiple comparisons test from three independent experiments.
C HEK293-T-REx GA149-GFP stable cells cultured in the presence of 10 ng/ml tetracycline were treated with anti-GA antibodies or isotype control as in (A) and
analyzed by filter trap. Representative filter-trap blot of three independent experiments is shown.
D, E Rat primary neurons were transduced with GA175-GFP after 5 days in vitro (DIV) and treated with 1 lg/ml antibody on the following day. Neurons were analyzed
after 6 days of treatment by GFP fluorescence and DAPI staining (scale bar 100 lm). The percentage of poly-GA-positive cells was quantified semi-automatically
using BioTek Gen5 software. Data are shown as mean  SD. P = 0.0366; *P < 0.05 by two-tailed unpaired t-test from n = 6 independent experiments.
F, G HEK293 cells transfected with (G4C2)80 were treated with cerebellar extracts pre-incubated with anti-GA or isotype control. The fraction of RAN translation-derived
GA80-flag was quantified by flow cytometry. Data indicated the means  SD of n = 3 patients and controls in independent experiments. Non-C9 + IgG2a vs. C9
mut + IgG2a P = 0.0438; C9 mut + IgG2a vs. C9 mut + anti-GA P = 0.0013; *P < 0.05, **P < 0.01 by one-way ANOVA with Dunnett’s multiple comparisons test.
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poly-D-lysine-coated coverslips. For co-culture experiments, primary
neurons on coverslips with 1 to 2 mm paraffin dots glued on to
them were transduced with lentivirus. After 3 days, coverslips were
extensively washed and put face to face into one well for 4 days.
Patient-derived fibroblasts
We included cell lines from three C9orf72 ALS patients as reported
previously (Japtok et al, 2015; Mori et al, 2016). All procedures were
in accordance with the Helsinki convention and approved by the
Ethical Committee of the University of Dresden (EK45022009;
EK393122012). Patients were genotyped using EDTA blood in the
clinical setting after given written consent according to German legis-
lation independent of any scientific study by a diagnostic human
genetic laboratory (CEGAT, Tübingen, Germany or Dept. Human
Genetics, University of Ulm, Germany) using diagnostic standards.
Poly-GA immunoassay
Poly-GA in neuronal media was measured by immunoassay on the
Meso Scale platform (MSD) using the anti-GA clone 5F2 (Mackenzie
et al, 2013). Streptavidin plates (MSD Gold 96-well streptavidin)
were coated overnight with biotinylated 5F2 antibody (capture anti-
body, 1:400) in PBS. The next day, the plates were washed three
times (0.05% Tween-20, PBS) and blocked for 1 h at room tempera-
ture (0.05% Tween-20, 1% BSA in PBS). Plates were incubated with
pre-cleared media (5 min, 1,000 g) for 2 h at room temperature on
a shaking platform. After three washes, the plates were incubated
with MSD sulfo-tag-labeled 5F2 antibody (detection antibody, 1:400)
for 2 h at room temperature on a shaking platform followed by
three final washing steps. Upon adding 100 ll MSD Read Buffer T,
the plates were immediately measured. The electrochemical signal
was detected using a Meso Scale Discovery SECTOR Imager 2400.
After background correction, data are presented in arbitrary units.
Transfection, immunofluorescence, and filter trap
HEK293FT cells and primary rat neurons were transfected using Lipo-
fectamine 2000 (Thermo Scientific) according to the manufacturer’s
instructions. For immunofluorescence, cells were fixed with 4%
paraformaldehyde and 4% sucrose for 10 min and stained with the
indicated antibodies in GDB buffer (0.1% gelatin, 0.3% Triton X-100,
450 mM NaCl, 16 mM sodium phosphate pH 7.4). Images were taken
using an LSM710 confocal laser scanning system (Carl Zeiss) with
40× or 63× oil immersion objectives. For filter trap, cells were lysed in
Triton buffer (1% Triton X-100, 15 mM MgCl2 in PBS, supplemented
with 10 lg/ml DNase and protease inhibitor) on ice. Protein concen-
tration was determined using BCA assay (Thermo Scientific), and
equal amount of protein was used. Insoluble pellets were collected by
centrifugation at 13,000 rpm/17,949 g at 4°C for 30 mins and resus-
pended in SDS–Tris buffer (2% SDS and 100 mM Tris pH = 7) for 1 h
at room temperature. Samples were diluted in SDS–Tris buffer as indi-
cated and filtered through a cellulose acetate membrane (0.2 lm pore).
Preparation of cell lysates and brain extracts for seeding
Transfected HEK293FT cells or human brain tissue were homoge-
nized in 0.1% Triton X-100 PBS buffer supplemented with
DNase, protease inhibitor, and phosphatase inhibitor cocktails,
and sonicated for 2 × 20 pulses with 10% amplitude (Branson
Digital Sonifier, W-250 D). After brief centrifugation (1,000 g for
5 min), the protein concentration in the supernatant was deter-
mined using BCA assay (Thermo Scientific). For the seeding
assay, 25 lg of cell lysates was applied. To promote aggregate
uptake of brain lysates, 25 lg of brain lysates was mixed with
4 ll Lipofectamine 2000 as described previously (Sanders et al,
2014). To block the aggregation and spreading of poly-GA, brain
lysates were pre-incubated with 2 lg anti-GA antibodies [clone
5F2 (Mackenzie et al, 2013)] or mouse IgG2a as control for
16 h.
Antibody treatment
HEK293 cells transfected with GA175-GFP were treated with anti-GA
antibodies or mouse IgG2a isotype control at the indicated concen-
tration for 3 days. To assess the efficacy of anti-GA antibodies in
neurons, rat primary neurons were transduced with GA175-GFP on
DIV 5 and treated with anti-GA antibodies or mouse IgG2a isotype
control at 1 lg/ml for 6 days. Cells were fixed and counterstained
with DAPI. Fluorescence microscopy image of GA-GFP aggregation
was taken using Cytation 3 image reader (BioTek). The percentage
of poly-GA-positive cells normalized to total cells was quantified
semi-automatically using BioTek Gen5 software. For filter trap,
HEK293-T-REx GA149-GFP stable cells cultured in the presence of
10 ng/ml tetracycline were treated with anti-GA antibodies or
isotype control.
RNA isolation and qPCR
Total RNA was prepared using the RNeasy and QIAshredder kit
(Qiagen) according to the manufacturer’s instructions. RNA prepara-
tions were treated with RNase-Free DNase Set (Qiagen) to minimize
residual DNA contamination. 2 lg of RNA was used for reverse
transcription with M-MLV Reverse Transciptase (Promega) using
oligo-(dT)12–18 primer (Invitrogen). qRT–PCR was performed using
CFX384 Real-Time System (Bio-Rad) with TaqMan technology.
Primers and probes to the tag region of (G4C2)80 construct were
designed as described previously (Mori et al, 2016). Signals of
repeat construct-derived cDNA were normalized to GAPDH cDNA
according to DDCT method.
Flow cytometry and fluorescence-activated cell sorting
HEK293 cells transfected with GFP or RFP were harvested and
resuspended in PBS containing 1% FCS and 0.1% (w/v) NaN3
(FACS-PBS). To perform intracellular staining of GA80-flag,
1–2 × 106 cells/staining were fixed with 4% PFA for 10 min at
37°C, washed once with PBS, permeabilized with FACS-PBS
containing 0.1% (w/v) saponin (FACS-saponin), and incubated with
4% goat serum for 10 min at 4°C to block unspecific binding sites.
Cells were then incubated with saturating amount of anti-
DYKDDDDK/flag antibody (1:250) or rabbit IgG (1:250) as control
for 30 min at 4°C in the dark, followed by a single wash and incuba-
tion with saturating amount of secondary antibody (Alexa Fluor
647-labeled anti-rabbit IgG) for 30 min at 4°C. Cells were then
washed two times with flow cytometry buffer and analyzed using
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MACSQuant VYB (Miltenyi). Data analysis was performed using
FlowJo vX software (Treestar).
To perform fluorescence-activated cell sorting of transmitted
hydrophobic DPR proteins in a co-culture assay, HEK293 cells were
transfected with RFP, GFP, or DPR-GFP for 24 h and mixed in the
indicated combination for additional 24 h. Double-positive cells
were sorted using a FACSAria Fusion (BD Biosciences) cell sorter
and plated on poly-D-lysine-coated coverslips for imaging 17 h
later.
In situ hybridization
In situ hybridization was performed as described previously with
minor changes (Mori et al, 2016). Cells were fixed with 4%
paraformaldehyde, rinsed twice with SSC, and then incubated in
pre-hybridization solution (40% formamide, 2× SSC, 2.5% BSA) at
65°C for 30 min. Cells were then incubated with hybridization solu-
tion (40% formamide, 2× SSC, 0.8 mg/ml tRNA (Roche), 0.8 mg/ml
single-stranded salmon sperm DNA (Sigma), 0.16% BSA, 8%
dextran sulfate (Sigma), 1.6 mM ribonucleoside vanadyl complex
(New England Biolabs), 5 mM EDTA, 10 lg/ll 50 Cy3-labeled 20-O-
methyl-(CCCCGG)4 probe [IDT probe as in (DeJesus-Hernandez
et al, 2011)] at 65°C for HeLa cells and 60°C for primary human
fibroblasts. The following day, cells were sequentially washed with
40% formamide/0.5× SSC for three times 30 min each at 65°C and
then with 0.5× SSC three times 10 min each at room temperature.
After a brief rinse with PBS, nuclei were counterstained with
0.5 lg/ml of DAPI for 20 min and then washed three times with
PBS (3 min each). Glass coverslips were mounted and analyzed on
an LSM710 confocal microscope (Carl Zeiss).
Patient tissue
Patient tissue was collected and provided by the Neurobiobank
Munich according to the guidelines of the ethical committee at the
Medical Faculty of Ludwig-Maximilians-University (LMU) Munich
following the WMA Declaration of Helsinki and the Department of
Health and Human Services Belmont Report.
Expanded View for this article is available online.
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Figure EV1. Transmission of hydrophobic DPR proteins in a co-culture assay.
HEK293 cells were transfected with RFP, GFP, or DPR-GFP for 24 h andmixed in the indicated combination for additional 24 h as in Fig 2 before cell sorting by flow cytometry.
Gating was performed on RFP-expressing cells vs. mixture of all green fluorescent cells. The fraction of double-positive cells is indicated in percent. Double-positive cells were
sorted and plated on poly-D-lysine-coated coverslips and imaged 17 h later. Images show uptake of DPR-GFP into RFP-positive cells. Arrows indicate co-localization of GA175-
RFP aggregates with GA175-GFP and GP47-GFP. Scale bar 10 lm.
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Figure EV2. Anti-GA antibodies do not reduce expression of poly-GR and repeat RNA.
HEK293 cells transfected with (G4C2)80 were treated with cerebellar extracts pre-incubated with anti-GA or isotype control.
A The fraction of RAN translation-derived GR80-HA was quantified by flow cytometry. Data indicated the means  SD of n = 3 patients and controls in independent
experiments. Statistics were performed by one-way ANOVA with Dunnett’s multiple comparisons test.
B Quantitative RT–PCR shows repeat RNA transcripts upon treatment with cerebellar extracts pre-incubated with anti-GA or isotype control. Data are shown as
mean  SD from n = 3 patients and controls in independent experiments. Statistics were performed by one-way ANOVA with Dunnett’s multiple comparisons test;
non-C9 + IgG2a vs. C9 mut + IgG2a P = 0.0168; *P < 0.05.
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Contribution to Publication IV 
As second author of this publication, I conducted experiments shown in Fig. 4C, D and Fig. 5.  
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